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Summary
The neuroblastoma x glioma hybrid cell line, NG108-15, 
expresses an apparent 1 - 1 . 5  pmoles of a high affinity IP prostanoid 
receptor. This receptor is coupled to Gs and activates adenylyl
cyclase. Chronic exposure of these cells to the prostanoid agonist,
iloprost, results in a desensitisation of prostanoid stimulated adenylyl 
cyclase activity. In agreement with earlier work (Kelly et al, 1990; 
McKenzie and Milligan, 1990), studies presented in this thesis 
demonstrate a 50-70% decrease in cellular G sa levels on prostanoid 
treatment of NG108-15 cells. Time courses and dose responses of 
prostanoid treatment showed the down-regulation of G sa to be 
concurrent with a down-regulation (50-70%) of the IP prostanoid 
receptor. Quantitative analysis of the polypeptide levels, on iloprost 
treatment, revealed that G sa and the IP prostanoid receptor were 
down-regulated in a ratio of approximately 8:1 at various degrees of 
receptor occupancy by agonist.
Although G-protein a-subunit down-regulation is now a well- 
documented phenomenon during long-term agonist exposure, it does 
not occur in all cases of chronic agonist treatment. In NG108-15 cells 
chronic agonist treatment of the A2 adenosine and secretin receptors, 
which also couple to adenylyl cyclase, does not result in a detectable 
down-regulation of G sa (McKenzie et al, 1990). These receptors are 
thought to be expressed at much lower levels than the IP prostanoid 
receptor (Kelly et al, 1990; Gossen et al, 1990) potentially activating 
less G-protein a-subunit in NG108-15 cells. NG108-15 expressing 
4000 fmoles/mg membrane protein 02-adrenergic receptor (/3N22 cells) 
demonstrate an approximate 50% down-regulation of G sa on treatment
with isoprenaline (lOpM; 16 hours), whereas NG108-15 cells 
expressing 300 finoles/mg membrane protein 02-adrenergic receptor 
(0N17 cells) show no apparent down-regulation of G sa on prolonged 
isoprenaline treatment.
These results show that isoprenaline mediated down-regulation 
of G sa in transfected NG108-15 cells is dependent on the level of 02- 
adrenergic receptor expression, indicating a role for the receptor in 
regulating G a levels. This could potentially prove to be a general 
phenomenon for other receptors and their related G-proteins.
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The abbreviations used in this thesis are as set out in 
’'Instructions to Authors" Biochemical Journal (1985), 225,1-26, with 
the following additions:
ADP adenosine 5' diphosphate
0ARK 0-adrenergic receptor kinase
ARF ADP ribosylating factor
ATP adenosine 5' triphosphate
BSA bovine serum albumin
cAMP adenosine 3',5'-cyclic monophosphate
CHO Chinese hamster ovary
DAG diacylglycerol
DHA dihydroalprenolol
DMEM Dulbeccos' modification of Eagles' medium
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EDTA ethylenediaminetetraacetic acid
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E.Coli Escherichia Coli
FCS foetal calf serum
GAP GTPase activating protein
GDP guanosine 5' diphosphate
Gpp(NH)p guanylyl 5' imidodiphosphate
G-protein guanine nucleotide binding protein
GTP7 S guanosine 5'-0-(3-thio)triphosphate
GTP guanosine 5' triphosphate
IAP islet activating protein
NAD nicotinamide adenine dinucleotide
NaF sodium fluoride
NaOAc sodium acetate
NECA 5 '-(N-ethy 1 )carboxamidoadenosine
PBS phosphate buffered saline
PGE1 prostaglandin El
PGE2 prostaglandin E2
PGI2 prostaglandin 12
PGF2 prostaglandin F2
PKA protein kinase A
PKC protein kinase C
PLC phospholipase C
SV40 simian virus 40
TEMED N,N,N',N‘ tetramethylethylenediamine
TCA trichloroacetic acid
Tris tris (hydroxymethyl) aminomethane
List of contents
Title i
Summary ii
Acknowledgements iv
Abbreviations v
List of Contents vii
List of Figures xiv
List of Tables xxiii
Chapter 1 - Introduction
1.1 Historical perspectives 1
1.2 The identification of the stimulatory 2
and inhibitory G-proteins; Gs and Gi
1.3 G-protein purification 4
1.4 G-protein heterogeneity 6
1.4.1 Gs family 6
1 .4.2 Gi family 7
1.4.3 Gq/11 family 9
1.4.4 G12/13 family 10
1.4.5 Cloning of 13 and 7  subunits 10
1.5 The mechanism of action of G- 13
proteins
1.5.1 The GTPase cycle 13
1.5.2 Regulation of the GTPase cycle 14
1.6 Structural and functional 15
characteristics of G-proteins
1.6.1 The domains in G a for GTP binding 16
and hydrolysis
1.6.2 Interaction of G a with other 17
signalling components
1.7 Covalent modifications of G-proteins 19
1.7.1 ADP-ribosylation 19
1.7.2 Prenylation 20
1.7.3 Myristoylation 21
1.7.4 Palmitoylation 23
1.7.5 Phosphorylation 26
1.8 The mechanism of G-protein 27
interaction with effector proteins
1.8.1 The effector protein 27
1.8 .1.1 Phospholipase C 27
1.8.1.2 Adenylyl cyclase 27
1.8.2 G a interaction with effector 29
1.8 .2.1 G a interaction with adenylyl cyclase 29
1.8.2.2 G a activation of phospholipase C 30
1.8.3 07 regulation of effector molecules 33
1.8.3.1 The 07 dimer 33
1.8.3.2 Effector regulation by 07 34
1.9 The structure of G-protein coupled 36
receptors
1.9.1 The identification of a G-protein 36
coupled receptor
1.9.2 The ligand binding domain of G- 40
protein coupled receptors
1.9.3 Identification of the G-protein 45
coupling domains of receptors
viii
1.10
1 . 10.1
1 . 1 0 . 1.1
1 . 1 0 . 1 . 2
1.10.1.3
1 . 10.2
1 . 1 0 . 2.1
1.10.2.2
1.10.3
1. 11.1
Desensitisation of the /32-adrenergic 47
receptor on exposure to agonist 
Desensitisation of the 02-adrenergic 48
receptor on short-term exposure to 
agonist
j3-adrenergic receptor kinase 49
/3-arrestin 50
Receptor sequestration 52
Desensitisation of G-protein coupled 53
receptors on long-term exposure to 
agonist
Receptor down-regulation 53
Regulation of gene expression 55
Heterologous desensitisation of the 56
02-adrenergic receptor
Regulation of cellular G-protein 58
levels
The involvement of the ADP- 60
ribosylation of Gsa: in its down- 
regulation
The involvement of G-protein 61
activation in G a down-regulation
Research aims 62
IV
Chapter 2 - Materials and Methods
Materials
2.1.1 General reagents 63
2.1.2 Tissue culture plasticware 65
2.1.3 Cell culture media 65
2.1.4 Radiochemicals 66
2.1.5 Standard buffers 66
2 .1.6 Molecular biology tools 66
Methods
2.2 Cell culture 68
2.2.1 Cell growth 68
2.2.2 Cell subculture 69
2.2.3 Cell maintenance 69
2.2.4 Cell harvesting 70
2.3 Production of a crude membrane 71
preparation
2.4 Protein determination 71
2.5 Antibody production 72
2.6 Gel electrophoresis 74
2.6.1 Resolving gel preparation 74
2.6.2 Stacking gel preparation 75
2.6.3 Sample preparation by protein 76
precipitation
2.6.4 Gel protein staining 76
2.6.5 Western blotting 77
2.6.6 Quantitation of immunoblots 78
2.7 Radioligand binding assay 78
\
2.8 Adenylyl cyclase assay 79
2.8.1 Sample preparation 79
2.8.2 Preparation of Dowex and Alumina 80
columns
2.8.3 Separation of cAMP on Dowex 81
columns
2.8.4 Determination of cAMP produced by 81
membrane fractions
2.9 Reconstitution of Gsa: into S49 82
lymphoma eye- membranes
Cloning technology 83
2.10 General solutions used during 83
cloning
2.11 Agarose gel electrophoresis 84
2.12 Phenol: chloroform extraction of 84
DNA
2.13 RNAase treatment of DNA 85
2.14 Restriction enzyme digests 85
2.15 DNA ligation reactions 86
2.16 Preparation of competent E. Coli 86
2.17 Transformation of E. Coli 87
2.18 DNA minipreps from transformed E. 87
Coli
2.19 "Geneclean" using the Geneclean kit 88
2.20 CsCl2 purification of DNA from a 88
large scale culture of transformed E.
Coli
2.21 Quantitation of DNA 90
2.22 Transfection of plasmid DNA into 90
mammalian cell lines
2.23 Data analysis 91
Chapter 3 - Prolonged agonist exposure of the IP prostanoid
receptor, in NG108-15 cells, results in a concurrent 
down-regulation of receptor and Gsa.
Introduction 92
Results 115
Discussion 123
Chapter 4 - Characterisation of the elements of the adenylyl 
cyclase signalling cascade in NG108-15 cells 
transfected with the j$2-adrenergic receptor.
Introduction 138
Results 163
Discussion 169
Chapter 5 - Examination of the effects of prolonged agonist 
treatment on membrane associated G-protein ot- 
subunit levels in transfected NG108- 15 cells.
Introduction 176
Results 198
Discussion 204
Chapter 6 - Discussion 212
Appendices 1. [3HJ-PGE1 binding analysis 216
11. Transfection of mammalian cells 221
with plasmid DNA 
References 236
M i l
List of Figures
Figure 1.1 
Figure 1.2 
Figure 1.3 
Figure 1.4 
Figure 1.5 
Figure 3.1
Figure 3.2
Figure 3.3
Figure 3.4
G-protein a-subunit amino acid 11
homology
The proposed mechanism of Gee 18
activation by receptor
Structure of adenylyl cyclase 31
isoforms
General model for the structure 41
of the jS-adrenergic receptor 
0-adrenergic receptor-ligand 42
interaction sites
Time course of [3H]-PGE1 96
binding to NG108-15 cell
membranes
The incubation of increasing 97
amounts of NG108-15 cell
membrane protein with [3H]- 
PGE1
Displacement of [3H]-PGE1 98
binding with increasing
concentrations of PGE1 in 
NG108-15 cell membranes 
Displacement of [3H]-PGE1 99
binding with increasing
concentrations of iloprost in
NG108-15 cell membranes
Y 1 V
Figure 3.5
Figure 3.6
Figure 3.7
Figure 3.8
Figure 3.9
Figure 3.10
Saturation binding of [3H]-PGE1 
in membranes prepared from 
NG108-15 cells
Western blotting analysis of 
membranes prepared from 
control and iloprost treated 
NG108-15 cells using the 
antisera CS1 and SGI 
Western blotting analysis of 
increasing amounts of control and 
iloprost treated NG108-15 cell 
membranes with an antiserum 
generated against the C-terminal 
decapeptide of Gsa, CS1 
Saturation binding of [3H]-PGE1 
in membranes prepared from 
control and iloprost treated 
NG108-15 cells
Measurement of adenylyl cyclase 
activity in response to increasing 
concentrations of iloprost in 
membranes prepared from 
control and iloprost treated 
N G 108-15 cells
Analysis of G sa levels, by 
western blotting, in membranes 
prepared from NG108-15 cells 
which were treated separately 
with iloprost and forskolin.
Figure 3.11
Figure 3.12
Figure 3.13
Figure 3.14
Figure 3.15
Figure 3.16
Measurement of G sa levels and 
[3H]-PGE1 binding in 
membranes prepared from 
NG108-15 cells treated for 
increasing lengths of time with 
iloprost
Analysis of Gi2a levels, by 
western blotting, in membranes 
prepared from NG108-15 cells 
treated with iloprost for 
increasing lengths of time 
Analysis of G sa levels, by 
western blotting, in membranes 
and cytosol prepared from 
control and iloprost treated 
NG108-15 cells.
Molar quantitation of membrane 
associated G sa levels in NG108- 
15 cell membranes.
Measurement of membrane 
associated G sa levels and [3H]- 
PGE1 binding in membranes 
prepared from NG108-15 cells 
which have been treated with 
increasing concentrations of 
iloprost
The effect of receptor occupancy on 
stoichiometry of Gsa receptor down 
regulation
Figure 4.1
Figure 4.2 
Figure 4.3
Figure 4.4 
Figure 4.5
Figure 4.6
Figure 4.7
Figure 4.8
Figure 4.9
Full length nucleotide and 
deduced amino acid sequence of 
a cDNA for the human 02- 
adrenergic receptor.
Plasmid map of the expression 
vector pSVL
[3H]-DHA binding analysis in 
membranes prepared from 
control COS-1 cells and COS-1 
cells which had been transfected 
with a cDNA for the human 02- 
adrenergic receptor.
Plasmid map of the expression 
vector pJM16 .
Increasing the incubation time of 
membranes prepared from 0N22 
and 0N17 cells with [3H]-DHA 
[3H]-DHA binding analysis on 
increasing amounts of 0N22 and 
0N 17 cell membranes 
[3H]-DHA saturation binding 
analysis in membranes prepared 
from clone 0N22 
[3H]-DHA saturation binding 
analysis in membranes prepared 
from clone 0N17 
Saturation binding of [3H]-PGE1 
in membranes from clones 0N22 
and 0N17
Figure 4.10
Figure 4.11
Figure 4.12
Figure 4.13
Figure 4.14
Figure 4.15
Western blotting analysis of Ga  150
in membranes prepared from 
0N22 and NG108-15 cells 
Western blotting analysis of Go; 151
in membranes from 0N17 and 
NG108-15 cells
Examination of the cellular 152
morphology of NG108-15 (a) and 
0N17 (b) cells.
Displacement of 0.5nM [3H]- 153
DHA by increasing
concentrations of isoprenaline ±
lOOgM GTP7 S, in membranes
prepared from 0N22 cells
Displacement of 0.5nM [3H]- 154
DHA with increasing
concentrations of isoprenaline ±
lOOpM GTP7 S, in membranes
prepared from 0N17 cells
Analysis of the ability of sodium 155
cholate extracts of membranes,
prepared from NG108-15 and
0N22 cell, to activate adenylyl
cyclase when reconstituted into
S49 lymphoma eye- cell
membranes
W i l l
Figure 4.16
Figure 4.17
Figure 5.1
Figure 5.2
Figure 5.3
Figure 5.4
Measurement of adenylyl cyclase 
activity in membranes prepared 
from 0N22 and /3N17 cells in 
response to increasing
concentrations of iloprost 
Measurement of adenylyl cyclase 
activity in membranes prepared 
from /3N22 and /3N17 cells in 
response to increasing
concentrations of isoprenaline 
Analysis of G sa levels in 
membranes prepared from 
control and isoprenaline treated 
NG108-15 cells by western 
blotting.
Analysis of G a levels, in
membranes prepared from
control and isoprenaline treated 
/3N22 membranes, by western 
blotting
Molar quantitation of G sa levels 
in membranes prepared from 
control and isoprenaline treated 
(lOpM, 16 hours) /3N22 cells 
Analysis of G-protein /3-subunit 
levels, by western blotting, in 
membranes prepared from
control and isoprenaline (lOpM, 
16 hours) treated /3N22 cells
Figure 5.5
Figure 5.6
Figure 5.7
Figure 5.8
Figure 5.9
Analysis of G sa levels, by
western blotting, in membranes 
prepared from 0N22 cells 
exposed to increasing 
concentrations of isoprenaline for 
16 hours
Analysis of G sa levels, by
western blotting, in membranes 
prepared from 0N22 cells which 
were treated with lOpM 
isoprenaline for increasing 
lengths of time
Analysis of G sa levels, by
western blotting, in membrane 
and cytosol prepared from /3N22 
cells treated individually with 
lOpM isoprenaline and lpM  
iloprost
Analysis of the ability of sodium 
cholate extracts of membranes, 
prepared from control and lOpM 
isoprenaline treated /3N22 cells, 
to activate adenylyl cyclase when 
reconstituted into S49 lymphoma 
eye- cell membranes 
Analysis of G a levels, by 
western blotting, in membranes 
prepared from control and 
isoprenaline treated 0N 17 cells
Figure 5.10
Figure 5.11
Figure 5.12
Figure 5.13
Figure 5.14
Figure 5.15
Analysis of G a levels, by
western blotting, in membranes 
prepared from control and
iloprost treated /3N22 cells 
Analysis of G a levels, by
western blotting, in membranes 
prepared from control and
iloprost treated /3N17 cells 
Analysis of G sa levels in
membranes prepared from 0N22 
cells treated with increasing 
concentrations of iloprost 
Analysis of G sa levels in
membranes prepared from 0N22 
cells treated with lgM  iloprost 
for varying lengths of time 
Measurement of the adenylyl 
cyclase activity, in response to 
increasing concentrations of 
isoprenaline, in membranes 
prepared from control and
isoprenaline treated /3N22 cells 
The effect of isoprenaline, 
iloprost and a combination of 
these agonists on membrane 
associated levels of G sa in 0N22 
cells as assessed by western 
blotting
List of Tables
Table 1.1
Table 1.2 
Table 2.1 
Table 3.1
Table 3.2
Table 4.1 
Table 4.2
Table 4.3
Properties of eukaryotic adenylyl 
cyclase isoforms
The G-protein coupled receptors 
identified to date
The generation of G-protein 
subunit-specific antisera 
The effect of lOOpM GTPyS on 
[3H]-PGE1 binding to control 
and iloprost treated NG108-15 
cell membranes
Measurement of adenylyl cyclase 
activity in membranes prepared 
from control and iloprost treated 
NG108-15 cells. The effect of 
20mM MnCb
Measurement of [3H]-DHA 
binding in membranes prepared 
from wild-type NG108-15 cells 
Incubation of membranes 
prepared from /3N22 and /3N17 
cells with [3H]-PGE1 in the 
presence of lOOgM GTPyS 
Measurement of agonist 
stimulated adenylyl cyclase 
activity in /3N22, /3N17 and 
NG108-15 cell membranes
Table 4.4
Table 4.5
Table 5.1
Table 5.2
Table 5.3
Measurement of basal adenylyl 161
cyclase activity, in the presence 
of 20mM M11CI2, in membranes 
prepared from clones /3N22 and 
0N17
Measurement of basal adenylyl 162
cyclase activity, in 0N22 and 
NG108-15 cell membranes, on 
incubation with lOgM 
propranolol
[3H]-PGE1 binding analysis in 193
membranes prepared from 
control and iloprost treated /3N22 
and 0N 17 cells
Measurement of adenylyl cyclase 194
activity in membranes prepared 
from control and isoprenaline 
treated 0N22 cells in the 
presence of 20mM MnCb 
Measurement of basal and 195
iloprost stimulated adenylyl 
cyclase activity in membranes 
prepared from control and 
iloprost treated /3N22 cells
W i l l
CHAPTER 1 - INTRODUCTION
1.1 Historical perspectives
The control of cellular activity is dependent upon the action of a 
variety of hormones, neurotransmitters and growth factors which bind 
extracellularly to specific plasma membrane spanning receptors. The 
mechanism by which the binding of a suitable ligand to such a receptor 
exerts an intracellular effect has been the subject of much investigation. 
Pioneering work by Sutherland and Rail, using liver homogenates, 
demonstrated that, in the presence of glucagon or adrenaline, a heat 
stable factor was produced which was able to activate phosphorylase in 
the supernatant fraction (Rail et al, 1957). The heat stable factor was 
later identified as a cyclic monophosphate termed 3’5-cyclic AMP 
(cAMP). Glucagon and adrenaline did not directly activate 
phosphorylase which suggested that adenylyl cyclase, the enzyme 
catalysing the production of cAMP from ATP, could be hormonally 
regulated (Rail et al, 1957). This data formed the basis for the "second 
messenger hypothesis", whereby binding of a hormone extracellularly to 
specific cell surface receptors resulted in the generation of a secondary 
messenger e.g. cAMP which then altered intracellular metabolism.
The discovery that hormonal regulation of adenylyl cyclase in 
hepatocytes required GTP (Rodbell et al, 1971a, b) suggested the 
involvement of a guanine nucleotide binding site (Schramm and Rodbell, 
1975). GTP resulted in a transient activation of adenylyl cyclase, 
whereas non-hydrolysable analogues of GTP e.g. guanylyl 5'-[0y- 
imido]diphosphate (Gpp[NH]p) were shown to persistently activate 
adenylyl cyclase (Londos et al, 1974). This allowed speculation that the 
binding site involved in the regulation of adenylyl cyclase activity was 
capable of binding and hydrolysing GTP. Cassel and Selinger (1976)
corroborated this theory, when they demonstrated that catecholamine 
stimulation of adenylyl cyclase in the turkey erythrocyte membrane 
system produced a concomitant increase in the rate of high affinity 
GTPase activity. GTP hydrolysis appeared to terminate the activation of 
adenylyl cyclase. This suggested two states, an active GTP bound state 
and an inactive GDP bound state. Receptor activation was believed to 
cause the release of bound GDP and its exchange for GTP. This has 
indeed proved to be the case and will be discussed in greater detail later.
As well as receptor mediated stimulation of adenylyl cyclase, the 
possibility of hormonal inhibition of adenylyl cyclase, which had been 
suggested by earlier studies (Murad et al, 1962), was clarified by Rodbell 
and colleagues. They demonstrated in adipocyte preparations that GTP 
exerts a biphasic effect on adenylyl cyclase activity (Rodbell, 1975). In 
the absence of stimulatory hormone, guanine nucleotides such as GTP, 
elicited an inhibition of adenylyl cyclase. It was therefore suggested that 
adenylyl cyclase activity may be regulated by both stimulatory and 
inhibitory G-proteins (Rodbell, 1980).
1.2 The identification of the stimulatory and inhibitory G-proteins; 
Gs and Gi
The isolation of certain exotoxins from cultures of both Vibrio 
cholerae and Bordetella pertussis, aided the identification of the 
stimulatory and inhibitory G-proteins, termed Gs and Gi respectively. 
Gill and Meren demonstrated that the cholera toxin activation of 
adenylyl cyclase in pigeon erythrocytes correlated with the radiolabelling 
of a 42kDa polypeptide, in the presence of [32P]-NAD+ (Gill and
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Meren, 1978). The presumed reaction of cholera toxin was an ADP- 
ribosylation, similar to that already detailed for the action of diphtheria 
toxin on a protein component required for protein synthesis (Collier, 
1975). The effect of cholera toxin was similar to that obtained by non- 
hydrolysable analogues of GTP, thus allowing the identification of Gs as 
both a substrate for cholera toxin catalysed ADP-ribosylation and a 
protein capable of binding and hydrolysing guanine nucleotides.
Pertussis toxin, which is also termed islet activating protein (IAP), 
was similarly isolated from Bordetella pertussis. It was shown to 
produce alterations in receptor mediated control of cyclic AMP 
production (Katada and Ui, 1981). Initial experiments in rat C6 glioma 
cells treated with pertussis toxin showed an increase in GTP activation of 
adenylyl cyclase, concomitant with the transfer of [32P]-ADP-ribose from 
[32P]NAD+ to a 41kDa membrane associated polypeptide (Katada and 
Ui, 1982). The release of tonic inhibition of adenylyl cyclase activity 
paralleled by the modification of the 41kDa protein thus identified this 
protein as the previously unidentified inhibitory G-protein of the adenylyl 
cyclase cascade (Gi). IAP functions in a similar manner to cholera toxin 
in that it is an ADP-ribosyl transferase, catalysing the transfer of ADP- 
ribose from NAD+ onto the G-protein a-subunit.
In contrast to pertussis toxin, cholera toxin requires the presence of 
a protein co-factor termed ADP-ribosylation factor (ARF) which is itself 
able to bind GTP (Kahn and Gilman 1984a), in order to catalyse the 
ADP-ribosylation of Gs. The functional effect of cholera toxin catalysed 
ADP-ribosylation of Gsc* is to attenuate the ability of G sa to hydrolyse 
GTP, thus producing an irreversibly activated Gs a-subunit (Cassel and 
Selinger, 1977; Bimbaumer et al, 1980). After treatment with cholera
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toxin, adenylyl cyclase becomes maximally activated and is no longer 
responsive to hormonal stimulation. In contrast, the functional effects of 
pertussis toxin catalysed ADP-ribosylation of G ia is to prevent 
productive coupling between the receptor and the G-protein, thus 
receptor mediated inhibition of adenylyl cyclase is attenuated after 
pretreatment with pertussis toxin (Katada and Ui, 1979; Bums et al, 
1983). This led to the hypothesis that any event which is attenuated by 
prior treatment with pertussis toxin was indicative of a role for Gi in 
mediating the response. This has been demonstrated to be too simplistic 
as will be described later.
1.3 G-protein purification
Initial attempts to purify Gs using GTP affinity chromatography 
were designed to resolve Gs from adenylyl cyclase, thus proving Gs to be 
a separate moiety from adenylyl cyclase (Pfeuffer and Helmreich 1975; 
Spiegel et al, 1979). Studies of mutants of the S49 murine lymphoma 
cell line provided further evidence that receptor, Gs and adenylyl cyclase 
were separate entities. This cell line was particularly useful as a model 
to dissect the adenylyl cyclase system since an increase in intracellular 
cAMP is cytocidal, a characteristic enabling the isolation of mutants 
which were defective in their ability to produce cAMP. Tomkins and 
co-workers isolated a clone of S49 which lacked the ability to synthesise 
cAMP (Bourne et al, 1975). Initially designated AC-, later eye-, the 
clone was shown to be deficient in Gs, and thus provide a powerful 
functional assay for the purification of Gs. This was exploited by Ross 
and Gilman who were able to reconstitute adenylyl cyclase activity into
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eye- membranes using a detergent extract of wild-type membranes in 
which adenylyl cyclase has been inactivated (Ross and Gilman, 1977).
Purified Gs obtained from rabbit liver was shown initially to be 
composed of a-subunits of either 52 or 45kDa and a 35 kDa 0-subunit 
(Northup et al, 1980). Gs was further purified from turkey (Hanski et al, 
1981) and human erythrocytes (Hanski and Gilman, 1982), using similar 
methods, although only the 45kDa form of the a-subunit was obtained. 
The o'-subunits corresponded to the guanine nucleotide binding site, as 
well as the substrate for cholera toxin catalysed ADP-ribosylation (Cassel 
and Pfeuffer, 1978). Subsequently a low molecular weight 7 -subunit 
(8kDa) was found to be associated with Gs and other G-proteins. Its 
presence had been missed before due to its poor ability to be stained with 
conventional protein stains (Hildebrandt et al, 1984). Demonstrations of 
the distinct activities of each subunit came from the activation of purified 
Gs by AMF (AICI3, MgCh and NaF) or guanosine 5’ [3-o-thio] 
triphosphate (GTP7 S - a non-hydrolysable analogue of GTP). Such 
treatments resolved the a-subunit which activated adenylyl cyclase 
(Northup et al, 1983a) and the 0-subunit which stimulated the rate of Gs 
deactivation (Northup et al, 1983b).
The pertussis toxin sensitive "Gia" was initially purified from 
rabbit liver (Bokoch et al, 1983) and human erythrocytes (Codina et al, 
1983), although the polypeptides isolated from each tissue were of 
dissimilar molecular weight (41 kDa and 39kDa respectively). Attempts 
to purify Gi from bovine and rat brain led to the conclusion that brain 
contained two (Stemweis and Robishaw, 1984; Milligan and Klee, 1985) 
or three (Neer et al, 1984) pertussis toxin sensitive polypeptides in the 
39-41 kDa range, along with the 0- and 7 -subunits.
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1.4 G-protein heterogeneity
Further purification studies and the advent of molecular cloning 
technology has now revealed a whole family of G-proteins. Indeed, 
Simon and co-workers (1991) examined the primary amino acid 
sequences of the distinct a-subunits and arbitrarily classified them into 
subfamilies which showed a high degree of amino acid homology.
1.4.1 Gs family
At least four forms of G sa exist, which are obtained from 
alternative splicing of a transcript produced from a single gene (Bray et 
al, 1986; Kozasa et al, 1988). These have been grouped into two 
subtypes which are termed long and short Gsa. The cDNAs that encode 
two of the forms of Gsc* have been isolated from a bovine adrenal cDNA 
library and are identical except for a sequence of 46 nucleotides in which 
the shorter form of Gsc* contains alterations in 4 nucleotides and a 
deletion of 42 others (Robishaw et al, 1986). Whereas at least two 
forms of Gs are expressed in most tissues, their relative amounts usually 
vary (Mumby et al, 1986). Although Gs was originally identified as the 
G-protein required for receptor mediated stimulation of adenylyl cyclase, 
the protein has also been shown to couple to the activation of the 
dihydropyridine-sensitive Ca2+ channels (Yatani et al, 1987b), the 
inhibition of the calcium pump in liver membranes (Jouneauz et al, 1993) 
and the inhibition of Na+ channels in cardiac myocytes (Schubert et al,
1989). Gso: has also been shown to mediate epidermal growth factor- 
elicited stimulation of rat cardiac adenylyl cyclase (Nair et al, 1990).
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A protein with 88% amino acid homology to G sa has been cloned 
from olfactory epithelia and termed Golf . Its sole location is in the 
olfactory neuroepithelia where it is responsible for olfactant regulation of 
adenylyl cyclase (Jones and Reed 1987; Bruch, 1989).
1.4.2 Gi family
Although previously identified by Neer and co-workers (1984) and 
Gierschik and co-workers (1986a), the pertussis toxin sensitive Go: 
40kDa was first purified from bovine brain. It was termed Gi2a, and 
has since been shown to couple to the inhibition of adenylyl cyclase 
(McKenzie et al, 1988), whereas the previously identified G a 41 kDa was 
termed G ila . HL-60 cells have also been a source of a G a (41 kDa) 
identified as Gi3a using antipeptide antisera directed against the 
predicted sequence from cDNA information (Goldsmith et al, 1988). Its 
role in the activation of potassium channels has been demonstrated 
(Codina et al, 1988). In addition to the three forms of G ia identified 
(G ila, Gi2a and Gi3a) other G-protein a-subunits have been termed 
"Gi-like" due to their high degree of amino acid homology with these 
proteins.
At least two forms of transducin occur, transducin 1 (G tl) and 
transducin 2 (Gt2), which are encoded by separate genes, and are found 
in rod and cone cells respectively (Lerea et al, 1986). These serve to 
couple rod and cone opsins to cGMP phosphodiesterases. The 
transducins show an approximate 80% homology with the "Gi-like" 
proteins. A novel transducin-like G-protein termed gustducin (Gg) has 
recently been identified from taste tissue (McLaughlin et al, 1992) and it
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is thought a phosphodiesterase may be involved in its means of signal 
transduction, due to sequence homology in those regions of the G-protein 
a-subunit known to interact with receptors and effectors.
Studies using purified preparations of pertussis toxin substrates 
from bovine brain (Stemweis and Robishaw, 1984; Milligan and Klee, 
1985; Neer et al, 1984) in conjunction with the purification of rat brain 
substrates (Katada et al, 1986) led to the identification of the 39kDa G- 
protein a-subunit termed Go for 'other' (Nukada et al, 1986; Itoh et al, 
1986). cDNA clones of Goa have been isolated from bovine retina (Van 
Meurs et al 1987), rat C6BU1 glioma cells (Itoh et al 1986, 1988) and rat 
olfactory epithelium (Jones and Reed 1987). Additional Goa isoforms 
have also been identified (Goldsmith et al, 1988; Kobayashi et al, 1989) 
immunologically (Goldsmith et al, 1988) and biochemically (Inanobe et 
al, 1989; Hsu et al, 1990). The function of Go remains unresolved, early 
evidence exists to suggest that the G-protein may be involved in the 
regulation of receptor mediated inhibition of voltage operated Ca2+ 
channels (Hescheler et al, 1987; Harris-Warrick et al, 1988; Ewald et al, 
1988). More recent studies demonstrate a role for Go in coupling to 
somatostatin receptors (Law et al, 1991, 1993) and the aiB-adrenergic 
receptor (Blitzer et al, 1993) which serve to inhibit adenylyl cyclase and 
stimulate phospholipase C activity respectively.
The subclass of "Gi-like" proteins also includes Gxa. Gxa cDNA 
was isolated from rat brain and was identical to one isolated from human 
retina and designated Gza (Fong et al, 1988). This protein is pertussis 
toxin insensitive, however it bears more homology to the "Gi-like" 
proteins than to members of the Gq class. Antisera specific to G za did 
not identify the Gq proteins (Taylor et al, 1990). G za exhibits a
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remarkably slow rate of guanine nucleotide exchange and a very slow 
intrinsic GTPase activity when compared to Gia. The biochemical 
properties of Gza appear, therefore, to differ from those of Gia, although 
as yet the physiological significance of this remains undetermined.
1.4.3 Gq/11 family
Numerous studies have implicated a role for G-proteins in coupling 
receptors to the phospholipid hydrolysing enzyme, phospholipase C 
(PLC). Recently unique a-subunits that are not substrates for pertussis 
toxin have been purified and their role in activating PLC is becoming 
increasingly evident (Exton et al, 1990; Pang and Stemweis, 1990).
Simon and colleagues have recently used the polymerase chain 
reaction (PCR) to detect additional G-protein a-subunit gene products in 
mouse brain. Five sequences termed G al0 -G al4  were detected. Four 
of these sequences were novel, as GalO was found to be equivalent to 
Gaolf. The sequence of the G al 1 clone is closely related to that of the 
G al 4 (Strathmann et al, 1989). Strathmann and Simon more recently 
obtained a murine cDNA clone termed Gqa which is 88% homologous to 
G i l a  and have proposed that these clones represent a third class of a- 
subunits - the Gq class. Also within this newly designated class of 
pertussis toxin insensitive G-proteins, three other isotypes have been 
discovered, which exhibit tissue specific expression. G al 4 is found in 
stromal and epithelial cells, whilst G a l 5 and G a l6 are found in cells 
derived from the haematopoetic lineage (Simon et al, 1991; Amatruda et 
al, 1991).
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1.4.4 G12/13 family
Simon and co-workers have also suggested that the less well 
characterised murine cDNA clones G a l2 and G al 3 represent another 
class of pertussis toxin resistant a-subunits. The translation products are 
predicted to share less than 45% identity with other a-subunits and 
transcripts have been detected in every tissue examined (Strathmann and 
Simon, 1991).
When the predicted amino acid sequences of the G-protein a- 
subunits are aligned they exhibit impressive sequence homolgy, as 
represented schematically in figure 1.1. Over 98% identity of amino 
acid sequence is maintained for Gi2a, Gi3a, Gza and Goa among 
evolutionary distinct mammalian species, presumably reflecting an 
evolutionary pressure to preserve the specific physiological function of 
each G-protein. The presence of heterotrimeric G-proteins has also been 
demonstrated in yeast Saccharomyces cerevisiae (Nakafuku et al, 1987,
1988), Drosophila melanogaster (Provost et al, 1988; Quan et al, 1989; 
Yoon et al, 1989; de Sousa et al, 1989) and Dictyostelium discoideum 
(Pitt e ta l, 1992).
1.4.5 Cloning of 0 and y subunits
To date four /3-subunits have been identified by a combination of 
purification and molecular cloning; 01 (Sugimoto et al, 1985, Fong et al, 
1986); 02 (Fong et al, 1987; Gao et al, 1987); 03 (Levine et al, 1990) 
and 04 (von Weizsacker et al, 1992). There is an overall homology of 
approximately 80% between 0 -subunit isoforms and their molecular
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Figure 1.1 G-protein a-subunit amino acid homology.
The G-protein a-subunits were grouped by their amino acid 
identity and the relationship between the different G-protein a-subunits 
was displayed. The diagram is adapted from Simon et al, 1991 (Science 
252: 802-808).
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weight is in the range of 35-37kDa. Interestingly the /3-subunit amino 
acid sequence comprises of seven repeating imits each about 43 amino 
acids long. Similar repeating units termed WD40 repeats occur in 
several other proteins whose functions seem unrelated to signal 
transduction (van der Voom and Ploegh, 1992). It is not known, as yet, 
what features of the repeating unit necessitate its conservation among so 
many different proteins.
A cDNA corresponding to the y  subunit (7 I), of transducin was 
initially cloned by Hurley and co-workers (1984). The predicted amino 
acid sequence from this cDNA suggests a hydrophilic protein of 8.4kDa. 
Subsequently at least six other 7 -subunits have been identified from a 
variety of tissues and cDNA libraries y2 from brain; 73 and y l  from a 
bovine brain cDNA library, 74  from mouse kidney and retina, 75  from 
the bovine and rat liver cDNA libraries and 76  from rat brain (Robishaw 
et al, 1989; Gautam et al, 1990; Fisher and Aronson, 1992; Cali et al, 
1992). There is a much greater diversity in amino acid composition 
between 7 -subunits (27-75% homology) than in the more highly 
conserved /3-subunit. This suggests that the 7 -subunit may play a more 
dominant role in determining the function and specificity of the G-protein 
than previously anticipated.
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1.5 The mechanism of action of G-proteins
1.5.1 The GTPase cycle
Using the available data on the effects of cholera toxin and non- 
hydrolysable GTP analogues on Gs, together with the ability to measure 
hormonal stimulation of high affinity GTPase activity, Cassel and 
Selinger were able to propose a cyclical model to account for G-protein 
function which is still applicable.
Binding of a ligand to its receptor causes the a-subunit to lose its 
bound GDP and bind GTP in a Mg2+ dependent manner. Agonists act to 
reduce the concentration of Mg2+ required for activation, for example 
glucagon lowers the magnesium concentration required for GTPyS 
activation of G sa from 25mM to IOjiM. As the intracellular Mg2+ is 
estimated to be of the order of 2mM it can then be utilised (Iyengar and 
Bimbaumer, 1982). The binding of GTP reduces the affinity of the 
receptor for the agonist, resulting in a dissociation of the receptor-G- 
protein complex and a magnesium dependent dissociation of the a- 
subunit from the fiy (Maguire et al, 1976). The Ga-GTP is now in an 
"active" conformation suitable for specific interaction with an effector 
protein. On completion of effector activation, GTP is hydrolysed to 
GDP by the intrinsic GTPase of the a-subunit (Rodbell, 1980). The now 
inactive Ga-GDP can reassociate with its fiy subunits. This system is 
cyclical and dependent on ligand binding, GTP and Mg2+ (Ransnas et al,
1992).
Necessity for agonist occupancy of the receptor can be 
circumvented by use of non-hydrolysable analogues of GTP, such as
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Gpp[NH]p and GTP7 S, although the reaction still requires magnesium 
(Codina et al, 1983). G-proteins can also be activated by aluminium
fluoride (AIF4-) which mimics the terminal phosphate of GTP when GDP 
is in the guanine nucleotide binding site (Bigay et al, 1985).
1.5.2 Regulation of the GTPase cycle
Several groups have shown that agonist-liganded receptors 
increase the dissociation rate of bound GDP, therefore vacating the 
guanine nucleotide binding site and subsequently allowing the binding of 
GTP (Rodbell, 1980; Schramm and Selinger, 1984). The receptor binds 
the afiy  complex much more tightly than it binds to a  alone (Fung, 1983; 
Fung and Nash, 1983; Florio and Stemweis, 1989). Enhanced receptor 
association with a  could, therefore, be a consequence of fiy  interaction 
with the receptor and indeed, there is evidence to suggest an interaction 
of fiy  with the 0-adrenergic receptor (Im et al, 1988). fiy  exhibits a 
preference for binding a-GDP and a receptor preferentially binds Gafiy 
as opposed to Ga, thus fiy may serve to ensure the reduction of 
spontaneous, receptor-independent release of GDP. Additionally fiy 
also inhibits the GTPase of the protein (Bourne et al, 1991) and the 
combination of these properties ensure exchange of GTP for GDP and 
not vice versa.
GTPase activating proteins (GAPs) have been identified as being 
necessary protein co-factors for the efficient GTPase activity in several 
GTP binding proteins. Compared to the GAP-triggered GTPase activity 
of p21ras and ribosome triggered GTPase of elongation factor (Ef-Tu), 
the G-proteins hydrolyse GTP much more slowly, kcat.GTP=2.4min-1
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(Freissmuth et al, 1989; Graziano and Gilman, 1989; Landis et al, 1989). 
However this GTP hydrolytic rate appears to be slow enough to enable 
signal transduction yet rapid enough to control a turn-off of signal 
transmission (Bourne et al, 1990, 1991). A recent finding has revealed 
that the effectors phospholipase C0-1 (Berstein et al, 1992) and cGMP 
phosphodiesterase (Arshavsky and Bownds, 1992) increase the intrinsic
GTPase activity of their activating G-protein a-subunit. It may be that all
*
effectors can deactivate their specific G-protein a-subunits through such 
a negative feedback mechanism, although this awaits formal 
demonstration.
1.6 Structural and functional characteristics of G-proteins
1.6.1 The domains in Ga for GTP binding and hydrolysis
Recently the crystalline structure of GTP7 S-liganded transducin 
was elucidated (Noel et al, 1993), although the crystal structures of the 
other G a have not been determined. The three dimensional folds of its 
GTP binding site are almost superimposable on those of the GTP binding 
proteins p21ras (La Cour, 1985; Pai et al, 1989; Milbum et al, 1990; Pai 
et al, 1990; Bourne et al, 1991) and the protein elongation factor EF-Tu, 
although the overall sequence homology between the proteins is only 
17% (Valencia et al, 1991). The structure of the GTP binding domain in 
both these proteins and transducin comprises of a hydrophobic core of 
alternating 0-sheets and hydrophilic a-helices. However a stretch of 113 
amino acids in transducin (conserved in G a chains, but missing in the 
other GTPases) composed of a-helices has been identified near the N- 
terminal of the protein. This structure has been heavily implicated in
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regulating both guanine nucleotide release (GDP) and the binding and 
hydrolysis of GTP (GAP activity). The helical domain is postulated to 
restrict movement out of and into the guanine nucleotide binding pocket 
of the core domain. It has been proposed that to promote the 
replacement of GDP by GTP the activated receptor potentially "moves" 
the helical domain, via a conformational change, allowing the exchange 
of guanine nucleotides. The helical insert is therefore thought to act as 
an intrinsic activator of GDP exchange for GTP. Indeed for some ras- 
like GTPases a class of separate proteins, guanine nucleotide dissociation 
inhibitors (GDI), serve to inhibit the release of bound guanine nucleotide. 
Therefore as well as regulating GTPase activity (acting as an intrinsic 
GAP protein), the Gee helical domain may also act as an intrinsic GDI 
that is subject to regulation by hormone receptors (Markby et al, 1993; 
Bourne, 1993) (figure 1.2).
The amino acid residues involved in GTP binding and hydrolysis 
have been extensively studied in p21nz? and corresponding residues in 
transducin have also been shown to bind GTP7 S. This is discussed in 
detail in the following references: Bourne et al, 1990; Bourne et al, 1991; 
Markby et al, 1993; Noel et al, 1993; Bourne, 1993.
1.6.2 Interaction of Ga with other signalling components
Mutational, biochemical and structural analysis of the G-protein a- 
subunit has elucidated the regions of the protein involved in its interaction 
with other polypeptides of the signalling cascade. The extreme C- 
terminal portion of G a is primarily responsible for its interaction with 
receptor (West et al, 1985; Sullivan et al, 1987; Rail and Harris, 1987; 
Simonds et al, 1989; Gutowski et al, 1991; Shenker et al, 1991). More
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1991). More recent work from Conklin and co-workers showed that in 
addition to contacting receptors, the extreme C-terminal of Go; also made 
a major contribution to determining the specificity of the receptor-G- 
protein interaction (Conklin and Bourne, 1993a). The extreme N- 
terminus of Gee has been shown to be important for the binding of fiy 
dimers to the protein (Fimg and Nash, 1983; Neer et al, 1988; Mazzoni 
and Hamm 1989; Mazzoni et al, 1991; Denker et al, 1992; Graf et al, 
1992; Joumot et al, 1992), although the GTP binding region has been 
demonstrated to play some part in this interaction (Lee et al, 1992). 
Mutagenesis studies of Gsa revealed that the key adenylyl cyclase 
interacting residues were located within a 121 amino acid sequence close 
to the C-terminal of the protein (Itoh and Gilman, 1991; Berlot and 
Bourne, 1992;), although other elements which determined the three 
dimensional structure of the G-protein a-subunit were involved in the 
regulation of the effector by the G-protein.
Taken together, the emerging picture of the overall three 
dimensional structure of the G-protein a-subunit, is with the GTP-binding 
pocket located at the front of the protein and facing the cytoplasm. The 
back of the protein is oriented towards the plasma membrane and 
provides binding surfaces for receptor, effector and G-protein 0y  
subunits, as well as attachment sites for fatty acids that enhance avidity of 
a-subunits for membranes and 0y  (Conklin and Bourne, 1993b).
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Figure 1.2 The proposed mechanism of G a  activation by its 
receptor.
The figure showing the mechanism o f G a  activation by a receptor 
has been adapted from Bourne, 1993 (Nature 366: 628-629). It shows 
how an activated receptor (R*) may turn on a G-protein, by inducing the 
helical domain of G a  to pivot away from the G a  core GTPase domain. 
By binding to surface features the receptor loosens a co-operative web of 
hydrogen bonds (circles), causing the helical domain to pivot away from 
the guanine-nucleotide binding site allowing free exchange of GDP for 
GTP.
a{empty;
Helical d om a in  
(Gail)
a GDP
Core d o m a in  
(Ralph)
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1.7 Covalent modifications of G-proteins
G-proteins can be covalently modified in several ways. These 
modifications are potentially important in regulating the function and 
cellular targetting of the G-protein and will be discussed below.
1.7.1 ADP-ribosylation
Pertussis toxin and cholera toxin catalysed mono ADP-ribosylation 
of G-protein a-subunits has been well characterised (section 1.2), but it is 
still uncertain if ADP-ribosylation of G-protein a-subunits occurs under 
normal cellular physiological conditions. Both arginine (Moss and 
Vaughan, 1988; Inageda and Tanuma, 1991) and cysteine specific 
(Tanuma et al, 1987; Tanuma et al, 1988) mono (ADP-ribosyl) 
transferases have been identified in several cell types. Enzymes that 
catalyse the removal of ADP-ribose from ADP-ribosylated arginine 
residues have also been identified (Moss et al, 1992), suggesting that 
ADP-ribosylation may be a reversible physiological event (Moss et al, 
1985). Certainly several groups have produced evidence in support of 
the ADP ribosylation of G-protein a-subunits by both arginine (Donnelly 
et al, 1992) and cysteine specific mono (ADP ribosyl) transferases 
(Tanuma and Endo, 1989), although the identification of an endogenously 
ADP-ribosylated G-protein a-subunit has not yet been reported in vivo. 
The function of this ADP-ribosylation remains unclear, but targetting the 
protein for an enhanced proteolysis, after agonist activation, has been 
suggested.
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1.7.2 Prenylation
Transfer of the prenyl moiety, famesyl, to a polypeptide was first 
described for the yeast mating factor (Kamiya et al, 1978; Ishibashi et al, 
1984; Anderegg et al, 1988). Schmidt and co-workers (1984) presented 
the first evidence that proteins in mammalian cells were also modified by 
prenyl groups.
*
Cysteine residues in the C-terminal of the protein are a common 
characteristic of prenylated proteins. These are organised in a Cys-Xaa- 
Xaa-Xaa, Cys-Cys or Cys-Xaa-Cys motif. Prenylation of proteins 
occurs post-translationally and involves the attachment of an isoprenoid 
moiety to the sulphydryl group of a carboxy terminal cysteine residue via 
a thioester linkage. Three residues downstream of the prenylated 
cysteine are then proteolytically removed and the newly exposed C- 
terminal cysteine residue is methylated (Clarke, 1992).
Parallel studies from two groups (Yamane et al, 1990; Mumby et 
al, 1990b) first showed that G-protein y-subunits purified from bovine 
brain and the neural cell line PC 12 were modified by geranylgeranylation 
and carboxymethylation on a C-terminal cysteine residue. Furthermore, 
the y-subunit of transducin was found to be modified by a famesyl group 
(Fukada et al, 1990; Lai et al, 1990).
The Q;-carboxy-methylation of mammalian proteins was first 
demonstrated in ras proteins overexpressed in a fibroblast cell line, which 
incorporated methyl groups with a stability consistent with a-carboxyl 
methyl esters (Clarke et al, 1988). On reconstitution in detergent 
stripped bovine brain membranes with a methyl transferase the y-subunit
20
of G-proteins was first shown to be a-carboxymethylated (Fung et al, 
1990). The function of the a-carboxymethylation is unknown, however 
the absence of an ce-carboxyl methyl ester on yeast mating factors results 
in the nearly complete loss of activity (Ishibashi et al, 1984; Anderegg et 
al, 1988; Hryeyna et al, 1991).
Several lines of evidence, mainly obtained from small molecular 
weight G-proteins, indicate that the prenyl modification is for the 
attachment of the protein to the plasma membrane (Hancock et al, 1989; 
Jackson et al ,1990; Simonds et al, 1991; Hiroyoshi et al, 1991; Kato et 
al, 1992). fiy  dimers of heterotrimeric G-proteins containing C-terminal 
mutants of the 7 -subunit demonstrated a low affinity for both a-subunits 
and adenylyl cyclase, both of which are associated with the plasma 
membrane. Recent evidence also suggests that the role of the prenyl 
moiety on the 7 -subunit is for the membrane attachment of the £ 7  dimer 
(Iniguez-Lluhi et al, 1992). Removal of the C-terminal prenylation 
signal and replacement with an amino terminal myristoylation site 
(myristoyl moieties will also bind the protein to the membrane), restores 
transforming activity to the ras protein (Buss et al, 1989). This suggests 
the sole function of prenylation is membrane binding and not interaction 
of the prenyl group with the receptor or effector.
1.7.3 Myristoylation
The enzyme, N-myristoyltransferase, catalyses the transfer of a 
myristate moiety to a glycine residue via an amide bond, at the N- 
terminal of a protein. The consensus sequence for N-terminal 
myristoylation has now been established to be an amino terminal glycine
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with a small uncharged amino acid such as alanine, serine or a 
hydroxyamine residue commonly found 4 amino acids downstream. 
Myristoylation is a co-translational rather than a post-translational 
modification. N-myristoyltransferase activity has been demonstrated in 
nearly every eukaryotic cell type (Deichaite et al, 1988).
The endogenous myristoylation of G-protein a-subunits was first 
found in isolated proteins from bovine brain (Schultz et al, 1987) and 
human astrocytoma cells (Buss et al, 1987). Metabolic labelling of 
human astrocytoma cells (Buss et al, 1987) with [3H]-myristate revealed 
that G ia and Goa, but not G sa proteins were myristoylated. On 
examination of the amino acid sequence of these proteins it was 
discovered that Gia and Goa had an amino terminal glycine with a serine 
residue four amino acids downstream. Although G sa has an amino 
terminal glycine it does not possess the serine residue, indicating that this 
residue is essential for myristoylation of Ga. The myristoylation of 
specific G-protein a-subunits was later studied in depth by their transient 
expression and subsequent metabolic labelling in COS cells (Jones et al, 
1990; Mumby et al, 1990a). These studies verified that the a-subunits 
of G il, Gi2, Gi3, Go and Gz were substrates for myristoylation and these 
a-subunits as well as G sa overexpressed in COS cells were localised to 
membrane fractions.
Mutagenesis of the N-terminal glycine to alanine in G ila  and G oa 
followed by expression of the mutant cDNAs in COS cells resulted in 
non-myristoylated a-subunits whose localisation was shifted from the 
plasma membrane to the cytosol (Jones et al, 1990; Mumby et al, 
1990a), indicating a role for myristoylation in membrane attachment. 
This was further corroborated by more recent studies of gip2, an
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oncogenic a-subunit of Gi with transforming activity (Lyons et al, 1992). 
Removal of the site of myristoylation by site directed mutagenesis 
resulted in non-myristoylated gip2 which lacked transforming activity 
(Gallego et al, 1992).
Co-expression of Go with N-myristoyl transferase in E. Coli 
resulted in a mixture of myristoylated and non-myristoylated Goa (Linder 
et al, 1991). These were purified to homogeneity and through 
reconstitution studies used to investigate the functional role of myristate. 
The most striking difference was the inability of the non-myristoylated a- 
subunit to interact effectively with Py complexes. In contrast the 
myristoylated Goa behaved identically to Goa purified from brain. 
These results are consistent with reports that the amino terminus of G ta 
and indeed other G a subunits is required for the protein's interaction with 
the py  complex (Navon et al, 1987; Neer et al, 1988; Osawa et al,
1990).
The relative importance of myristoylation in py  interaction and 
membrane localisation appears to vary among the a-subunits ie G sa is 
not myristoylated, yet it is still attached to the membrane and interacts 
with Py.
1.7.4 Palmitoylation
Palmitoylation of proteins occurs via a thioester linkage on a 
cysteine residue and is a post-translational modification. As yet no 
palmitoyltransferases have been purified or cloned and palmitoylation
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appears at least in some cases to be non-enzymatic (Yamane and Fung,
1993).
Until recently only members of the ras family of small molecular 
weight G-proteins had been shown to be palmitoylated (Hancock et al,
1989). Early studies reported that the a-subunit of the heterotrimeric G- 
protein Gs, would not undergo palmitoylation, but more recent work by 
two groups (Degtyarev et al, 1993a; Linder et al, 1993) demonstrated 
that G sa will incorporate [3H]-palmitate. It is thought that the early 
work missed the palmitoylation due to the low abundance of G sa in most 
cells and the resulting low level of incorporation of palmitate. Certainly 
Linder and co-workers (1993) used high performance liquid 
chromatography to demonstrate that palmitate and not some other acyl 
group (for example myristoyl) was incorporated. Furthermore, mutation 
of a cysteine residue at position 3 of the N-terminal of G sa (Degtyarev et 
al, 1993a) and Goa (Parenti et al, 1993) prevents palmitate 
incorporation, indicating that this cysteine residue is the site of 
palmitoylation .
Studies on the palmitoylation of heterotrimeric G-proteins are very 
much in their preliminary stages and the role of palmitoylation in the 
functioning of these proteins is still unclear. It seems however that 
palmitate may play a role in mediating interactions of the G-protein a- 
subunit with the plasma membrane. Certainly non-palmitoylated G oa 
shows reduced binding to the membrane (Parenti et al, 1993).
The palmitoylation of G sa may be particularly important because 
this protein is not myristoylated and the means of membrane attachment 
outwith its interaction with Py remains elusive. Controversy exists over 
the role of palmitate in G sa membrane attachment. Degtyarev and co­
24
workers (1993a) demonstrated that removal of the palmitate moiety from 
G sa still produced a protein which is localised to the plasma membrane, 
whilst Wedegaertner and co-workers (1993) showed by mutational 
analysis that palmitoylation of G sa was important for membrane 
attachment. Audigier and co-workers (1990) by mutational and 
proteolytic analysis of G sa demonstrated a role for the C-terminus in 
membrane attachment, indicating that perhaps palmitoylation of G sa has 
a function other than membrane attachment and some other residue 
and/or covalent modification is responsible for membrane attachment in 
Gsa. Recent work by Degtyarev and co-workers (1993b) shows an 
increased palmitoylation of G sa after activation by both the /3-adrenergic 
receptor and cholera toxin. An explanation for this remains to be found, 
however, an increased hydrophobicity of the G-protein results and this 
may function to increase the membrane attachment of the GTP bound 
form of Gsa, resulting in effector activation.
More investigation is needed to determine unequivocally the role 
of palmitoylation in membrane attachment of heterotrimeric G-proteins. 
Palmitoylation has been shown to be a reversible process and it may be 
that deacylation and acylation of G-proteins controls its function and 
regulation. Certainly an increased turnover rate of palmitoylation of the 
0 2 -adrenergic receptor is observed on treatment with an agonist 
(Mouilliac et al, 1992) although the function of this palmitate turnover 
remains undetermined (O'Dowd et al, 1989; Moffett et al, 1993).
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1.7.5 Phosphorylation
Phosphorylation of G-proteins is the least well defined of the 
covalent modifications. The first evidence that G-proteins may be 
regulated by phosphorylation came with the observation that treatment of 
platelet membranes with partially purified PKC resulted in 
phosphorylation of a 41kDa protein, later demonstrated to be Gice, in a 
stoichiometry of 1 mole Pi per mole of substrate (Katada et al, 1985). 
More recent studies with recombinant G-proteins have shown that the a- 
subunit of Gz is stoichiometrically phosphorylated by partially purified 
PKC on a serine residue near the N-terminal, whereas recombinant G ila , 
Gi2a and Gi3a are not labelled under the same conditions (Lounsbury et 
al, 1991). Phosphorylation of G-protein a-subunits has also been 
reported to occur on both serine and tyrosine residues in a reconstituted 
system containing purified insulin protein kinase (Krupinski et al, 1989) 
and PKC (Pyne et al 1992).
Although these results demonstrate that the a-subunit of G- 
proteins can be phosphorylated 'in vitro', a link with physiological events 
has yet to be conclusively demonstrated. Clearly phosphorylation of G- 
proteins has strong implications in "cross-talk" between signalling 
systems.
26
1.8 The mechanism of G-protein interaction with effector proteins
1.8.1 The effector protein
Among the growing number of effector proteins identified which 
are regulated by G-proteins are a number of ion channels, the retinal 
cGMP phosphodiesterase and the expanding adenylyl cyclase and 
phospholipase C families. The regulation of the latter two families will 
be detailed here; for information on the regulation of the retinal cGMP 
phosphodiesterase (Pfister et al, 1993) and ion channels (Stemweis and 
Pang, 1990) the mentioned reviews will prove to be useful.
1.8.1.1 Phospholipase C
Phospholipase C (PLC) catalyses the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate to produce two important 
intracellular second messengers: diacylglycerol (DAG) and inositol 1,4,5- 
trisphosphate. Molecular cloning has revealed at least three classes of 
phospholipase C; phospholipase C-/3, -y and -6. A number of isoforms 
of each class of phospholipase C have been identified (Rhee and Choi, 
1992; Rhee, 1991). To date there are four isoforms of PLC-0, and only 
isoforms from the PLC-/3 class have been shown to be regulated by 
heterotrimeric G-proteins (Rhee and Choi, 1992; Kritz et al, 1990).
1.8.1.2 Adenylyl cyclase
Adenylyl cyclase catalyses the conversion of intracellular ATP to 
cAMP, increasing intracellular levels of cAMP. It was only recently that
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detailed molecular information about the adenylyl cyclase enzyme has 
been acquired, following the cloning of several isoforms of the enzyme. 
Most adenylyl cyclases are associated with the plasma membrane, 
although certain bacterial enzymes (and perhaps one form in mammalian 
sperm [Rojas et al, 1993]) are cytosolic.
These membrane associated adenylyl cyclases have short 
cytoplasmic N- and C-terminal regions and two 40kDa cytoplasmic 
domains (Cl and C2) punctuated by two intensely hydrophobic stretches 
(Ml and M2), each of which are hypothesised to contain six 
transmembrane helices (figure 1.3). cDNAs encoding numerous 
adenylyl cyclases of this type have now been cloned, 6 of these are from 
mammalian sources: type 1 from brain (Krupinski et al, 1989), typell 
from brain and lung (Feinstein et al, 1991), type 111 from olfactory 
specific neurons (Bakalyar and Reed, 1990), type IV from peripheral 
tissue and the CNS (Gao and Gilman, 1991) and types V (Ishikawa et al, 
1992) and VI (Premont et al, 1992; Katsushika et al, 1992) from S49 
lymphoma cells; one is the product of the rutabaga gene from 
Drosophila melanogaster (Levin et al, 1992), two are from 
Dictyostelium discoideum (Pitt et al, 1992) and one is from 
Saccharomyces cerevisiae (Kataoka et al, 1985).
Portions of the Cl and C2 domains (C la and C2a) are well 
conserved (50-92% homologous). These are very similar to each other 
and also to the catalytic domains of a series of membrane bound guanylyl 
cyclases (Chinkers and Garbers, 1991). Catalytic activity of adenylyl 
cyclase requires both C la  and C2a, suggesting that these two domains 
may interact to produce the catalytic activity of the enzyme (Tang et al,
1992). Similarly the N-terminal and the C-terminal are both required for
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the catalytic activity of the protein (Tang et al, 1991). The exact site on 
the adenylyl cyclase polypeptide required for catalytic activity and G- 
protein interaction is not yet known. The amino acid sequence 
homology is limited beyond the Cl a and C2a domains, but the overall 
structure is well conserved, suggesting that the two sets of 6 
transmembrane helices may play an as yet undiscovered role in the 
functioning of the enzyme.
Potential for "cross-talk" between signalling pathways exists at the 
level of the adenylyl cyclase protein. The isoforms of mammalian 
adenylyl cyclase display differential regulation by dimers and calcium 
ions which are detailed in table 1.1. Additionally, several isoforms (types 
1, 11 and 111) of adenylyl cyclase have recently been shown to be 
regulated by protein kinase C (Choi et al, 1993; Jacobiwitz et al, 1993; 
Yoshimura and Cooper, 1993).
1.8.2 Ga interaction with effector
1.8 .2.1 Ga interaction with adenylyl cyclase
All the mammalian adenylyl cyclase enzymes are activated by 
Gsa, the G a originally identified because of this action. For a long time 
it was thought that inhibition of adenylyl cyclase could not be obtained 
with activated a-subunits of the putative inhibitory G-proteins (Gi). /3y
dimers were shown to have an inhibitory effect on adenylyl cyclase 
activity. A mechanism of hormonal inhibition based on this phenomenon 
was proposed, whereby fty  dimers that were generated by the inhibitory 
receptor quenched the activity of the stimulatory G-protein, Gsa.
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Inhibition was thus proposed to come about by removal of the stimulatory 
signal. However, the finding that eye- S49 lymphoma cells which lacked 
a functional G sa still exhibited normal inhibitory regulation of adenylyl 
cyclase argued against this as the sole mechanism of inhibition (Katada et 
al, 1984a). Later McKenzie and co-workers (1988) demonstrated the 
ability of antibodies specific to Gi2a to suppress receptor mediated 
inhibition of adenylyl cyclase in NG108-15 cells. Recently cDNAs 
encoding persistently activated Gia were expressed in several cell 
systems. Inhibition of, at least some, subtypes of adenylyl cyclase by all 
three Gia subunits was shown to occur (Wong et al, 1991; Lowndes et 
al, 1991; Hermout et al, 1991; Wong et al, 1992; Taussig et al, 1993), 
indicating a direct role for Gia in the inhibition of adenylyl cyclase.
1.8.2.2 Ga activation of phospholipase C
The G-protein mediated activation of the PLC-/3 subclass of 
phospholipase C is specific for the Gq family of heterotrimeric G-proteins 
(Simon et al, 1991). The members of the other G-protein classes have 
not been found to directly activate PLC. The Gq class only activates 
PLC-/3 and not the members o f the b or y  class of phospholipase C 
(Taylor et al, 1990; Wu et al, 1992a, 1992b). Both G a l4 and G a l6 
activate PLC-01 (Wu et al, 1992b), whereas only G a l 6 activates the 
PLC-/32 isozyme (Lee et al, 1992b) to a significant degree.
3 0
Figure 1.3 Structure of adenylyl cyclase isoforms.
Figure 1.3 represents the structure of the eukaryotic adenylyl 
cyclases (adapted from Tang and Gilman, 1992 [Cell 70: 869-872]).
M M .
2a
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Table 1.1 Properties of eukaryotic adenylyl cyclase isoforms
(adapted from Tang and Gilman, 1992 [Cell 70: 869-872]).
Effect of G-proteins
Type Expression G sa Ca2+
1 brain + - +
11 brain, lung + + 0
111 olfactory + 0 +
IV brain, others + + 0
V heart,brain,others + 0 0
VI heart,brain,others + 0 0
rutabaga mushroom body + 0 +
AC-A during aggregation ? ? 7
AC-G fruiting body ? ? ?
CYR1 constitutive 0 0 0
Adenylyl cyclase types 1-V1 are mammalian; rutabaga is from 
Drosophila melanogaster, AC-A and AC-G are from Dictyostelium 
discoideunr, CYR1 is from Saccaromyces cerevisiae. References: type 1 
(Krupinski et al, 1989), type 11 (Feinstein et al, 1991), type 111 (Bakalayer 
and Reed, 1990), type IV (Gao and Gilman, 1991), type V (Ishikawa et 
al, 1992), type VI (Premont et al, 1992; Katsushika et al, 1992), rutabaga 
(Levin et al, 1992), AC-A and AC-G (Pitt et al, 1992) and CYR1 
(Kataoka et al, 1985).
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1.8.3 fiy  regulation of effector molecules
1.8.3.1 The 07 dimer
0  and 7  subunits copurify and although they are not covalently 
linked, denaturing conditions are still required for their separation. To 
circumvent the difficulty in purifying individual 0  and 7  subunits, the 
expression of recombinant 0 and 7  subunits in baculovirus-infected Sf9 
insect cells has allowed the purification of dimers composed of different 
subtypes of 0 and 7  (Robishaw et al, 1992; Graber et al, 1992). The 
functional interaction of the different dimers of 0 7  has thus been 
investigated.
Using the Sf9 baculovirus expression system recent studies have 
revealed that not all of the 0 -subunits can form dimers with all of the 7 - 
subunits. 7 I will associate with 01 but not 02 (Pronin and Gautam, 
1992; Iniguez-Lluhi et al, 1992; Clapham and Neer, 1993). However 7 I 
and 02  are not likely to encounter each other in a physiological situation 
since expression of 7 I appears restricted to photoreceptors, whereas 
these cells have been shown not to express 0 2 .
Studies using chimeric 01/02 subunits have demonstrated the 
involvement of the N-terminal of the 0-subunit in its interaction with the 
7 -subunit (Pronin and Gautam, 1992). Cysteine 25 has been postulated 
to participate in the interaction, however the amino acid sequence 
surrounding this residue is very similar throughout the 0 -subunit family. 
It may be that there are very subtle differences in primary sequence or 
post-translational modifications of the N-terminal of the distinct 0- 
subunits, thus determining the specificity of their interactions with 7 .
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1.8.3.2 Effector regulation by fiy
For a long time it was thought that the G-protein a-subunit 
determined the protein's interaction with receptor and its activation of the 
effector. The first indication that G-protein fiy  subunits could directly 
control effector molecules came from the observation that fiy purified 
from bovine brain activated the cardiac K+ channel normally regulated by 
the muscarinic acetylcholine receptor (Logothetis et al, 1987; Codina et 
al, 1987). More recent evidence has demonstrated that both G a and fiy 
can activate the K+ channel separately (Yamada et al, 1993), although it 
is still uncertain if fiy  subunits activate the channel directly or indirectly 
through activation of an arachidonic acid metabolite produced by 
phospholipase A2 activity (Jelsema and Axelrod, 1987; Kim et al, 1989; 
Kurachi et al, 1989).
Until recently fiy dimers had been assigned an indirect role in the 
regulation of adenylyl cyclase, as described in section 1.8.2.1. The 
cloning of fi and y subtypes and also of adenylyl cyclase isoforms, has 
allowed their co-expression in cells and subsequent functional analysis. 
Using this procedure it has been shown that fiy  regulates adenylyl 
cyclase activity in a subtype specific manner. Whereas fiy inhibits type 
1 adenylyl cyclase when it is stimulated by either G sa or 
Ca2+/calmodullin; fiy greatly potentiates the stimulatory effect of G sa on 
either type 11 or type IV adenylyl cyclase (Tang and Gilman, 1991). 
Inhibition of adenylyl cyclase by fiy  is independent of G sa activation, 
whereas stimulation by fiy  has an underlying prerequisite for the
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stimulation of adenylyl cyclase by Gsa. Other adenylyl cyclases cloned 
to date have been shown to be insensitive to @y.
The PLC-0 isoforms 1-3 have also been shown to be activated by 
fiy  subunits (Rhee, 1991; Stemweis and Smrcka, 1992, Camps et al, 
1992 a,b), PLC/34 however is not activated by fiy  (Clapham and Neer, 
1993). The sensitivity of the different isoforms of PLC-0 to both fiy  and 
G a varies between isoforms (Camps et al, 1992a; Katz et al, 1992; 
Boyer et al, 1992; Smrcka and Stemweis, 1993). Unlike some of the 
adenylyl cyclase isoforms the effect of G a and @y on the activation of 
PLC/3 isoforms are not dependent on each other suggesting separate 
regulatory sites for a  and 0y  on the PLC/3 polypeptide. Expression of 
mutated PLC-jftl in COS-7 cells allowed the identification of the C- 
terminal of PLC-/31 as the site required for activation by Gqa (Wu et al, 
1993). Preliminary evidence suggests that @y binds to the N-terminal of 
the PLC polypeptide (Clapham and Neer, 1993).
The emerging pattern for G-protein regulation of both adenylyl 
cyclases and phospholipase C (Clapham and Neer, 1993) seems to be 
that all forms of the enzyme which are regulated by the heterotrimeric G- 
proteins are regulated by the a-subunits, though the potency with which 
and the extent to which the a-sub units regulate the effector may vary. 
Certainly, the discovery that fiy  can regulate some isoforms of the 
effector proteins alongside G a indicates that one receptor may regulate 
two effectors by merely activating one G-protein, thus giving the 
potential for "cross-talk" between signalling pathways.
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1.9 The structure of G-protein coupled receptors
The first step in the transfer of information from the outside to the 
inside of the cell is the binding of a hormone, neurotransmitter or growth 
factor to a transmembrane receptor which is present on the plasma 
membrane of the cell. Cell surface receptors may be functionally 
classified into several categories, according to the specific signal 
transduction pathways that they stimulate. These classes include
a) growth factor receptors which have intrinsic tyrosine kinase 
activity (for example receptors for insulin, PDGF and EGF)(Hunter and 
Cooper, 1985)
b) multi-subunit receptors which are ion channels (the nicotinic 
acetylcholine, 7 -amino butyric acid and the glycine receptors) (Changeax 
etal, 1987)
c) receptors which function as carrier proteins (transferrin 
receptor)(Goldstein e ta l, 1985)
d) receptors which activate G-proteins (Dohlman et al, 1987; Strader 
et al, 1989a)
1.9.1 The identification of a G-protein coupled receptor
The effect of guanine nucleotides on ligand binding to receptor was 
first noted by Rodbell and co-workers (1971a), with the demonstration 
that the affinity of glucagon binding to the plasma membrane of rat liver, 
was decreased by the presence of guanine nucleotides. Maguire and co-
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workers (1976) were later able to demonstrate that in rat C6G1A glioma 
cell membranes, the binding of /3-adrenergic agonists but not antagonists 
were reduced by the presence of the GTP analogue, Gpp[NH]p. Further 
studies on /3-adrenergic receptors revealed that whilst competition curves 
for antagonist versus radiolabelled antagonist had pseudo Hill coefficients 
close to 1, competition curves for agonist versus radiolabelled antagonist 
are shallower with pseudo Hill coefficients less than 1 (De Lean et al, 
1980). This data suggested the existence of two affinity states of the 
receptor for agonist, but only one affinity state for antagonist. In the 
presence of guanine nucleotides a low affinity state of receptor for 
agonist was adopted, whereas in the absence of guanine nucleotides the 
receptor demonstrated a higher affinity for agonist.
In an attempt to account for the body of data emerging on guanine 
nucleotide effects on ligand binding, De Lean and co-workers (1980) 
proposed a model involving a ternary complex. In the unstimulated state 
the inactive G-protein a-subunit (G-inact), coupled to ffy, may interact 
with the receptor (R), leading to the agonist (H) promoted formation of a 
high affinity ternary complex (H>R>G-inact). In the presence of 
guanine nucleotides which activate Gee, the ternary complex is 
destabilised and both agonist and G-protein can dissociate from the 
receptor.
Although the ternary complex was originally proposed to account 
for the effect of guanine nucleotides on agonist binding to receptors 
linked to stimulation of adenylyl cyclase, ligand binding experiments 
performed on receptor signalling systems linked to the inhibition of 
adenylyl cyclase yielded similar results (U'Prichard et al, 1978; Koski 
and Klee, 1981) and led to the general conclusion that if a receptor's
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affinity is altered by the presence of guanine nucleotides, then that 
receptor functions through the activation of a G-protein.
A large number of individual G-protein coupled receptors have 
now been cloned and sequenced (table 1.2), and the structure and 
function of these receptors has been a subject of much research in recent 
years. G-protein coupled receptors have been subdivided into several 
classes including those for dopaminergic receptors (Vallar and Meldolesi,
1989), muscarinic cholinergic (Birdsall and Hulme, 1983), serotonergic 
(Schmidt and Peroutka, 1989), adrenergic (Lands, 1967; Gilman, 1987) 
and olfactory (Jones and Reed, 1987) receptors which each couple to a 
variety of effectors and ion channels.
When the amino acid sequences of the various cloned G-protein 
coupled receptors were compared the greatest homology was found in 
seven hydrophobic regions each consisting of between 20-25 amino 
acids. Each of these hydrophobic regions is thought to span the plasma 
membrane once, hence the receptor is thought to be composed of seven 
transmembrane helices. The regions of greatest diversity are at the 
receptor's extracellular amino terminus and at the intracellular carboxy 
terminus and cytoplasmic domains (figure 1.4).
Both the ligand bound and the G-protein activated by the receptor 
determines the specific cellular response mediated by it. These two 
structural features of the G-protein coupled receptors have been studied 
in great depth and will be detailed below.
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Table 1.2 The G-protein coupled receptors identified to date
(adapted from Savarese and Fraser, 1992 [Biochem J 283:1-19]).
Peptide receptors
Angiotensin
Adrenocorticotrophin (ACTH)
Bombesin*
Cholecystokinin (CCK)
Choriogonadotrpin*
Corticotropin-releasing hormone 
Follicle-stimulating hormone 
Glucagon
Gonadotrpin-releasing hormone (GnRH) 
Growth-hormone-releasing hormone (GRF) 
Kinins (bradykinin, substance P, substance K)* 
Luteinizing hormone (LH)* 
Melanocyte-stimulating hormone (MSH) 
Neurotensin*
Opiates
Oxytocin
Parathyroid hormone*
Somatostatin 
Thyrotropin (TSH)*
Thyrotropin-releasing hormone (TRH)* 
Vasoactive intestinal polypeptide (VIP)* 
Vasopressin
* Denotes the existence of subtypes of the receptor.
Neurotransmitter receptors
Adenosine*
a-adrenergic*
0-adrenergic*
dopamine*
GABAb
Histamine*
Muscarinic acetylcholine* 
Octopamine*
5-hydroxy-tryptamine (serotonin)*
Sensory systems
Rhodopsins (visual)*
Olfaction*
Taste
Other agents
C5a anaphylatoxin*
Cannabinoids* 
mas oncogene* 
fMet-Leu-Phe*
Prostanoids (PGEs, leukotrienes)* 
Thrombin*
IgE*
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1.9.2 The ligand binding domain of G-protein coupled receptors
A large number of mutagenesis studies have been undertaken to 
elucidate the domains and specific amino acid residues essential for 
agonist and antagonist binding to G-protein coupled receptors. 
Particularly well studied is the &2-adrenergic receptor, and the emerging 
bank of data suggests that there are structural similarities in the ligand 
binding domains of all G-protein linked receptors.
/3-agonists and /3-antagonists exhibit distinct structural similarity. 
The substituents on the aromatic ring determine whether the compound 
activates or blocks the receptor (Andrews et al, 1986) for example the 
catechol-hydroxyl groups of isoprenaline, a full agonist appear to be 
necessary for maximal stimulation of the (32-adrenergic receptor (Strader 
et al, 1989b). Most competitive antagonists, like propranolol, lack these 
essential hydroxyl moieties and therefore do not activate the receptor 
(figure 1.5).
Disulphide bridges formed by cysteine 106 and 184 (Dohlman et 
al, 1990); and cysteine 190 and 191 (Fraser et al, 1989), in the 
extracellular domain of the (32-adrenergic receptor are necessary for the 
high affinity binding of agonists to the receptor. Incubation, and thus 
activation, of the (32-adrenergic receptor with agonists results in 
disulphide bond reduction (Rashidbaigi et al, 1983), and similarly 
incubation with disulphide reducing agents activates the /32-adrenergic 
receptor (Malbon et al, 1987; Pederson and Ross, 1985). It has been 
hypothesised that reversible sulphydryl rearrangements in the 
extracellular domain of the receptor may stabilise the receptor and G sa 
as a high affinity ternary complex and hold the receptor in the active
40
Figure 1.4 General model for the structure of the ^-adrenergic 
receptor (adapted from a similar figure in Jasper and Insel, 1992 
[Biochemical Pharmacology 43:119-130]).
EXTRACELLULAR
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Figure 1.5 0-adrenergic receptor-ligand interaction sites.
Each interaction of a catechol ligand with the 02-adrenergic 
receptor requires the aliphatic hydroxyl and amino groups. The 
catechol-hydroxyl groups of isoprenaline interact with sites on the 0 - 
adrenergic receptor (serine 204 and 207) to elicit the conformational 
changes in the receptor necessary for activation. Propranolol, on the 
contrary, lacks two of these hydroxyl groups not permitting receptor 
activation through a conformational change. The diagram is adapted 
from a similar figure in Jasper and Insel, 1992 (Biochemical 
Pharmacology 43: 119-130).
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A n ta g o n is t (P ro p ra n o lo l)
state, after agonist dissociation, thus promoting the activation of multiple 
Gs molecules.
Photoaffinity labelling studies have demonstrated that the 
hydrophobic domains of the turkey 0-receptors (Wong et al, 1988), the 
human platelet a?2-adrenergic receptor (Matsui et al, 1989) and the D2 
dopamine receptor (Pollock et al, 1992) were involved in ligand binding. 
Biophysical analysis of the 02-adrenergic receptor (Tota and Strader,
1990), bacteriorhodopsin (Bayley et al, 1981; Mullen et al, 1981) and 
bovine rhodopsin (Findlay et al, 1981) also indicated that the ligand 
binding site was present in the hydrophobic core of the receptor. It has 
been proposed that the seven transmembrane spanning regions present in 
G-protein linked receptors form a hydrophobic pocket for ligand binding. 
Residues on the "inside" of this pocket may therefore confer ligand 
binding specificity.
Aspartate 113 (which is located in the transmembrane portion of 
the receptor) is highly conserved among all G-protein coupled receptors 
that bind agonists or antagonists containing a protonated amine group, 
like isoprenaline, propranolol and alprenolol. Mutation of aspartate 113 
to an asparagine in the 0 2 -adrenergic receptor abolished the binding of 0 - 
antagonists and 0-agonists (Strader et al, 1987a). It has been postulated 
that the carboxyl group on residue 113 of the 02-adrenergic receptor 
forms a salt bridge with the amine group present on the 
aryloxyalkylamines, agonist or antagonist. Similar conclusions on the 
role of a similarly positioned aspartate residue in ligand binding have 
been drawn from studies on the oil CIO receptor and muscarinic 
receptors (Fraser et al, 1988). Using a mutant 02-adrenergic receptor 
and chemically engineered agonists, serine 204 and serine 207 (in the
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fifth transmembrane spanning domain of the receptor) were found to form 
a hydroxyl bond with the para- and meta- hydroxyl of isoprenaline 
respectively (Strader et al, 1989b). This gives a model of isoprenaline 
binding to the 0 2 -adrenergic receptor through a carboxy-amine salt 
bridge at aspartate 113 and hydrogen bonds at serines 204 and 207 
(figure 1.5).
More recent work using chimeric receptors points to residues in 
the seventh membrane spanning domain conferring antagonist/agonist 
specificity in 01- and 02- adrenergic receptors (Frielle et al, 1988; 
Suryanarayana and Kobilka, 1993a), « 2-adrenergic receptors (Kobilka et 
al, 1988) and the 5HT1A receptor (Guan et al, 1992). Additional 
findings from studies of the ligand binding domain of 0 -adrenergic 
receptors, and also from parallel studies on a 2-adrenergic receptors 
(Wang et al, 1991), ml muscarinic receptors (Fraser et al, 1989) and D2 
dopamine receptors (Neve et al, 1991) suggest that antagonists and 
agonists bind to distinct sites, and although these sites are not identical 
there is likely to be some overlap. The emerging data suggests that 
although G-protein coupled receptors share common structural domains, 
the molecular interactions between agonists and antagonists and their 
corresponding receptors are specified by a very small change in amino 
acid sequence. Although studies have begun on determining the folding 
and spatial relationships within the 0 2 -adrenergic receptor 
(Suryanarayama et al, 1992) more investigation is needed to fully 
elucidate the structure of the ligand binding domain.
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1.9.3 Identification of the G-protein coupling domains of receptors
The interaction of a receptor with its G-protein is assumed to occur 
on the intracellular face of the plasma membrane, on one of the receptor's 
intracellular loops or its hydrophilic C-terminal tail. The regions of the 
first and second cytoplasmic loops are highly conserved among G-protein 
coupled receptors and this led to the suggestion that the more diverse 
third cytoplasmic loop may be involved in the coupling of the receptor to 
its specific G-protein(s).
Initial studies demonstrated that deletion of two thirds of the third 
intracellular loop resulted in a 0 2 -adrenergic receptor which was 
incapable of activating adenylyl cyclase in mouse L cells (Dixon et al,
1987). More specific deletion mutations in the C-terminal and N- 
terminal of the 0 2 -adrenergic receptor's third intracellular loop again gave 
a marked decrease in receptor activated adenylyl cyclase (Strader et al, 
1987b; O'Dowd et al, 1988; Hausdorff et al, 1990). Similar studies in 
rhodopsin (Franke et al, 1988, 1990) and muscarinic cholinergic 
receptors (Wess et al, 1989) have also demonstrated major roles for the 
N-and C-terminal of the third intracellular loop in G-protein coupling. 
Although the third intracellular loop appears to be essential for G-protein 
coupling, the first and second intracellular loops may also play a minor 
role (O'Dowd et al, 1988; Liggett et al, 1991; Cottechia et al, 1992), 
possibly through allosteric interactions with the third intracellular loop 
and other components of the receptor. Indeed the fifth transmembrane 
spanning domain in both the D2 dopamine receptor and the ocl- 
adrenergic receptor has been demonstrated to be essential for ligand 
binding and receptor activation (Pollock et al, 1992).
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The C-terminal of the third intracellular loop has also been 
implicated as an important site involved in G-protein interaction 
(Kjelsberg et al, 1992; Ren et al, 1993; Samama et al, 1993). All 19 
possible mutations of alanine 293 and threonine 348 in the C-terminal of 
the third intracellular loop of the alB-adrenergic (Kjelsberg et al, 1992) 
and a2C10 (Ren et al, 1993) receptors respectively, confer constitutive 
activity of phospholipase C and an increased affinity for agonists. The 
fact that all the mutations at a single amino acid site in both receptors 
results in an increased activity of the receptor suggests that this region 
may normally function to constrain the G-protein coupling of the 
receptor, a constraint which is normally relieved by agonist occupancy, 
although this awaits formal demonstration.
The C-terminal tail of the G-protein coupled receptors may also be 
involved in determining the receptor's G-protein specificity. Cysteine 
341 in the C-terminal tail of the /32-adrenergic receptor is palmitoylated 
(O'Dowd et al, 1989). Mutant receptors lacking this residue and hence 
lacking palmitoylation are uncoupled from Gs and the receptor is highly 
phosphorylated (O'Dowd et al, 1988), suggesting that this mutation 
promotes the accessibility of specific receptor sites to kinases and leads 
to receptor uncoupling in the absence of receptor activation. Certainly 
acylation of proteins has been to be shown necessary for the translocation 
of proteins to the plasma membrane (James and Olsen, 1990) and it is 
possible that the palmitoylated cysteine 341 in the 02-adrenergic receptor 
forms a fourth intracellular loop by this means. Agonist activation of the 
(32-adrenergic receptor has been shown to result in an increased turnover 
of palmitate on this protein (Mouilliac et al, 1992). The release of 
palmitate is most likely to result in a conformation change, perhaps the 
release of the membrane association of this fourth intracellular loop, and
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the exposure of potential phosphorylation sites. Interestingly, direct 
activation of protein kinase A, by dibutyryl cAMP results in the 
phosphorylation of the consensus PKA sequences located in the third 
intracellular loop but not of the site located near cysteine 341 (Bouvier et 
al, 1989). Phosphorylation of this site may only occur on removal of 
palmitate and thus result in an uncoupling of the receptor from its G- 
protein.
The role of palmitoylation in receptor-G-protein coupling still 
remains controversial. Removal of palmitate from a cysteine residue on 
the C-terminus of the a l  A-adrenergic receptor resulted in no decrease in 
receptor-G-protein coupling (Kennedy and Limbird, 1993). Chemical 
removal of palmitate from a cysteine residue at the C terminus of 
rhodopsin resulted in an enhanced receptor-Gt coupling (Morrison et al, 
1991) whereas mutational analysis showed no perturbed rhodopsin-Gt 
coupling (Kamik et al, 1988). The differing findings observed for 
palmitoylation at this site suggest that receptor acylation may play 
distinct functional roles at different receptor-G-protein interfaces.
1.10 Desensitisation of the j$2-adrenergic receptor on exposure to 
agonist
For most receptors agonist stimulation is followed by 
desensitisation. Desensitisation is characterised by a reduction in the 
response mediated by the receptor over time, despite the continuous 
presence of the stimulus. Of the G-protein coupled receptors the 
mechanism of desensitisation of the /32-adrenergic receptor to agonists
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has been the most widely investigated (Hausdorff et al, 1990; Collins et 
al, 1992).
The mechanism of the agonist mediated desensitisation of the 02- 
adrenergic receptor varies depending on the length of time of agonist 
exposure and the concentration of both agonist and magnesium ions used 
in the assay. Most studies to date have detailed the mechanism of 02- 
adrenergic receptor desensitisation at relatively high concentrations of 
both agonist (fiM) and Mg2+ (mM) and these will be discussed below.
1.10.1 Desensitisation of the 02-adrenergic receptor on short-term 
exposure to agonist
Exposure of the 02-adrenergic receptor to agonist is followed by a 
rapid uncoupling of the receptor from Gs and homologous desensitisation 
of the 02-adrenergic receptor. Initially on agonist binding, the cytosolic 
kinase, 0-adrenergic receptor kinase (0ARK), is translocated to the 
plasma membrane where it phosphorylates the 0 2 -adrenergic receptor 
partially uncoupling it from Gs. The interaction of 0ARK with the 
receptor allows its interaction with a second protein, 0 -arrestin, which 
serves to completely uncouple Gs from the receptor by binding to the 
receptor (Benovic et al, 1987b; Lohse et al, 1990). The receptor is then 
sequestered from the plasma membrane into distinct vesicles within the 
cell (Hertel et al, 1983). A similar mechanism for regulating rhodopsin 
function was found in the visual system (Wilden et al, 1986; Palczewski 
and Benovic, 1991a; Hargrave and McDowell, 1992)
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1.10.1.1 /3-adrenergic receptor kinase
The 80kDa protein /3-adrenergic receptor kinase (jSARK) was 
originally identified as enzyme activity present in a crude cytosolic 
fraction of S49 lymphoma cells which specifically phosphorylated the 
agonist occupied form of the receptor (Benovic et al, 1986). Now 
several isoforms of /3ARK have been cloned namely 0ARK1 (Benovic et 
al, 1989), /3ARK2 (Benovic et al, 1991), rhodopsin kinase (Lorenz et al, 
1991) and Drosophila GPRK1 and GPRK2 (Cassill et al, 1991). Recent 
evidence points to the additional existence of a muscarinic acetylcholine 
receptor kinase (Haga and Haga 1989, 1990). 0ARK is present in a 
number of tissues (Benovic et al, 1987b; Benovic et al, 1989; Arriza et 
al, 1992) and its specificity is poorly defined. It will phosphorylate the 
agonist occupied forms of the human platelet c*2 -adrenergic receptor 
(Benovic et al, 1987a), the chicken heart muscarinic receptor (Kwatra et 
al, 1989), rhodopsin (Palczewski et al, 1988, Lorenz et al, 1991), a 
PGE1 receptor (Strasser et al, 1986), the somatostatin receptor (Mayor et 
al, 1987) and the human muscarinic cholinergic receptors (Richardson et 
al, 1993). It was initially proposed that /3ARK may be a general 
adenylyl cyclase linked kinase, but recently both 0ARK1 and 2 have 
been shown to phosphorylate the substance P receptor, which couples to 
Gq/11 and phospholipase C (Kwatra et al, 1993). Unlike 0ARK, 
rhodopsin kinase exhibits high specificity for rhodopsin and a poor 
affinity for the /32-adrenergic receptor (Palczewski et al, 1991a). 0ARK 
may be a general receptor kinase which functions only on the agonist 
occupied conformation of any G-protein coupled receptor but this 
remains to be established.
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The increased association of PARK  with the plasma membrane on 
agonist occupancy of the receptor has been shown to be promoted by the 
Py subunits of the heterotrimeric G-proteins (Kameyama et al, 1993). 
Py attaches to PARK at its C-terminal 130 amino acids (Koch et al, 
1993). The geranylgeranyl isoprenoid residue on the 7 -subunit of the G- 
protein (Mumby et al, 1990; Simonds et al, 1991) serves as a membrane 
anchor for the kinase (Pitcher et al, 1992; Inglese et al, 1992), allowing it 
to associate with the membrane and phosphorylate the /32-adrenergic 
receptor. Indeed peptide inhibition studies have demonstrated that the 
first and third intracellular loops of the receptor, appear to be essential for 
its phosphorylation by PARK , although phosphorylation appears to be 
predominantly on the C-terminal tail (Benovic et al, 1987a; Bouvier et al, 
1988; Clark et al, 1989).
Py has also been shown to facilitate the activation of the 
muscarinic acetylcholine receptor kinase (Haga and Haga 1990, 1992; 
Kameyama et al, 1993), although phosphorylation of rhodopsin by 
rhodopsin kinase is not stimulated by py  (Kelleher and Johnson, 1988; 
Haga and Haga, 1992). The interaction of /3ARK and indeed the 
muscarinic acetylcholine receptor kinase with different Py dimers could 
potentially be a way for refining receptor substrate specificity. Indeed, 
preliminary studies have shown specific Py dimers to be more potent than 
others in enhancing PARK activity (Muller et al, 1993).
1.10.1.2 /S-arrestin
The 48kDa protein arrestin was originally identified through its 
enhanced binding to phosphorylated and not to unphosphorylated
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rhodopsin (Wilden et al, 1986). Now at least three isoforms of 
mammalian arrestin have been isolated and cloned; arrestin from the 
retina and 0-arrestin 1 (Lohse et al, 1990) and 2 (Attramada et al, 1992) 
from bovine brain. These isoforms exhibit an overall homology of 60%. 
Southern blot analysis suggests there may be as many as four distinct 
genes which hybridise with a 0-arrestm cDNA probe in bovine brain 
(Attramada et al, 1992), indicating the potential for additional isoforms of 
mammalian arrestin to exist.
Unlike 0ARK the arrestins appear to be highly specific in their 
interaction with a receptor, arrestin with rhodopsin and 0 1 - and 0 2 - 
arrestin with the 02-adrenergic receptor. Arrestins bind to their specific 
receptor with a 1:1 stoichiometry (Lohse et al, 1990; Palczewski et al, 
1991b). The most divergent part of the arrestin polypeptide is its C- 
terminal tail. It is tempting to speculate that this region determines 
receptor specificity. Some sequence similarity has been noted between 
the C-terminal tail of arrestin and the C-terminal tail of transducin 
(Shinohara et al, 1987). The C-terminal portion of the G-protein a- 
subunit also interacts with the receptor (Masters et al, 1986). This 
suggests that arrestin/0-arrestin may mimic the G-protein a-subunits and 
bind to receptors at an identical site resulting in the receptor G-protein 
uncoupling.
It has recently been shown that arrestins can bind nucleotides 
(Glitcher and Ruppel, 1989), inositol phosphates (Palczewski et al, 
1991a), Ca2+ ions (Huppertz et al, 1990) and be phosphorylated 
(Matsumoto and Yamada, 1991; Weyland and Kuhn, 1990; Levine et al,
1991). Binding of these small intracellular signalling molecules may 
contribute to the regulation of arrestin function. The existence of
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different subtypes of arrestin, as well as the possibility of modifying the 
proteins via binding of certain ligands or via phosphorylation, may allow 
arrestin to play different roles in cell signalling, and also gives it the 
potential to be involved in "cross-talk" between signalling pathways.
1.10.1.3 Receptor sequestration
Receptor sequestration is the process whereby the plasma 
membrane bound receptor is removed from the plasma membrane but 
remains in the cell, usually in distinct membrane vesicles. On removal of 
agonist the receptor quickly returns to the plasma membrane and is fully 
functional (Hertel et al, 1983). Receptor down-regulation, on the 
contrary, is the means by which a plasma membrane bound receptor is 
internalised and lost completely from the cell.
On exposure to agonist there is a rapid uncoupling of the 02- 
adrenergic receptor from Gs and then a sequestration of the receptor 
away from the cell surface. jS2-adrenergic ligand binding has been 
detected in membrane vesicles distinct from the plasma membrane (and 
devoid of Gs and the adenylyl cyclase catalytic subunit) using a 
combination of hydrophobic and hydrophilic radiolabelled antagonist 
binding (Hertel et al, 1983; Stadel et al, 1983).
Early studies expressing mutant 02-adrenergic receptors in mouse 
L cells suggested a role for Gs coupling in 02-adrenergic receptor 
sequestration (Strader et al, 1987c). However, further studies using 
mutants of the S49 lymphoma cell line have indicated that the presence of 
Gs in the plasma membrane was not a necessity for receptor
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sequestration, but was required for receptor down-regulation (Rich et al, 
1989; Gonzales et al, 1992) (see section 1.10.2.1). There is no strong 
evidence for receptor sequestration being mediated by cAMP, 0ARK or 
PKC (Perkins et al, 1991) and only agonist occupation is clearly required 
for receptor sequestration.
1.10.2 Desensitisation of G-protein coupled receptors on long term 
exposure to agonist
Long term exposure to hormones or agonists is unlikely to occur in 
a physiological situation although it may be important in certain clinical 
conditions (for example in alcoholism where cells are exposed to high 
concentrations of ethanol for long periods of time [Mochly-Rosen et al,
1988]). On long term exposure to agonist the -adrenergic receptor 
undergoes down-regulation and there is a resulting homologous 
desensitisation of adenylyl cyclase. Existing evidence suggests that 
several discrete processes contribute to the regulation of membrane 
associated /32-adrenergic receptor levels on prolonged (hours) exposure 
to agonist. These include, firstly, a proteolytic degradation of the 
receptor protein, and secondly, transcriptional regulation and changes in 
mRNA stability to maintain the new lower levels of receptor expression.
1.10.2.1 Receptor down-regulation
Receptor down-regulation is the process whereby the total cellular 
levels of a particular receptor is decreased on agonist exposure. Down- 
regulation can be demonstrated by the very slow return of the receptor to
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the plasma membrane on removal of agonist, indicating the necessity for 
de novo protein synthesis.
Mutant cell lines with lesions in adenylyl cyclase can still undergo 
receptor down-regulation indicating the cAMP independent nature of the 
effect (Mahan et al, 1985; Gonzales et al, 1989; Hadcock et al, 1989b). 
Additionally, mutant receptors with impaired phosphorylation sites for 
protein kinases can still be both down-regulated and sequestered (Strader 
et al, 1987c; Campbell et al, 1991). Studies using mutant cell lines, 
indicated the necessity for unimpaired receptor-G-protein coupling for 
down-regulation to occur (Gonzales et al, 1989; Rich and Iyengar, 1990).
Several lines of evidence suggest that endocytosis by clathrin 
coated vesicles is the mechanism whereby 02-adrenergic receptors are 
sequestered (Hertel et al, 1985; Hertel et al, 1986; Heuser et al, 1989; 
Liao et al, 1990). Tyrosine residues in the C-terminal tail of several G- 
protein coupled receptors have been implicated in agonist induced 
endocytosis (Davis et al, 1986; Vega and Strominger, 1989; Lobel et al,
1989). Certainly Valinquette and co-workers (1990) have demonstrated 
the involvement of two tyrosine residues in the C-terminal tail of the 02- 
adrenergic receptor in receptor down-regulation. Mutations of these 
tyrosine residues also affect G-protein coupling again suggesting that G- 
protein coupling is a necessity for down-regulation. Although there have 
been findings to the contrary (Hertel et al, 1990; Hausdorff et al, 1991) 
the majority of the evidence to date indicates a role for the C-terminal of 
G-protein coupled receptors in receptor down-regulation (Liggett et al, 
1993; Nussenzveig et al, 1993)
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Receptor-G-protein coupling and hence the C-terminal of the 02- 
adrenergic receptor appear to both be involved in determining receptor 
down-regulation. However conflicting evidence exists for the 
involvement of G-protein coupling and the receptor's C-terminal in 
receptor sequestration. Indeed it has yet to be established unequivocally 
whether receptor sequestration and down-regulation are distinct 
processes acting through different pathways, or if the two processes are 
sequential. Agonist regulated internalisation of the 02-adrenergic 
receptor shares common cellular components used by the constitutively 
recycling receptor for transferrin (von Zastrow et al, 1992). Having 
shown that 0 2 -adrenergic receptors are internalised into endosomes von 
Zastrow and co-workers (1992) have suggested that endosomes may be a 
common branchpoint in recycling and protein sorting to lysosomes. This 
hypothesis is however difficult to reconcile with the fact that the avian 
02-adrenergic receptor does not undergo sequestration (Hertel et al, 
1990) and that mutant receptors and cell lines with impaired receptor-G- 
protein coupling will undergo down-regulation but not sequestration. 
Indeed, more investigation is needed to fully elucidate the fate of the 
receptor after internalisation.
1.10.2.2 Regulation of gene expression
The marked increase in intracellular cAMP observed following 
agonist binding to the 0 2 -adrenergic receptor leads to the activation of 
many cellular substrates, including members of the CREB family of 
transcription factors (Karpinski et al, 1992 and references therein). 
Activation of CREB, through a cascade of events, results in its binding to 
the cAMP response element (CRE) in the 5' promoter region of the 02-
55
adrenergic receptor gene (Collins et al, 1990), which in turn increases the 
rate of transcription, leading to a transient increase in receptor 
expression.
A sustained decrease in 02-adrenergic receptor mRNA levels on 
prolonged agonist exposure has been observed (Hadcock and Malbon, 
1988), in both DDT1-MF2 hamster vas deferens cells and S49 lymphoma 
cells, and is a result of an increased destabilisation of the receptor mRNA 
(Hadcock et al, 1989a). It is partially dependent on cAMP (Hadcock et 
al, 1989b; Hough and Chuang, 1990). The actual sequences necessary 
for destabilisation of the receptor mRNA remain to be determined, but 
the 02-adrenergic receptor mRNA contains the consensus destabilisation 
sequences (AUUUA) in its 3' non-coding region. Recently proteins have 
been identified that bind to AUUUA sequence in RNA coding for 
lymphokines and proto-oncogenes (Gillis and Malter, 1991; Bohjanen et 
al, 1991). The complexing of RNA with such adenosine-uridine binding 
factors has been suggested to regulate RNA degradation. The mRNA 
poly A tract length has also been implicated in the regulation of mRNA 
stability (Bernstein and Ross, 1989).
1.10.3 Heterologous desensitisation of the 02- adrenergic receptor
A brief synopsis of the heterologous desensitisation of the 02- 
adrenergic receptor will be detailed below. Heterologous desensitisation 
and "cross-talk” between signalling pathways in a variety of systems will 
be discussed in greater depth in the forthcoming chapters. Heterologous 
desensitisation is the process whereby a response mediated through one
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receptor is desensitised through activation of a distinct receptor. It has 
been demonstrated with receptors that activate the same signalling 
pathway or distinct pathways, and is usually mediated through some 
component of the signal transduction cascade downstream of the 
receptor, for example the G-protein, the effector or the second 
messenger. The most widely characterised mechanism of heterologous 
desensitisation of the 02-adrenergic receptor is its phosphorylation by the 
protein kinases A and C, which are activated by the second messengers 
cAMP and DAG (diacylglycerol) respectively.
Early studies using mutant S49 cell lines that demonstrated that 
heterologous desensitisation did not require either cAMP or G sa, led to 
the conclusion that cAMP-dependent protein kinase played little or no 
role in this desensitisation (Green and Clark, 1981). The finding that 
concentrations of free Mg2+ in cell free assays of adenylyl cyclase 
exceeding l-2mM obscured the cAMP-dependent and PKC-mediated 
desensitisations, whereas assays in the physiological range of free Mg2+ 
for S49 cells (0.2-0.6mM) allowed the observation of the cAMP- and 
PKC-induced heterologous desensitisations (Clark et al 1987, 1988; 
Johnson et al, 1986, 1990), led workers to reconsider.
The site of phosphorylation on the 02-adrenergic receptor by both 
PKA (Clark et al, 1989; Hausdorff et al, 1989) and PKC (Johnson et al,
1990) was found to be in the third intracellular loop of the receptor. 
Similarly PKA consensus sequences in the third intracellular loop of the 
Ml muscarinic receptor (which activates PLC) have been implicated in 
mediating its heterologous desensitisation (Lameh et al, 1992; Lee and 
Fraser, 1993). This same region is involved in receptor-G-protein 
coupling suggesting that phosphorylation of the receptor by PKA (Kunkel
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et al, 1989) or PKC during desensitisation uncouples it from its G- 
protein. Recently, studies on reconstituted liposomes have demonstrated 
that the cAMP-mediated effect requires only the receptor and the 
receptor-Gs interaction and PKA mediated phosphorylation appears to 
disrupt the receptor-G-protein coupling (Bouvier et al, 1987; Pitcher et 
al, 1992).
The demonstration that the 02-adrenergic receptor can be 
phosphorylated by PKC, and that the M l muscarinic receptor can be 
phosphorylated by PKA, clearly suggests the existence of "cross-talk” 
between signalling pathways, although the exact role of these 
modifications remain to be determined. There is obviously the potential 
for other proteins to contribute to heterologous desensitisation. 
Modification of G-protein a-subunit levels during prolonged exposure to 
agonist has become an increasingly documented phenomenon, and 
recently much work has been focused on determining its role in 
heterologous desensitisation.
1.11 Regulation of cellular G-protein levels
Prolonged exposure of the HM1 receptor in CHO cells (Mitchell et 
al, 1993), the GnRH receptor in aT3 cells (Shah and Milligan, 
unpublished observations) and the TRH receptor long form in EMBK 
cells (Kim and Milligan, unpublished observations) to agonist results in a 
non-selective down-regulation of Gq/llo'. In rat adipocytes agonist 
treatment of the Al adenosine receptor results in a 90% decrease in 
membrane associated levels of Gilo: and GiBcx and a 50% decrease in 
Gi2a and 0-subunit (Green et al, 1990). Treatment of NG108-15 cells
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with PGE1 (an agonist at the IP prostanoid receptor) results in an 
approximate 50% loss of membrane associated G sa (McKenzie and 
Milligan, 1990). The mechanism behind the down-regulation of the G- 
protein a-subunit remains to be unequivocally determined, however 
evidence exists for control at the level of transcription (Hadcock et al,
1990) and protein degradation (Mitchell et al, 1993).
Enhanced proteolysis of the G-protein a-subunit has been shown 
to follow prolonged agonist treatment of the receptor (Green et al, 1992; 
Mitchell et al, 1993). The mechanism behind the proposed proteolysis 
has been the subject of much investigation. Treatment of cells with 
cholera toxin permanently activates the Gso: subunit. Cholera toxin 
catalyses the transfer of an ADP-ribose moiety to Gso: in the presence of 
NAD+ and a 20kDa GTP binding protein, ARE (ADP-ribosylating 
factor), which is necessary for cholera toxin function (Schleiffer et al, 
1982). Cholera toxin treatment of NG108-15 cells and rat liver 
membranes resulted in a cAMP-independent decrease in Gsc* present at 
the plasma membrane (MacLeod et al, 1989; Lynch et al, 1990) with no 
change in G sa mRNA levels. In GH3 cells Chang and Bourne (1989) 
demonstrated that activation of G sa by cholera toxin enhanced its rate of 
proteolytic degradation. It is uncertain if the increased proteolytic 
degradation is a result of the dissociation of G sa from Py, or of the ADP- 
ribosylation of the protein, or indeed of some other less well- 
characterised post-translational modification (see section 1.7).
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1.11.1 The involvement of the ADP-ribosylation of Gsa in its down- 
regulation
The hypothesis that the adenylyl cyclase cascade is regulated 
through endogenously, reversible (mono) ADP-ribosylation of the G sa 
protein by mono (ADP-ribosyl) transferases and ADP-ribose 
glycohydrolase has been investigated (Tanuma et al, 1987, 1988; 
Tanuma, 1990; Tanuma and Endo 1989, 1990). Certainly, endogenous 
ADP-ribosylation of Gso: has been demonstrated in chicken spleen 
(Obara et al, 1991), human platelets (Inageda et al, 1991) and rat 
adipocytes (Jacquemin et al, 1986). Recent studies from Donnelly and 
co-workers (1992) demonstrated that inhibition of the mono (ADP- 
ribosyl) transferases increased the membrane associated levels of G sa in 
NG108-15 cells, indicating a potential role for ADP-ribose in releasing 
Gso: from the plasma membrane.
The discovery that ADP-ribosylation of G sa was capable of 
regulating its membrane associated levels suggested that agonist 
treatment of cells may result in the activation of a mono (ADP-ribosyl) 
transferase, ADP-ribosylating G sa and thus activating it and releasing it 
from the plasma membrane. This was shown not to be the case for the 
IP prostanoid receptor which couples to G sa in NG108-15 cells 
(Donnelly et al, 1992). It remains to be unequivocally determined 
whether agonist induced ADP-ribosylation is the mechanism whereby 
G sa is lost from the plasma membrane of other cells by distinct 
receptors. Treatment of mouse mastocytoma cells with both a prostanoid 
(activating adenylyl cyclase via Gsa) and cholera toxin, resulted in an 
additive activation of adenylyl cyclase and G sa release, indicating that in
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this cell line the two processes appear to involve different mechanisms 
(Negishi et al, 1992).
1.11.2 The involvement of G-protein activation in Ga 
down-regulation
Ransnas and co-workers (1992) demonstrated that the release of 
G sa from the plasma membrane is likely to accompany Gs subunit 
dissociation. Certainly, Gsa is less hydrophobic than the holomeric Gs 
and is thus more soluble and attracted to the cytosol (Stryer and Bourne, 
1986; Stemweis, 1986; Neer and Clapham, 1988). Levis and Bourne 
(1992) showed an increased degradation rate of Gsa on release from the 
plasma membrane after agonist activation of S49 lymphoma cells. This 
enhanced proteolysis was not a direct result of the loss of membrane 
attachment, and the authors suggest that the conformational change in G sa 
induces the loss of membrane attachment.
Whether receptor activation results in a promotion of the rate of 
degradation of the G-protein by a conformational change, which allows 
greater access to a proteolytic enzyme, or from a covalent modification 
(or loss of one) of the G-protein a-subunit, or a combination of these will 
remain a subject of much research in forthcoming years.
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1.12 Research aims
The role the receptor plays in the agonist mediated control of G- 
protein a-subunit levels has still to be fully determined. In some cells 
both the receptor and G-protein a-subunit are down-regulated on 
prolonged agonist treatment, and in others only the G a or receptor is 
down-regulated. Chapter 3 aims to further examine the role of the 
receptor in G sa down-regulation. The effect of varying the levels of 
receptor expression, by cellular transfection, on the agonist mediated 
down-regulation of the G-protein a-subunit will be examined and 
discussed in later chapters.
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CHAPTER 2 - MATERIALS AND METHODS
Materials and Methods
Materials
All materials were of the highest quality available and obtained 
from the following suppliers;
2.1.1 General reagents
BRL, Paisley, Scotland
Prestained molecular weight markers, Lipofectin reagent, 
restriction enzymes, restriction enzyme react buffers, agarose.
Bio 101 Incorporated, Stratech Scientific Ltd., Luton, UK.
Geneclean kit.
Boehringer (UK) Ltd, Lewes, East Sussex, UK.
GTP7 S, GppNHp, GDP, GDP/3S, AppNHp, dithiothreitol, creatine 
phosphate, creatine phosphokinase, triethanolamine hydrochloride, tris, 
thymidine.
DIFCO Laboratories, Detroit, Michigan, USA.
Bacto-agar.
Lab. Supplies, Loughborough, UK.
Acrylamide, N,N'-methylenebisacrylamide, hydrogen peroxide.
Koch-Light Lab.Ltd, Haverhill, Suffolk, UK.
DMSO, sodium potassium tartrate.
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M and B, Dagenham, UK.
Ammonium persulphate.
National Diagnostics, Aylesbury, Buckinghamshire, UK.
"Ecoscint" scintillation fluid.
New England Biolaboratories, Bishop's Stortford, Herts., UK 
DNA molecular weight standards.
Promega, Chilworth Research Centre, Southampton, UK.
T4 DNA ligase.
Schering Health Care, Burgess Hill, Sussex, UK.
Iloprost.
Sigma Chemical Company, Poole, Dorset.
Cholera toxin, bovine serum albumin, NAD, TEMED, trypsin, 
arginine hydrochloride, N-ethylmaleimide, o-diansidine hydrochloride, 
ATP disodium salt, cAMP sodium salt, Coomassie blue R-250, 
Bromophenol blue, thimerosal, Protein A Sepharose, Dowex AG50W-X4 
(200-400 mesh), Alumina (neutral), forskolin, (-) propranolol, (-) 
isoproterenol [(+) bicarbonate salt], PGE1.
Whatman International Ltd. Maidstone, UK.
GF/C Glassfibre filters, 3mm Chromatography paper, No 1 filter
paper.
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All other reagents used were obtained from BDH (Dorset, 
Poole,England).
2.1.2 Tissue culture plasticware
A. and J. Beveridge Ltd., Edinburgh, Scotland.
Falcon tissue culture 100mm petri dishes.
Bibby Science Products Ltd, Stone, Staffordshire, UK.
75cm2 tissue culture flasks.
Costar, 205 Broadway, Cambridge M.A., U.S.A.
Biofreeze vials.
Elkay Products, Shrewsbury, M.A., U.S.A.
50ml centrifuge tubes.
2.1.3 Cell culture media
GIBCO Life Technologies, Paisley, U.K.
Dulbeccos' modification of Eagles’ medium (lOx), Donor calf 
serum, glutamine (200mM), sodium bicarbonate, HAT (50x): 
hypoxanthine (0.1 mM), aminopterin (ImM), thymidine (16mM), 
penicillin (100 I.U./ml) and streptomycin (lOOmg.ml) (lOOx).
Imperial Labs., West Portway, Andover, Hants., UK.
Foetal calf senim, normal calf serum.
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Sigma Chemical Company, Poole, Dorset, UK.
CPSR-3.
2.1.4 Radiochemicals
Amersham PLC, Amersham, Buckinghamshire.
[8-3H] Adenosine 3',5'-cyclic phosphate, ammonium salt (26Ci/mmol) 
Adenosine 5'-[a-32P] triphosphate, triethylammonium salt (400Ci/mmol) 
[3H]-Prostaglandin E l (54Ci/mmol)
[3H]-Dihydroalprenolol (56Ci/mmol)
2.1.5 Standard buffers
Phosphate buffered saline (lOx PBS)
2g potassium chloride 
80g sodium chloride
2g potassium dihydrogen orthophosphate
11.4g disodium hydrogen orthophosphate, heptahydrate 
to a final volume of 1 litre, pH 7.4.
2.1.6 Molecular biology tools
The cDNA for the /32-adrenergic receptor was a kind gift from Dr 
S. Griffiths, Department of Biochemistry, University of East Anglia, UK.
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The plasmid pJM16 (LK444) was a kind gift from Dr John Miles, 
Department of Biochemistry, University of Glasgow, UK.
The plamid pSVL was a gift from Dr Yasmin Shakur, Department 
of Biochemistry, University of Glasgow, UK.
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Methods
2.2 Cell Culture
2.2.1 Cell growth
NG108-15 neuroblastoma x glioma hybrid cells were a kind gift 
from Dr W. Klee (N.I.H., Bethesda, M.D. USA). NG108-15 cells, 
/3N22 and /3N17 cells were grown in 75cm2 tissue culture flasks in 
0.0375% (w/v) sodium bicarbonate buffered Dulbecco's modification of 
Eagle's Medium (DMEM), containing 10% (v/v) CPSR-3 which had been 
heat inactivated at 56°C for 2 hours. The medium was supplemented 
with glutamine (2mM), hypoxanthine (0.1 mM), aminopterin ( lpM) and 
thymidine (16juM). Both penicillin (100 units/ml) and streptomycin 
(lOOmg/ml) were routinely included. This medium will henceforth be 
termed DMEM/10% (v/v) CPSR. /3N clones were selected for by the 
addition of 0 .8mg/ml geneticin sulphate to the growth medium.
S49 lymphoma and eye- cells were a kind gift from Dr K. P. Ray 
(Glaxo Group Research Ltd, Greenford, Middlesex, U.K.). They were 
grown in 25cm2 tissue culture flasks in 0.0375% (w/v) sodium 
bicarbonate buffered Dulbeccos' modification of Eagles' Medium 
(DMEM), containing 10% (v/v) foetal calf serum which had been heat 
inactivated at 56°C for 2 hours. This medium was supplemented with 
glutamine (2mM), penicillin (100 units/ml) and streptomycin (lOOmg/ml). 
These cells were maintained in cell culture at a density of between 5 x 
105 - 2 x 106 cells/ml medium.
68
COS-1 cells (a kind gift from Dr Yasmin Shaknr; Biochemistry 
Department, University of Glasgow) were grown in DMEM/10% (v/v) 
FCS supplemented with glutamine (2mM), penicillin (100 units/ml) and 
streptomycin (lOOmg/ml) as described for S49 lymphoma cells. COS-1 
cells were subcultured in a manner identical to NG108-15 cells.
All cell types were grown in a humidified atmosphere of 5% 
C 0 2/95% air.
2.2.2 Cell subculture
Confluent cells (approximately 107 cells per 75cm2 flask) were 
passaged using 0.1% (w/v) trypsin, 0.67mM EDTA and lOmM glucose 
in PBS (xl). Growth media was removed from the cells and 3ml trypsin 
solution added. When the cells had been removed from the surface of 
the flask, trypsinisation was stopped by the addition of three volumes of 
growth medium. This cell suspension was centrifuged at 800 x g in an 
MSE centaur centrifuge for two minutes to pellet the cells. The cell 
pellet was resuspended in growth medium and plated out as required.
2.2.3 Cell maintenance
Confluent cells were removed from the surface of the flask by 
trypsinisation and the cells resuspended in freezing medium, which 
consisted of 8% (v/v) DMSO in CPSR (for NG108-15 cells and j8N 
clones) or 8% (v/v) DMSO in FCS (for S49 lymphoma and COS-1 cells). 
This suspension was aliquoted into 1.0ml volumes into Biofreeze vials,
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frozen overnight packed in cotton wool at -80°C, and then transferred to 
liquid nitrogen for storage.
Cells to be brought up from liquid nitrogen storage were thawed 
immediately at 37°C, resuspended in 10ml appropriate growth medium, 
and centrifuged at 800 x g in an MSE centaur centrifuge for two minutes 
to pellet the cells. In the case of NG108-15 cells, /3N clones and COS-1 
cells the cell pellet was resuspended in growth medium and plated out in 
a final volume of 10ml in a 75cm2 flask. For S49 lymphoma cells the 
pellet was resuspended in 1ml growth medium, the cell number was 
counted using a haemocytometer, and the pellet resuspended in an 
appropriate volume of growth medium to ensure the cells were 
maintained between 5xl05 - 2xl06 cells/ml medium.
2.2.4 Cell harvesting
When confluent, growth medium was removed from the cell 
culture flask and 10 ml ice cold PBS (xl) added. Cells were gently 
washed from the surface of the flask, collected in a 50ml centrifuge tube 
and centrifuged at 800 x g in a Beckman TJ6 centrifuge for 5 minutes. 
The resulting cell pellet was washed with ice cold PBS (xl) and re­
centrifuged. The final pellet was stored at -80°C until use. Pellets 
which had been stored for up to one year were found to retain full 
activity.
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2.3 Production of a crude membrane preparation
Membranes were prepared according to Koski and Klee (1981). 
Frozen cell pellets were thawed and suspended in approximately 4ml ice 
cold lOmM Tris-HCl, 0.1 mM EDTA pH 7.5 and homogenised with 25 
strokes of a Potter homogeniser.
The homogenate was centrifuged at 500 x g for 10 minutes in a 
Beckman L5-50B centrifuge with a Ti50 rotor, to remove unbroken cells 
and nuclei. Plasma membranes were collected by centrifugation of the 
supernatant at 48,000 x g for 10 minutes, washed in 5ml of the same 
buffer and after a second centrifugation, were resuspended in the same 
buffer to a final protein concentration of between 1-4 mg/ml, aliquoted, 
and stored at -80°C until required.
2.4 Protein determination
The method used was based on that of Lowry et al, 1951.
Stock solutions
2% (w/v) sodium carbonate in 0.1 M sodium hydroxide.
1 % (w/v) copper sulphate 
2% (w/v) sodium potassium tartrate
Just prior to use the stock solutions were mixed in the following 
ratio A:B:C 100:1:1 to produce solution D.
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Protein standards were prepared using a 1 mg/ml bovine serum 
albumin fraction V, and a standard curve constructed for a maximum of 
25pg protein per sample. Unknowns were assayed in 2 and 4pl volumes 
in duplicate. 1ml solution D was added to each sample, mixed and left 
to stand for 10 minutes. lOOgl Folin's Ciocalteau reagent diluted 1:1 with 
H2O was added to each sample, mixed and allowed to stand for a further 
20 minutes. The absorbance of light by each sample was assessed 
spectrophotometrically at 750nm in an LKB Ultrospec 2 
spectrophotometer.
2.5 Antibody production
All antisera were generated against synthetic peptides, essentially 
as described by Goldsmith and colleagues, (Goldsmith et al, 1987). 
Synthetic peptides were obtained from Dr. C.G. Unson, the Rockefeller 
University, New York, U.S.A. with the exception of the peptide 
NLKLEDGISAAKDVK, which was synthesised by Dr. A. I. Magee, 
N.I.M.R., Mill Hill, London, and the peptide KNNLKECGLY which was 
obtained from Biomac Ltd., Glasgow, U.K.
A range of anti sera were produced in a similar manner as 
summarised in table 2.1
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Table 2.1 The generation of G-protein subunit-specific antisera
Antiserum Peptide used G protein sequence Antiserum
identifies
IMI NLKEDGISAAKDVK Goa22-35 Goa
I3B KNNLKECGLY Gi3a345-354 Gi3a
CS1 RMHLRQYELL Gsa385-39 Gsa
BN1 MSELDQLRQE G01-1O 181,182
CQ2 QLNLKEYNLV Gqa351-360 
G i la  350-359
G q /lla
SGI KENLKDCGLF Tda341-350 Gi2a,
G ila
Tda
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2.6 Gel electrophoresis
Gel electrophoresis was carried out according to the method of 
Laemmli (1970).
2.6.1 Resolving gel preparation
Stock solutions (stored at 4°C)
Solution A 1.5M Tris, 0.4% (w/v) SDS, pH 8.8 with HC1.
Solution B 0.5M Tris, 0.4% (w/v) SDS, pH 6.8 with HC1
Solution C 30% (w/v) Acrylamide, 0.8% (w/v) N ,N-
methylene bisacrylamide 
Solution D 50% (v/v) glycerol
Solution E 10% (w/v) Ammonium persulphate (made daily)
Solution F TEMED
Reservoir Buffer; 0.025M Tris, 0.192M Glycine, 0.1% (w/v) SDS, pH
7.5.
10% (w/v) acrylamide/0.25% (w/v) N,N'-methylene-bisacrylamide 
gels were prepared from the stock solutions as follows:-
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Solution Volume (ml) 
6 
8
A
C
D 1.6
0.09
0.008
E
F
To a final volume of 24ml with H2O.
The solution was immediately mixed and poured into a Bio-Rad 
Protean 11 gel casting apparatus, which consisted of 200 x 200 mm glass 
plates with 1.5mm spacers. The gel was layered with 0.1% (w/v) SDS 
to exclude air and left to set at room temperature for approximately 2 
hours.
2.6.2 Stacking gel preparation
Solution Volume (ml)
B 3.75
C 1.5
E 0.15
F 0.008
To a final volume of 15ml with H2O.
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The solution was mixed, layered on top of the resolving gel and 
allowed to polymerise around a 15 well Teflon plate. Electrophoresis 
was performed overnight at 60V.
2.6.3 Sample preparation by protein precipitation
Samples were prepared for gel electrophoresis by sodium 
deoxycholate/trichloroacetic acid precipitation; 6.25pi of 2% (w/v) 
sodium deoxycholate was added to each sample, followed by 750pl of 
H2O, and then 250pl of 24% (w/v) trichloroacetic acid. Samples were 
centrifuged in a microfuge at 12000 x g for 10 minutes, after which time 
the supernatants were removed and the pellets dissolved in 20pl of 1M 
Tris base followed by 20pl of Laemmli buffer, which consisted of 5M 
urea, 0.17M SDS, 0.4M DTT, 50mM Tris-HCl pH 8.0, 0.01% (w/v) 
bromophenol blue.
2.6.4 Gel protein staining
After electrophoresis, the gel was placed in a tray on a stirring 
table and covered in stain solution which consisted of 0 .1% (w/v) 
Coomassie blue in 50% (v/v) H2O, 40% (v/v) methanol, 10% (v/v) 
glacial acetic acid for approximately 1 hour. The stain solution was 
discarded and the gel soaked in destain solution (identical to stain 
solution but lacking Coomassie blue) until excess stain had been removed 
to leave a clear background, and the proteins were apparent on the gel in 
discrete bands.
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2.6.5 Western blotting
Proteins were separated under appropriate resolving conditions on 
SDS polyacrylamide gels overnight at 60V. The proteins were 
transferred to a nitrocellulose sheet for 2 hours at 1.5mA in an LKB 
transblot apparatus (Towbin et al, 1979) with blotting buffer which 
consisted of 0.192M glycine, 25mM Tris, 20% (v/v) methanol. The 
sheet was then "blocked" for 2 hours in 5% (w/v) gelatin in PBS (lx), 
after which time the gelatin was washed off with distilled water and the 
nitrocellulose sheet incubated for at least 2 hours at 30°C with the 
appropriate dilution of antiserum in 1% (w/v) gelatin in PBS/0.2% (v/v) 
NP40. The antiserum was then removed and the nitrocellulose sheet 
given two ten minute washes with PBS/0.2% (v/v) NP40, after which the 
blot was incubated with a second antibody (peroxidase conjugated goat 
anti-rabbit IgG) for at least 2 hours at 30°C. The second antibody was 
then removed and the sheet subjected to two ten minute washes in PBS 
(xl). The blot was then developed in 40ml PBS (xl) pH 7.4 with 
0.025% (w/v) o-diansidine as substrate. Development of the blot was 
initiated by the addition of up to 2 0 pi of hydrogen peroxide, and then 
stopped by immersion of the blot into sodium azide ( 1% w/v).
First antibodies could be reused up to three times and second 
antibodies could be reused twice. Both antibodies were stored at 4°C 
using 0.004% (w/v) thimerosal as an anti-bacterial reagent.
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2.6.6 Quantitation of immunoblots
Initially immunoblots were quantified by overlaying the 
colorimetrically developed blot with [125I]-labelled goat anti-rabbit IgG 
(O.ljiCi/ml) in 1% (w/v) gelatin / PBS (xl) / 0.2% (v/v) NP40 for 2 
hours. After extensive washing firstly with PBS / 0.2% (v/v) NP40 and 
then with PBS (xl), the blot was air-dried, the coloured bands were 
excised and the radioactivity was assessed in a gamma radiation counter.
The acquisition of a Shimadzu Flying Spot Scanning machine 
allowed the colorimetrically developed blots to be densitometrically 
scanned and the results were expressed as a percentage of control values.
2.7 Radioligand binding assay
Binding assays were performed by the rapid filtration method as 
described by Pert and Snyder (1973), in lOmM Tris-HCl, 50mM sucrose, 
20mM magnesium chloride pH 7.3, containing 5-100gg of membrane 
protein and radiolabelled ligand in a final volume of 250pl. Non-specific 
binding was assessed in parallel tubes containing an appropriate drug. 
Blank values were determined by replacement of membrane protein with 
buffer.
The assay was initiated by the transferral of tubes to a 30°C water 
bath for 30 minutes, after which time the tubes were removed to ice. 
The samples were then rapidly filtered through Whatman GF/C glassfibre 
filters which had been presoaked in assay buffer, followed with three 
washes of the filter with 5ml ice cold assay buffer using a Brandell Cell
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Harvester. Initially, before the acquisition of the Brandell Cell 
Harvester, a ten well binding manifold was used, samples were spotted 
on to Whatman GF/C filters and the filters washed three times with 5ml 
ice cold buffer. Filters were soaked overnight in Ecoscint scintillation 
fluid prior to counting in a Rackbeta scintillation counter.
In some instances, the binding data was manipulated according to 
the equations derived by Scatchard (1949) or DeBlasi et al, 1989.
2.8 Adenylyl cyclase assay
This was essentially the method of Salomon and co-workers 
(1979), except that the amount of [a-32P]-ATP was reduced to lpCi per 
sample. This assay measures the production of [32P]-cAMP from the 
substrate [ce-32P]-ATP. The cAMP thus produced is separated from the 
unreacted [a-32P]-ATP by a two-step column method.
2.8.1 Sample preparation
Reaction mixtures of 50pi containing; 4mM creatine phosphate, 
lOOmM NaCl, lOOU/ml creatine phosphokinase, 200mM Tris.HCl pH
7.5, lOmM magnesium chloride, 0.4mM ATP pH 7.5, 2.0mM cAMP, 
2.0pM GTP pH 7.5, [a-32P]-ATP (lxlO 6 cpm), were added to tubes 
containing between 5-20gg membrane protein and the appropriate ligands 
to a final volume of lOOpl. Reaction tubes were kept on ice at all times 
and the reaction started by removal to a 30°C water bath. After 15 
minutes the reaction was terminated by removal to ice and the addition of
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lOOpl stopper solution which comprised 2% (w/v) SDS, 45mM ATP, 
1.3mM cAMP. 50pl of [8-3H]-3'5'cAMP (approximately 10000 cpm) 
was added to each tube prior to boiling for 10 minutes. 750gl H2O was 
then added to each sample, and the [32P]-cAMP content of each tube 
determined.
2.8.2 Preparation of Dowex and Alumina columns
The method used to quantitate the amount of cAMP produced by 
each sample was identical to that of Salomon (1979) and involves the 
separation of cyclic AMP from other nucleotides by Dowex and then 
Alumina chromatography. Dowex H+ 50x4(200-400) was washed in 
twice its volume of firstly, 1M hydrochloric acid, then 1M NaOH and 
finally 1M Hydrochloric acid. The Dowex was mixed with water to a 
slurry (1:1 v/v) and then 2ml removed and added to glass wool stoppered 
columns. The water was allowed to drain out and the columns washed 
with 2ml 1M hydrochloric acid and stored at room temperature. Prior to 
use, the columns were washed with 4ml 1M NaOH and then 4ml 1M 
hydrochloric acid followed by 20ml water.
The alumina columns were prepared by the addition of l.Og dry 
neutral alumina to glass wool stoppered columns and the columns washed 
with 12ml 1M imidazole buffer pH 7.3 followed by 15ml 0.1M imidazole 
pH 7.3 and then stored at room temperature. On the day of use, each 
column was washed with 8ml 0.1M imidazole pH 7.3.
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2.8.3 Separation of cAMP on Dowex columns
Prior to sample chromatography, the nucleotide elution profiles for 
each column were determined. This was performed by applying [3H]- 
cAMP to the columns and determining the elution volume.
Stock [3H]-cAMP was diluted in water to give approximately 
10000 cpm in 50gl. 50gl cAMP solution were added to 950pl of water 
and applied to a Dowex column. The cAMP was eluted from the column 
by successive washes of the column with 0.5ml water. Fractions were 
collected in a vial with 5ml Ecoscint and radioactivity determined by 
scintillation counting using a dual label programme. The elution volumes 
required to elute the cAMP from the Dowex columns were then 
determined graphically. Recovery from the Dowex columns was always 
greater than 70%.
The elution volume required to elute the cAMP from the alumina 
columns was determined as for the Dowex columns except the eluting 
buffer was 0.1M imidazole pH 7.3. Recoveries were similar to that 
obtained for the Dowex columns.
2.8.4 Determination of cAMP produced by membrane fractions
Samples (total volume 950pi) were added to prepared Dowex 
columns and the ATP eluted with 0.5ml water. 6.0ml water was then 
added to the Dowex columns and this eluate allowed to run directly onto 
the alumina columns. The cAMP fraction was eluted into vials 
containing 14 ml Ecoscint, with 6ml 0.1M imidazole pH 7.3. The
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recovery of cAMP from the columns was routinely greater than 75%, 
when recovery fell below 60% the columns were discarded and fresh 
columns prepared. This gave a column life of approximately 6 months.
The cAMP fractions obtained were counted on a dual label 
scintillation counting programme which automatically corrected for 
spillover from each channel. The amount of cAMP produced by each 
sample was calculated by taking into account the recovery from each 
column, based on the recovery of the [3H]-cAMP internal standard. Data 
was thus calculable in pmoles of cAMP produced per minute per 
milligram of membrane protein, and the assay was sensitive to 
approximately 5 pmoles/min/mg.
2.9 Reconstitution of Gsa into S49 lymphoma eye- membranes
Reconstitution assays were performed according to the method of 
Milligan and Klee (1985). Sodium cholate (1%, w/v) was used (1 hour, 
4°C) to extract protein from membrane preparations of NG108-15 cells. 
Samples were centrifuged at 25 p.s.i. (150000 x g) in an airfuge 
(Beckman instruments) and the supernatant fraction was taken as the 
soluble extract. Up to 5pi extract (containing the equivalent of up to 5pg 
NG108-15 membrane protein) was added to a final volume of lOOpl 
containing lOmM NaF or lOmM NaCl, 50mM HEPES pH 8.0, lOpg 
bovine serum albumin, 10 units of creatine phosphokinase, 6mM MgCh, 
0.2mM EGTA, 2mM 2-mercaptoethanol, [3H]-cAMP (15000 cpm), 
0.2mM [a-32P]ATP (2 x 106 cpm) and 10 pg S49 lymphoma eye- cell 
membranes. Samples were incubated at 30°C for 60 minutes and the
82
[32P]-cAMP generated was measured using the Salomon cyclase assay 
(section 2 .8).
Up to 5pg solubilised NG108-15 cell membranes gave a linear 
increase in reconstituted adenylyl cyclase activity in lOgg eye- cell 
membranes (McKenzie and Milligan, 1990).
Cloning technology (Sambrook e t  a l , 1989)
Glassware, eppendorfs, pipette tips and buffer solutions, were 
autoclaved for 45 minutes at 15 p.s.i. before being used in contact with 
bacteria or DNA.
2.10 General solutions used during cloning
50xTAE: 242g Tris base
57.1ml glacial acetic acid 
100ml 0.5MEDTA (pH 8.0) 
made up to 1 litre
DNA loading buffer (sample incubation buffer):
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol FF 
15% (w/v) Ficoll (Type 400, Pharmacia) 
in water
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2x YT medium: 16g/l Bactotryptone 
(pH 7.4) 10g/l yeast extract
5g/l NaCl
Agar plates: 15g Bacto-agar made up to 1 litre with 2x YT medium
and the appropriate concentration of antibiotic.
2.11 Agarose gel electrophoresis
The DNA sample was mixed with approximately lOpl sample 
incubation buffer and loaded onto a 1% (w/v) agarose gel. Ethidium 
bromide was added to the electrophoresis buffer (lx  TAE) to a final 
concentration of 0.5pg/ml. The gel was run at 100mA for approximately 
30 minutes. It was then examined under UV light and photographed.
2.12 Phenol:chloroform extraction of DNA
The sample containing the DNA was diluted 1:1 with 
phenol:chloroform:isoamyl alcohol (25:24:1) and subsequently vortexed 
and pulsed in a microfuge. The DNA present in the upper aqueous phase 
was removed and diluted 1:1 with chloroform:isoamyl alcohol (24:1), 
vortexed, pulsed and the chloroform:isoamyl alcohol extraction repeated 
on the supernatant.
The supernatant from the second extraction was collected and 0.3 
volumes 3M sodium acetate (NaOAc) pH 5.0 and 2.5 volumes ethanol 
were added. The sample was frozen at -20°C for 60 minutes and then
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spun in a microfuge at 4°C for 30 minutes to collect the precipitated 
DNA. The supernatant was discarded and the eppendorf containing the 
sample was half-filled with ice cold 70% ethanol. The sample was 
vortexed and spun at 4°C for 15 minutes. The supernatant was removed 
and the sample dried under vacuum in an Aqua vac. The DNA sample 
was resuspended in an appropriate volume of sterile water.
*
2.13 RNAase treatment of DNA
lp l RNase (100pg/ml) was added to the DNA sample 
(approximate volume 30pl) and incubated at 37°C for 1 hour. The 
sample was then purified by phenol:chloroform extraction of the DNA 
(section 2.12). (The RNase was prepared in lOmM Tris-HCl , 15mM 
NaCl pH 7.5 and boiled for 15 minutes to remove any DNase activity 
before use.)
2.14 Restriction enzyme reactions.
Up to 10pg DNA was incubated with lp l restriction enzyme and 
lx react buffer specific for that restriction enzyme, at 37°C for 90 
minutes. The sample was then RNAase treated (section 2.13) and 
phenol:chloroform treated in order to extract the digested DNA (section
2 .12).
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2.15 DNA ligation reactions
The predigested DNA vector and insert (in a ratio of vector:insert 
1:10) were heated to 65°C for 5 minutes in the same sterile eppendorf 
tube. The DNA was then cooled on ice. The reaction reagents were 
added to the tube as follows : 0.5mM ATP, lx  T4 DNA buffer and lg l 
T4 DNA ligase to a final volume of between 10-20 pi. The reaction was 
kept at 4°C overnight.
T4 DNA ligase buffer (lOx):
0.5M Tris.HCl (pH 7.6) 
lOOmM MgCl2 
1 OOmM dithiothreitol 
500pg/ml BSA (Fraction V, Sigma)
2.16 Preparation of competent E .C o l i
2ml of an overnight culture of E.Coli (either NM522 or HB109) 
was incubated with 40ml 2xYT medium for 3 hours. The E. Coli 
suspension was spun at 3000 rpm for 5 minutes in a TJ6 Beckman 
centrifuge. The supernatant was discarded and 20ml ice cold 50mM 
CaCl2 added. The sample was left for 20 minutes on ice and then spun at 
3000 rpm for 5 minutes. The supernatant was discarded and 4ml 50mM 
CaCl2 added. The competent E. Coli could be left at 4°C for up to 48 
hours. Maximum transforming efficiency occurred between 12-24 hours 
of CaCl2 treatment.
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2.17 Transformation of competent E .C o l i
200pl competent E.Coli was added to the plasmid DNA (ligation 
reaction) and gently mixed. The reaction was left on ice for 90 minutes 
and then heat shocked at 37°C for 90 seconds. The sample was returned 
to ice, 400pi 2xYT medium was added and it was then shaken at 37°C
i
for 1-2 hours. The samples were plated out on the appropriate antibiotic 
bactoagar plates to select for the E.Coli which had taken up the plasmid. 
The bactoagar plates were incubated at 37°C overnight and inspected the 
next day for colonies. Colonies were picked and grown in 3ml 2xYT 
medium overnight.
2.18 DNA minipreps from transformed E .C o l i
From 3ml overnight cultures of E.Coli a 1.5ml suspension was 
taken and spun for 30s in a microfuge. The supernatant was removed and 
the pellet redissolved in lOOpl glucose buffer (50mM glucose, 25mM 
Tris.Cl pH 8.0, lOmM EDTA pH 8.0). The sample was left for 5 
minutes on ice for the cells to lyse. 200gl freshly prepared 1% (w/v) 
SDS/0.2M NaOH was added, the sample shaken and left on ice for 20 
minutes to allow solubilisation of the membranes. 300pl 3M K/5M OAc 
was added and the sample left on ice for 5 minutes. The sample was 
spun for 5 minutes in a microfuge and the supernatant removed. 
Phenol:chloroform was used to extract the DNA from the sample (section
2 . 12).
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2.19 "Geneclean" using the Geneclean kit
The appropriate fragment of DNA was cut out of the agarose gel. 
500pi sodium iodide solution, from the Geneclean kit, was added to the 
fragment of gel in an eppendorf tube and incubated at 47°C-55°C for 
several minutes, until the agarose was completely melted. 5pi heavily 
vortexed glassmilk was added, and the sample was left on ice for 5 
minutes. It was pulsed for 5 seconds in a microfuge, the supernatant was 
discarded and 500pl Geneclean solution added to the sample. It was 
then washed three times in Geneclean and the pellet resuspended in e.g. 
lOpl sterile water and incubated at 50-55°C for 3 minutes. The sample 
was spun for 30 seconds in a microfuge, the supernatant removed and 
this procedure repeated on the supernatant. The resulting supernatant 
contained the DNA from the gel fragment.
2.20 CsCl2 purification of DNA from a large scale culture of 
transformed E .C o l i
500ml of an overnight culture of transformed E.Coli was spun in a 
JAM rotor in a Beckman J2.21 centrifuge at 2000 x g for 5 minutes at 
4°C. The pellet was resuspended in 9ml glucose buffer (50mM glucose, 
25mM Tris.HCl pH 8.0, lOmM EDTA pH 8.0) and left for 5 minutes on 
ice. To each tube was added 0.5ml lysozyme (50mg/ml) and the tubes 
were left to stand at room temperature for 5 minutes. 10ml 0.2M 
NaOH/1% (w/v) SDS was added to each tube and left for 5 minutes at 
room temperature. 7.5ml 3MK/5M OAc buffer was then added to each
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tube which were shaken vigorously. The samples were left for at least 
10 minutes on ice, and then spun at 30000 x g for 20 minutes at 4°C.
The supernatant was transferred to a new tube by passing it 
through 2 layers of muslin. It was mixed with an equal volume of 
propan-2-ol and left at room temperature for at least 30 minutes. The 
samples were spun at 12000 x g for 30 minutes at room temperature and 
the supernatant discarded. The pellet was washed with 20ml 70% 
ethanol, again at room temperature. The ethanol was discarded, the 
pellet dried, resuspended in 30ml lOmM Tris/O.lmM EDTA pH 7.4 and 
then transferred to sterile tubes containing 30.0g caesium chloride. The 
tubes were mixed gently until all the caesium chloride had dissolved and 
2.4ml of lOmg/ml ethidium bromide solution was added and the tube 
mixed gently.
The samples were transferred to Beckman VTi50 tubes and spun at 
242000 x g for 20 hours at 20°C, in the VTi50 vertical rotor, in the 
Beckman L8 centrifuge. The linear DNA, present half-way up the tube, 
was extracted out. Any ethidium bromide present was removed by 
washing repeatedly with an equal volume of water saturated butan-l-ol. 
The aqueous phase was then dialysed against 2 litres lOmM Tris/O.lmM 
EDTA pH 7.4 for 4 hours at 4°C.
The DNA solution was removed from the tubing and precipitated 
with 2.5 volumes ethanol at -20°C overnight. The samples were spun at 
6500 x g for 30 minutes at 4°C in a Beckman J2.21 centrifuge, then 
washed with 70% ethanol and the pellet dried using an Aquavac. The 
pellet was redissolved in a total of 500pl lOmM Tris/O.lmM EDTA pH 
7.4.
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2.21 Quantitation of DNA
5 pi and 1 Ofj.1 DNA sample were made up to 1ml with water and 
the absorbance at 260 nm read. An absorbance of 1.0 at this wavelength 
indicated the presence of 50pg plasmid DNA, thus allowing the 
calculation of the amount of DNA in the sample.
The ratio OD(260nm)/OD(280nm) allows the purity of the nucleic 
acid to be calculated. Pure preparations of DNA and RNA have 
OD(260nm)/OD(280nm) values of 1.8 and 2.0, respectively. If there is 
contamination with protein or phenol, the OD(260nm)/OD(280nm) is 
significantly less than the values given above and accurate quantitation of 
the amount of nucleic acid present was not possible.
2.22 Transfection of plasmid DNA into mammalian cells
Cells were transfected using the Lipofectin reagent according to 
the manufacturer's instructions (GIBCO BRL).
NG108-15 or COS-1 cells were plated out to 30-50% confluency 
for stable transfections, and 80% confluency for transient transfections, 
on 100mm petri dishes in DMEM/10% (v/v) CPSR or DMEM/10% (v/v) 
FCS respectively. lOpg DNA was diluted with sterile water to 50gl. 
50pg Lipofectin Reagent was diluted to 50gl with sterile water. 50pl 
each of the DNA and Lipofectin were mixed in a polystyrene tube and 
left for 15 minutes at room temperature. The cells were washed twice 
with 5ml serum-free media and 5ml serum-free media then added to the
9 0
cells. The lOOgl DNA/Lipofectin complex was added to the cells 
dropwise and then left for 5-24 hours at 37°C in 5% CO2. After the 
appropriate time 5ml 20% serum was added to the cells and they were 
left for 2-3 days. For transient transfections the cells were then 
harvested. For stable transfections the cells were plated out in the 
appropriate selection medium, in this case 0.8mg/ml geneticin sulphate. 
Cell colonies grew which were resistant to 0.8 mg/ml geneticin sulphate 
and these were selected and expanded.
0.8mg/ml geneticin was determined to be the minimum 
concentration of geneticin that would kill every wild-type NG108-15 cell 
within 7 days. This was demonstrated by treating NG108-15 cells with 
increasing concentrations of geneticin and assessing their viability by eye 
daily. When NG108-15 cells die they become non-adherent to the flask 
surface. After 7 days incubation in 0.8mg/ml geneticin all the NG108-15 
cells had become non-adherent and expired.
2.23 Data analysis
Where appropriate, data were analysed for statistical significance 
using the Student's two-tailed t-test (paired). Dose response and 
displacement curves were analysed using the Kaleidograph curve fit 
programme, courtesy of Syntex Research Centre, Edinburgh.
The IC50 (corrected for receptor occupancy) was calculated by dividing 
the measured IC50 by (1 + L/Kd) where L is the concentration of 
radioligand used.
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CHAPTER 3
Prolonged agonist exposure of the IP prostanoid receptor in 
NG108-15 cells, results in a concurrent down-regulation of
receptor and Gsa.
Introduction
Human platelets aggregate on damaged epithelial cells that line 
blood vessel walls during vascular injury. Numerous factors initiate 
this aggregation process, and these include exposed collagen on the 
subendothelial matrix (Wilner et al ,1968), and ADP released from 
damaged cells (Born, 1962). The developing platelet plug is further 
increased in size by the pro-aggregatory factors ADP (Bom 1962, Bom 
and Kratzer 1965), thromboxane A2 and the prostaglandin 
endoperoxides released from platelets during aggregation (Hamberg et 
al 1975). The increase in the size of the platelet aggregate is finally 
attenuated by several anti-aggregatory factors including prostaglandin 
12 (PGI2) (Moncada et al, 1976) and adenosine (Bom et al , 1965) (a 
product of ATP hydrolysis) released from the adjacent endothelial cells 
during injury. Both PGI2 (Gorman et al, 1977, Tateson et al, 1977) 
and adenosine (Haslam and Rosson, 1975, Huttemann et al, 1984) 
mediate inhibition of platelet aggregation through activation of adenylyl 
cyclase. Both adenosine and PGI2 analogues, therefore, have 
therapeutic potential as 'anti-platelet' aggregation agents, but this has 
proved problematic with the discovery that exposure of human platelets 
to PGI2 and to adenosine eventually results in a desensitisation of 
adenylyl cyclase, which serves to relieve the inhibition of platelet 
aggregation (Sinzinger et al, 1981). The ability to control the 
desensitisation of adenylyl cyclase to adenosine and PGI2 is therefore 
important in controlling platelet aggregation .
The neuronal-like hybrid cell line, NG108-15, was formed by the 
cell fusion of the 6-thioguanine-resistant clonal mouse neuroblastoma 
cell line N18TG2 and the bromodeoxyuridine-resistant rat glioma cell
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line C6-BU1, followed by selection with hypoxanthine, aminopterin and 
thymidine (HAT) medium (Hamprecht et al, 1985) and these cells are 
readily grown in cell culture. Like human platelets, NG108-15 cells 
express receptors for adenosine (of the A2 subtype) and prostaglandins 
(of the IP prostanoid subtype), both of which couple to the activation of 
adenylyl cyclase. Because of this, the NG108-15 cell line has been used 
as a readily available system to study both types of receptor and their 
respective mechanisms of desensitisation on exposure to agonist or 
hormone.
Several groups have attempted to determine the mechanism of 
both homologous and heterologous desensitisation of adenylyl cyclase 
activation in NG108-15 cells, through exposure of these cells to 
hormones and agonists acting at the A2 adenosine receptor and the IP 
prostanoid receptor. Kenimer and Nirenberg (1981) showed that on 
prolonged exposure (hours) of NG108-15 cells to prostaglandin E l 
(PGE1), there was a reduction in the capacity for adenylyl cyclase 
activation by each of PGE1, the A2 adenosine receptor agonist, 2- 
chloroadenosine and sodium fluoride (NaF). Prostanoid treatment of 
NG108-15 cells therefore resulted in both homologous and heterologous 
desensitisation of adenylyl cyclase. This was accompanied by a 30-50% 
decrease in membrane associated levels of Gsa, measured both 
immunologically (McKenzie and Milligan, 1990) and by cholera toxin 
catalysed [32p]-ADP-ribosylation (Kelly et al, 1990).
Heterologous desensitisation of an effector is postulated to be 
mediated through some component downstream of the receptor in the 
signal transduction cascade. Protein kinases A (Clark et al, 1989; 
Hausdorff et al, 1989) and C (Johnson et al, 1990), activated by the
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second messengers cAMP and diacylglycerol (DAG) respectively, will 
phosphorylate the (32-adrenergic receptor and result in a desensitisation 
of receptor-mediated adenylyl cyclase activity through the uncoupling 
of the G-protein from its receptor. The role of the guanine nucleotide 
binding protein in heterologous desensitisation has also been implicated 
in several systems (Kassis and Fishman, 1982; Garrity et al, 1984; Rich 
et al ,1984). Studies, initially using toxin-catalysed [32p]-ADP- 
ribosylation of G-protein a-subunits (Parson and Stiles 1987; Kelly e t  
al, 1990) and, subsequently, using antisera specific to G-protein a- 
subunits (Green e t  al, 1990; McKenzie and Milligan, 1990; Mullaney et 
al, 1993), have demonstrated that prolonged agonist stimulation of many 
G-protein coupled receptors results in a down-regulation of the 
activated G-protein a-subunit. In several of these systems, 
heterologous desensitisation of the effector stimulated by the activated 
G-protein a-subunit is a coincidental occurrence (Kelly e t  al, 1990; 
McKenzie and Milligan 1990; Green et al 1990, 1992).
The apparent loss of G sa from the plasma membrane on 
prostanoid treatment of NG108-15 cells may play an important role in 
the prostanoid-mediated heterologous desensitisation of adenylyl cyclase 
in these cells, although this remains to be unequivocally demonstrated. 
If Gsa down-regulation is to account, even partially, for the 
heterologous desensitisation, then it must be the limiting factor in the 
signal transduction cascade activating adenylyl cyclase. This could 
occur simply through the quantity of G sa present in the plasma 
membrane being insufficient to couple to all of the receptor or effector 
or, alternatively, because of constraints, perhaps cytoskeletal, 
preventing receptor-G-protein and G-protein-effector interactions. It 
is, therefore, important to quantify the amount of both IP prostanoid
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receptor:Gsa and A2 adenosine receptorrGsa in the cells and also the 
ratio of activation/down-regulation to further elucidate if Gsa is 
stoichiometrically responsible for heterologous desensitisation. Recent 
estimates of receptor:Ga ratios in several cell lines predict a molar ratio 
of between 1:10 and 1:200 (Neubig et al, 1985; Alousi et al, 1991; 
Ransnas et al 1988). G-protein a-subunits appear to be present in 
excess over their respective receptors. Additionally, the receptor-Ga 
ratio of activation is in the region of 1:10 for "Gi-like" proteins in both 
rat adipocytes and human neutrophils (Green et al, 1990; Mueller et al, 
1991). The ratios for Gsa:IP prostanoid and A2 adenosine receptor 
activation/down-regulation remain to be determined in NG108-15 cells 
and, until the stoichiometry is resolved, the question of whether G sa is 
quantitatively limiting for prostanoid mediated adenylyl cyclase 
activation will stay unanswered.
In this chapter a brief characterisation of prostanoid binding in 
NG108-15 cells will be discussed and the levels of IP prostanoid 
receptor expression in NG018-15 cells determined. The mechanism 
behind the homologous desensitisation of the IP prostanoid receptor will 
be explored and discussed. The IP prostanoid receptor:Gsa 
stoichiometry in the plasma membrane will be determined, as will the 
ratio of receptor:Gsa down-regulation and the implication of these 
results discussed.
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Figure 3.1 Time course of [3H]-PGE1 binding to NG108-15 cell
membranes.
25pg NG108-15 cell membranes were incubated at 30°C with 
lOnM [3H]-PGE1. At various times the samples were removed from the 
water bath and placed on ice to terminate the reaction. The samples 
were then rapidly filtered through Whatman GF/C filters and washed 
three times with 5ml ice cold buffer, as described in section 2.7. A 
parallel series of incubations was performed in the presence of lOpM 
PGE1 for each time point in order to determine non-specific binding. 
The results were expressed as the specific binding of [3H]-PGE1 to the 
cell membrane (mean ± SD, n=3), from a single experiment.
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Figure 3.2 The incubation of increasing amounts of NG108-15 
cell membrane protein with [3H]-PGE1.
Increasing amounts of NG108-15 cell membranes (5 - lOOgg) 
were incubated at 30°C for 30 minutes with lOnM [3H]-PGE1. Samples 
were then placed on ice, rapidly filtered through Whatman GF/C filters 
and washed three times with 5ml ice cold buffer, as described in section
t
2.7. A parallel set of incubations was performed in the presence of 
10gM PGE1 to determine non-specific binding. The results were 
expressed as specific binding in dpm (mean ± SD, n=3) of a single 
experiment, of which one other produced similar data.
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Figure 3.3 Displacement of [3H]-PGE1 binding with increasing
concentrations of PGE1 in NG108-15 cell membranes.
NG108-15 cell membranes (25pg) were incubated for 30 minutes 
at 30°C with lOnM [3H]-PGE1 and increasing concentrations of PGE1 
(between lOOpM - O.lnM). Samples were then placed on ice, rapidly 
filtered through Whatman GF/C filters and washed three times with 5ml 
ice cold buffer as described in section 2.7. The results were expressed 
as the specific binding of [3H]-PGE1 (the mean of triplicates), from a 
single experiment of which two others gave similar results. SD values 
for the individual points were always less than 15% of the mean value. 
The IC50 (corrected for receptor occupancy) for the experiment 
displayed was 26.2nM.
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Figure 3.4 Displacement of [3H]-PGE1 binding with increasing 
concentrations of iloprost in NG108-15 cell 
membranes.
25pg NG108-15 cell membranes were incubated for 30 minutes at 
30°C with lOnM [3H]-PGE1 and various concentrations of iloprost 
(between lOpM - O.lnM). Samples were then placed on ice, filtered 
through Whatman GF/C filters and washed three times with 5ml ice cold 
buffer as described in section 2.7. The results shown were expressed as 
specific binding of [3H]-PGE1 (the mean of triplicates), of a single 
experiment of which four others gave similar results. SD values for the 
individual points were always less than 10% of the mean value. The 
IC50 (corrected for receptor occupancy) for the experiment displayed 
was 17.4nM.
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Figure 3.5 Saturation binding of [3H]-PGE1 in membranes 
prepared from NG108-15 cells.
50jig NG108-15 cell membranes were incubated with 5 or lOnM 
[3H]-PGE1 and increasing concentrations of PGE1 (10-90nM) for 30 
minutes at 30°C as described in appendix 1 and section 2.7. The 
reaction was terminated by returning the samples to ice prior to rapid 
filtration through Whatman GF/C filters and subsequent washing with ice 
cold buffer as described in section 2.7. A saturation binding curve was 
constructed (figure 3.5a) as described in appendix 1. The data was then 
manipulated according to Scatchard (1949) (figure 3.5b). A Bmax of 
1080 fmoles bound/mg membrane protein and a Kd of 29.4 nM was 
calculated. This was a representative experiment (mean ± SD, n=3), of 
which four others were performed and gave similar results.
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Figure 3.6 Western blotting analysis of membranes prepared
from control and iloprost treated NG108-15 cells using 
antisera CS1 and SGI.
40pg membrane protein prepared from control and iloprost (lpM ; 
16 hours) treated NG108-15 cells were TCA precipitated, run on a 10% 
(w/v) acrylamide/0.25% (w/v) N,N'-methylene-bisacrylamide gel and 
western blotted for G sa using the antiserum CS1, at a dilution of 1:250, 
as described in section 2.6 (figure 3.6a). Similarly, lOOpg membranes 
from control and iloprost treated cells were western blotted for the 
presence of Gi2o: using SGI at a dilution of 1:400 (figure 3.6b). Lanes 1 
and 3 in both figures were control membranes and lanes 2 and 4 were 
membranes from iloprost treated cells. The blots were quantified by 
overlaying them with an [125I]-labelled goat anti-rabbit IgG as described 
in section 2.6. There was a 66±6% (mean ± SD) decrease of membrane 
associated G sa levels in iloprost treated NG108-15 cells. There was no 
change in Gi2o? levels (95±6%, mean ± SD).
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Figure 3.6c Coomassie blue stained SDS gel from figures 3.6a and 
3.6b
After western blotting the gel from figures 3.6a and b was stained 
in Coomassie blue stain and then destained to assess if equal amounts of 
protein had been loaded on the different lanes. Lanes 1-4 correspond to 
lanes 1-4 in figure 3.6a and lanes 5-8 correspond to lanes 1-4 in figure 
3.6b.
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Figure 3.7 Western blotting analysis of increasing amounts of 
control and iloprost treated NG108-15 cell 
membranes, with an antiserum generated against 
the C-terminal decapeptide of Gsa, CS1.
5 - 100 pg membrane protein from control and iloprost treated 
(lpM ; 16 hours) NG108-15 cells were TCA precipitated, run on a 10% 
(w/v) acrylamide / 0.25% (w/v) N,N'-methylene bisacrylamide gel and 
western blotted using the Gsa specific antiserum CS1 at a dilution of 
1:250 as described in section 2.6. Lanes 1-6 were control membranes; 
lanes 7-12 were iloprost treated membranes. Lanes 1 and 7 were loaded 
with 5pg membrane protein, lanes 2 and 8, lOpg; lanes 3 and 9, 25pg; 
lanes 4 and 10, 50pg; lanes 5 and 11, 75pg; lanes 6 and 12, lOOpg. The 
blots were quantitated using densitometric scan analysis as described in 
section 2.6. Membrane associated Gsa levels from iloprost treated cells 
were calculated as a percentage of control, for each amount of 
membrane protein loaded as follows: 5pg, 24%; lOpg, 46%; 25pg, 49%; 
50pg, 59%; 75pg, 60%; lOOpg, 54%.
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Figure 3.8 Saturation binding of [3H]-PGE1 in membranes
prepared from control and iloprost treated NG1 OS- 
15 cells.
50gg NG108-15 cell membranes were incubated with 5 or lOnM 
[3H]-PGE1 and increasing [PGE1] (0-90nM), for 30 minutes at 30°C as 
described in appendix 1. Non-specific binding was determined in the 
presence of lOpM PGE1. The reaction was terminated by returning the 
samples to ice prior to rapid filtration through Whatman GF/C filters and 
subsequent washing with ice cold buffer as described in section 2.7. A 
saturation binding curve was constructed as described in appendix 1. 
The data was then manipulated according to Scatchard (1949). A Bmax 
of 1530 finoles bound/mg membrane protein and a Kd of 38.5 nM was 
calculated for control membranes (□). Membranes from iloprost treated 
cells gave a Bmax of 550 finoles bound/mg membrane protein and a Kd 
of 30.4 nM (♦). This was a representative experiment (mean ± SD, 
n=3), of which one other was performed which gave a similar result.
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Figure 3.9 Measurement of adenylyl cyclase activity in response 
to increasing concentrations of iloprost in membranes 
prepared from control and iloprost treated NG108-15 
cells.
Adenylyl cyclase activity was assessed in lOgg each of control (o) 
and iloprost treated (lpM ; 16 hours) (□) NG108-15 cell membranes as 
described in section 2.8. Adenylyl cyclase activity was amplified in the 
presence of increasing concentrations (0 - 10pM) of iloprost. EC50 
values for adenylyl cyclase stimulation in control (15.3nM) and iloprost 
treated (37.0nM) cells were calculated. The results shown were the 
mean of triplicates, from a single experiment which was representative of 
three experiments performed. SD values for the individual points were 
always less than 15% of the mean value.
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Figure 3.10 Analysis of Gsa levels, by western blotting, in
membranes prepared from NG108-15 cells which 
were treated separately with iloprost and forskolin.
40gg NG108-15 cell membranes prepared from control, forskolin 
treated (lOpM; 16 hours) and iloprost treated (lpM ; 16 hours) cells were 
TCA precipitated, loaded onto a 10% (w/v) acrylamide / 0.25% (w/v) 
N,N'-methylene bisacrylamide gel and western blotted for Gsa using a 
1:250 dilution of antiserum CS1, as described in sections 2.6. Lane 1 
represented control membranes, lane 2 forskolin treated and lane 3 
iloprost treated. Densitometric scan analysis was performed as 
described in section 2.6 and the data taken as a percentage of control 
levels. For this single experiment forskolin treatment gave 108% and 
iloprost 36% of control levels of Gsa. This data was from a single 
experiment but four others performed gave similar results.
106
Figure  3 .10
M W t (kDa)
Figure 3.11 Measurement of Gsa levels and [3H]-PGE1 binding in 
membranes prepared from NG108-15 cells which 
were treated for increasing lengths of time with 
iloprost.
NG108-15 cells were treated for various times ( 0 - 1 2  hours) with 
1 gM iloprost. Membranes prepared from each of the time points were 
TCA precipitated, run on a 10% (w/v) acrylamide / ,0.25% (w/v) 
methylene bisacrylamide gel and western blotted for Gsa, using a 1:250 
dilution of CS1 antisera. Immunoblots of G sa (a ) were quantitatively 
analysed using an [125I]-labelled anti-rabbit IgG second antibody overlay 
as described in section 2.6. Results were expressed as a percentage of 
control G sa levels. The same membranes from the time course were 
solubilised (2/zg) and analysed for NaF stimulated adenylyl cyclase 
activity when reconstituted into 10/zg eye- cell membranes (o) as 
described in more detail in section 2.9
25gg membranes prepared from cells from the various time 
incubations with iloprost were assayed for [3H]-PGE1 binding (□) as 
described in section 2.7 and appendix 1. Non-specific binding was 
determined in the presence of lOgM PGE1. Results were expressed as a 
percentage of control levels.
Results for eye- reconstitution experiments were expressed as the 
mean from three individual experiments. Results for both G sa levels 
and [3H]-PGE1 binding were expressed as the mean ± SD, from three 
individual experiments, performed on separate membrane preparations.
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Figure 3:12 Analysis of Gi2a levels, by western blotting, in
membranes prepared from NG108-15 cells treated 
with iloprost for increasing lengths of time.
lOOgg membranes prepared from NG108-15 cells from the time 
course of 1 gM iloprost treatment in figure 3.12 were TCA precipitated, 
nui on a 10% (w/v) acrylamide / 0.25% (w/v) N,N’-methylene 
bisacrylamide gel and western blotted for Gi2a using the antiserum SGI 
(1:400) as described in section 2.6 (figure 3.12a). Lane 1 - 0 hours; lane 
2 - 2  hours; lane 3 - 4  hours; lane 4 - 6  hours; lane 5 - 8  hours; lane 6 - 1 2  
hours. The immunoblot was quantified by overlaying it with an [125I]- 
labelled goat anti-rabbit IgG as described in section 2.6 and expressing 
the results as a percentage of control Gi2a levels (figure 3.12b).
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Figure 3.13 Analysis of Gsa levels, by western blotting, in
membranes and cytosol prepared from control and 
iloprost treated NG108-15 cells.
NG108-15 cells were treated with lgM  iloprost for 3 hours. The 
cells were harvested, washed twice with PBS (xl) and homogenised as 
described in section 2.3. The homogenate was spun at 150 000 x g for 
30 minutes. The supernatant was taken as "cytosol" and jthe pellet as 
"membranes". 40pg membranes (lanes 1 and 3) and cytosol (lanes 2 and 
4) from control (lanes 1 and 2) and iloprost (lanes 3 and 4) treated cells 
were TCA precipitated, run on a 10% (w/v) acrylamide / 0.25% N,N'- 
methylene bisacrylamide gel and western blotted for Gscx, using a 1:250 
dilution of CS1 antiserum, as described in section 2 .6 .
The immunoblot was densitometrically scanned and the iloprost 
treated membrane fraction taken as a percentage of the control (57%). 
The cytosolic fractions were too low in G sa levels to detect accurately 
on the densitometric seamier. The results were taken from a single 
experiment that was representative of three performed.
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Figure 3.13
Figure 3.14 Molar quantitation of membrane associated Gsa?
levels in NG108-15 cell membranes.
40|ig control (lane4 ) and iloprost treated (lpM ; 16 hours) (lane 3 ) NG1 OS- 
15 cell membranes were TCA precipitated, run on a 10% (w/v) acrylamide / 0.25% 
N,N'-methylene bisacrylamide gel and western blotted for Gsa using CS1, at a 
dilution o f 1:250, as described in section 2.6. Alongside E. Co/i expressed Gsa long 
(45KDa) and Gsa short (42KDa) were run. Lanes 1 and 2 were loaded with Gsa 
long 6ng and 18ng respectively and lanes 5 and 6 were loaded with Gsa short 6ng 
and 18 ng. The blot was quantitated with [ 125I]-labelled goat anti-rabbit IgG. In the 
experiment displayed, Gsa45 in untreated membranes bound 836 cpm, whereas that 
in iloprost-treated membranes bound 494 cpm as measured in a gamma counter, a 
decrease o f some 41% (figure 3 .14a).
40pg membranes from control and iloprost treated NG108-15 cells were 
TCA precipitated and loaded on to a SDS polyacrylamide gel alongside various 
amounts (0-24ng) o f E. Co/i- expressed Gsa long. The gel was immunoblotted using 
the antiserum CS1 at a 1:250 dilution as described in section 2.6. The immunoblot 
was quantitated using an [ 12:T]-labe11ed goat anti-rabbit IgG overlay as described in 
section 2.6, and counted on a gamma counter. The amount o f Gsa long form loaded 
onto the gel was plotted against the corresponding number o f [125I] counts bound on 
the blot (figure 3 .14b). The amount o f Gsa long form in the membranes prepared 
from control and iloprost treated NG108-15 cells was then calculated from the 
standard curve. Control NG108-15 cell membranes expressed 9.6±1.5 pmoles 
Gsa/mg membrane protein and membranes from iloprost treated cells expressed 
3.0±0.3 pmoles Gsa/mg membrane protein. The results were expressed as the mean 
± SD (n=3) taken from analysis o f  three individual membrane preparations.
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Figure 3.15 Measurement of membrane associated Gsa levels and 
[3H]-PGE1 binding in membranes prepared from 
NG108-15 cells which have been treated with 
increasing concentrations of iloprost.
NG108-15 cells were treated with increasing concentrations of 
iloprost (0 - lpM ) for 8 hours. Membranes were prepared, and 40pg 
membrane protein was TCA precipitated, resolved on a 10% (w/v) 
acrylamide / 0.25% N,N'-methylene bisacrylamide gel and western 
blotted for Gsa, using a 1:250 dilution of the antiserum CS1, as 
described in section 2.6. The blot was quantitated using [l25I]-labelled 
goat anti-rabbit IgG and the results expressed as a percentage of control 
Gsa levels (□).
The cell membranes from the treatments with iloprost were also 
analysed for [3H]-PGE1 binding using lOnM [3H]-PGE1, and lOpM 
PGE1 to define non-specific binding as described in section 2.7 and 
appendix 1. Results were taken as a percentage of the control [3H]- 
PGE1 binding (■).
The results were expressed as the mean ± SD (n=3), for a single 
experiment which was performed three times with similar results.
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Figure 3.16 The effect of receptor occupancy on the stoichiometry 
of Gsor: receptor down-regulation.
The fractional occupancy of the IP prostanoid receptor during 
treatment with various concentrations of iloprost was calculated based 
on an estimated IC50 (corrected for receptor occupancy) of 14.8nM for 
iloprost, calculated from the membrane preparations analysed. Molar 
ratios of the G sa and IP prostanoid receptor that is eliminated from the 
plasma membrane remained essentially constant with the fractional 
occupancy of the receptor. Fractional occupancy varied between 0.2 
and 0.96. Ratios of the stoichiometry of loss of Gsa : receptor in the 
experiment displayed were between 8.5 and 10.1. In two further 
experiments the ratios of G-protein a-subunit to receptor loss were 
between 6.9 and 9 .4 .
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Table 3.1 The effect of lOOpM GTP7S on pHl-PGEl binding
to control and iloprost treated NG108-15 cell
membranes.
50pg control and iloprost treated (lpM , 16 hours) NG108-15 cell 
membranes were incubated for 30 minutes at 30°C with 40nM [3H]- 
PGE1, in the presence of lOOpM GTP7 S. Non-specific binding was 
defined in the presence of lOpM PGE1. The reaction was terminated by 
returning the samples to ice and the [3H]-PGE1 binding measured as 
described in section 2.7. The results were expressed as the mean ± SD 
(n=3), from a single representative experiment of which two others 
produced similar results.
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Table 3.1
[3H]-PGE1 (fmoles bound/ % 
Treatm ent mg membrane protein) control
control 912±88 100
+ GTPyS 496±44 54
iloprost (lpM ) 276±20 30
iloprost + GTPyS 140±40 15
Table 3.2 Measurement of adenylyl cyclase activity in
membranes prepared from control and iloprost 
treated NG108-15 cells. The effect of 20mM MnCh.
Adenylyl cyclase activity was assessed in lOpg of both control and 
iloprost treated (lgM , 16 hours) NG108-15 cell membranes as described 
in section 2.8. Additionally, when the adenylyl cyclase assay was 
performed in the presence of 20mM MnCh the MgCh routinely included 
in the assay mix was excluded. The results were expressed as mean ± 
SD (n=3), for a single experiment which was representative of three 
performed.
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Table 3.2
Treatment
control
control + Mn
iloprost 
iloprost + Mn
Adenylyl cyclase activity 
(pm oles/m in/m g protein)
45.8 ± 6.2
14.3 ± 2 .9
11.0 ±2 . 4
14.2 ± 2.5
Results
Equilibrium binding of [3H]-PGE1 (lOnM) to NG108-15 cell 
membranes was achieved after 10-20  minutes incubation at 30°C (figure
3.1). An incubation time of 30 minutes at 30°C was subsequently used to 
ensure equilibrium binding. Increasing the amount of membrane protein 
in each assay increased the specific binding of [3H]-PGE1 linearly up to 
100/Ag membrane protein (figure 3.2). Routinely up to 50fig membrane 
protein was used per assay.
Both PGE1 (figure 3.3) and iloprost (figure 3.4) competed the 
binding of lOnM [3H]-PGE1 with high affinity. The IC50 (corrected for 
receptor occupancy) for PGE1 displacement of [3H]-PGE1 was 25.6±6.0 
nM (mean ± SD, n=3) and the IC50 (corrected for receptor occupancy) 
for iloprost displacement was 16.9±5.4 nM (mean ± SD, n=5). The 
IC50 values (corrected for receptor occupancy) were calculated using the 
measured Kd=30nM (figure 3.5) for [3H]-PGE1 binding. No further 
displacement of [3H]-PGE1 was obtained above lO^tM PGE1 and IfiM  
iloprost. 10fiM PGE1 was subsequently used to define non-specific 
binding of [3H]-PGE1. Routinely non-specific binding was 
approximately 20% of the total binding.
Saturation binding of [3H]-PGE1 was performed on membranes 
prepared from NG108-15 cells to determine the levels of IP prostanoid 
receptor (figure 3.5) as described in appendix 1. Manipulating the data 
according to Scatchard (1949) (figure 3.5) gave an apparent Bmax of 
1208±397 fmoles/mg membrane protein (mean ± SD, n=5) and a Kd of
31.1 ±4.3 nM (mean ± SD, n=5) was calculated. Manipulating the data 
produced from [3H]-PGE1 self-displacement curves (figure 3.3)
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according to the equations derived by DeBlasi et al (1989) (described in 
appendix 1), gave a calculated Bmax of 994 ±410 fmoles/mg membrane 
protein (mean ± SD, n=3) and a Kd of 35.7± 19.2 nM (mean ± SD, n=3,), 
not statistically different to the results obtained by Scatchard analysis of 
the saturation binding data (figure 3.5) (p=0.80 for Bmax values and 
p=0.82 for the Kd values). The calculated Bmax and Kd, using the 
equations derived by DeBlasi et al (1989) are, however, based on the 
assumption that the high [Mg2+] used in the PGE1 binding assay will 
force the entire population of the IP prostanoid receptor into a single high 
affinity state (Costa et al, 1990) as discussed more fully in appendix 1.
Saturation binding of [3H]-PGE1 was performed on both control 
and iloprost treated NG108-15 cell membranes as described in appendix 
1 (figure 3.8), and the data manipulated according to Scatchard (1949). 
A Bmax of 1530 fmoles/mg membrane protein and a Kd of 38.5 nM was 
calculated for the IP prostanoid receptor population in control membranes 
in these experiments, whilst in membranes prepared from iloprost treated 
cells the Bmax was 550 fmoles/mg membrane protein and the Kd was
30.4 nM. No significant change in the Kd of the IP prostanoid receptor 
for [3H]-PGE1 was observed on iloprost treatment (p=0.73). Using a 
single concentration of both [3H]-PGE1 (lOnM) and PGE1 (10^M), 
binding analysis was performed on membranes prepared from control and 
iloprost treated NG108-15 cells. The estimated percentage decrease in 
[3H]-PGE1 binding on iloprost treatment of NG108-15 cells was 
69.2±9.6 % (mean ± SD, n=7). This indicated an apparent loss of IP 
prostanoid receptor from the plasma membrane. The pseudo Hill 
coefficients for [3H]-PGE1 binding in control NG108-15 cell membranes 
was 1.05±0.25 and in iloprost treated cell membranes was 1.11±0.17, 
indicating an apparent single affinity state of the IP prostanoid receptor in
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both control and iloprost treated NG108-15 cells indicating that the high 
[Mg2+] used in the binding assay appeared to have been effective in 
coupling all of the IP prostanoid receptor to a G-protein (appendix 1).
However it was further necessary to examine the IP prostanoid 
receptor and its coupling to G-proteins in both control and iloprost 
treated NG108-15 cells. Both control membranes and membranes 
prepared from iloprost treated cells were incubated with lOOpM GTP7 S, 
and analysed for [3H]-PGE1 binding using a single concentration of both 
radioligand (lOnM) and PGE1 (lOpM) as described in appendix 1 (table
3.1). Incubation with lOOpM GTP7 S resulted in a 54% decrease in 
specific [3H]-PGE1 binding in membranes prepared from untreated 
NG108-15 cells. Following treatment of NG108-15 cells with iloprost 
there was a 51% decrease in specific [3H]-PGE1 binding to the 
membranes when incubated with GTP7 S. The IP prostanoid receptor 
appears still to be coupled to a G-protein after iloprost treatment.
Treatment of NG108-15 cells with lpM  iloprost for 16 hours 
resulted in a 56±8% (mean ± SD, n=8) decrease in the amount of 
membrane associated G sa detectable by the C-terminal decapeptide 
antibody CS1 (figure 3.6a). The antiserum SGI will only recognise 
Gi2a in NG108-15 cells because these cells do not express detectable 
levels of Gi l a  (McKenzie and Milligan, 1990). Using SGI no detectable 
changes in membrane associated Gi2a levels were observed on iloprost 
treatment (figure 3.6b). When examining the levels of G-protein a- 
subunits immunologically by western blotting, the gel was subsequently 
stained in Coomassie blue for every experiment. The protein loadings 
in each lane, for different cell treatments, were examined and determined 
to be very similar, indicating that any changes observed in
117
immunologically detectable G a were not a result of varying amounts of 
protein in each lane. Additionally iloprost treatment of NG108-15 cells 
did not produce any detectable gross alteration in membrane protein 
profile (figure 3.6c).
High concentrations of ethanol (mM) have been shown to reduce 
membrane associated levels of G sa in NG108-15 cells (Mochley-Rosen 
et al, 1988). The vehicle for the agonist iloprost contains approximately 
0.1% ethanol and treatment of NG108-15 cells with vehicle only, resulted 
in no significant down-regulation of Gsa (McKenzie and Milligan, 1990), 
indicating that the vehicle itself plays no role in iloprost induced G sa 
down-regulation.
Increasing amounts of membrane protein (5-100/xg) from both 
control and iloprost treated NG108-15 cells were analysed for G sa levels 
by western blotting. The percentage of G sa lost from the plasma 
membrane on treatment with iloprost was calculated for each amount of 
membrane protein: 5pg 24%; lOpg 46%, 25pg 49%; 50pg 59%, 75pg 
60%, lOOpg 54% (figure 3.7).
A robust stimulation of adenylyl cyclase by iloprost was observed 
in untreated NG108-15 cells (figure 3.9) with an EC50 of 25.8±9.1 nM 
(mean ± SD, n=3). The EC50 for adenylyl cyclase activation by iloprost 
in membranes from iloprost treated cells [EC50 = 57.7±18.6 nM (mean ± 
SD, n=3)] was approximately two-fold higher than in control cells 
(p=0.035). Iloprost treatment of NG108-15 cells (16 hours, lpM ) 
resulted in a 59±13% (mean ± SD, n=6) decrease in the basal levels of 
adenylyl cyclase activity and a 61 ±14% (mean ± SD, n=6) decrease in 
maximal (lgM ) iloprost stimulated adenylyl cyclase.
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Basal adenylyl cyclase activity was measured in the presence of 
20mM MnCh. This is believed to be a condition which attenuates the 
interaction of G sa and the adenylyl cyclase catalytic subunit (Limbird et 
al, 1979). The basal level of adenylyl cyclase activity, without the 
contribution of tonic G sa activation of its catalytic moiety, can thus be 
measured. No significant difference (p=0.977) was observed between 
basal adenylyl cyclase activity in both control membranes and iloprost 
treated cell membranes in the presence of MnCh (table 3.2). Iloprost 
treatment of NG108-15 cells therefore did not modify the levels of 
activity of the adenylyl cyclase polypeptide.
NG108-15 cells were treated for 16 hours with lOpM forskolin to 
determine if the loss of G sa from the plasma membrane was dependent 
on elevated intracellular cAMP levels. Forskolin activates a combination 
of the catalytic moiety of adenylyl cyclase and Gsa, independently of 
receptor, increasing intracellular levels of cAMP (Darfler et al, 1982). 
On prolonged exposure of NG108-15 cells to lOpM forskolin and hence 
to high levels of cAMP there was no significant change in membrane 
associated levels of Gsa. Expressed as a percentage of control values, 
densitometric scan analysis revealed levels of G sa in forskolin treated 
cells to be 100±7% (mean ± SD, n=3) (figure 3.10), indicating the 
cAMP-independent nature of G sa down-regulation.
A half-maximal time of 2-3 hours for both IP prostanoid receptor 
and G sa down-regulation was observed in membranes prepared from 
NG108-15 cells which had been treated with lpM  iloprost over a range 
of times (0-12 hours) (figure 3.11). To determine if G sa remaining in 
the plasma membrane after iloprost treatment was fully functional, and
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could activate adenylyl cyclase, membranes prepared from iloprost 
treated NG108-15 cells over a time course were solubilised with 1% 
(w/v) sodium cholate (1 hour, 4°C). Solubilised extracts were 
reconstituted into eye- S49 lymphoma cell membranes and adenylyl 
cyclase activity measured, in the reconstituted system, as described in 
section 2.9. The level of G sa activity (as assessed by NaF stimulated 
adenylyl cyclase activity) remaining in the NG108-15 plasma membrane 
after iloprost treatment, was expressed as a percentage of control 
membranes. This was very similar to the amount of immunologically 
detectable G sa lost from the plasma membrane on iloprost treatment at 
every time point, indicating the temporal loss of both G sa protein and 
activity. There was no corresponding change in membrane associated 
Gi2a levels over the time course of iloprost treatment (figure 3.12).
Cytosolic preparations from control and iloprost treated cells were 
examined for the presence of G sa to determine if the G-protein a-subunit 
was released into the cellular cytosol on iloprost treatment of NG108-15 
cells (figure 3.13). A very small proportion (not capable of being 
accurately quantitated by densitometric scanning) of the total cellular 
G sa was present in the cytosol of control NG108-15 cells. No increased 
levels of G sa were observed in cytosol derived from cells which had 
been treated with iloprost for 3 hours. [3 hours was the time determined 
to be half-maximal for iloprost mediated G sa down-regulation (figure 
3.11)].
Membranes prepared from control and iloprost treated NG108-15 
cells were resolved by SDS polyacrylamide gel electrophoresis alongside 
recombinant E. Coli. expressed Gsa45 and Gsa42, and western blotted 
for Gsa using an antiserum raised to the C-terminal decapeptide of G sa
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(table 2.1). Gsa45, was the most abundant form of G sa expressed in 
NG108-15 cells. Less than 10% of the total membrane associated Gsa 
was Gsa42, and although it also appears to be down-regulated, because 
of its low level of expression this effect was difficult to characterise 
(figure 3.14a). All further reference to Gsa in these cells will refer to the 
45kDa form unless otherwise stated.
To quantify the molar amount of G sa present within control 
NG108-15 membranes and the amount of G sa down-regulated on 
iloprost treatment of cells, membranes prepared from control and iloprost 
treated NG108-15 cells were resolved by SDS polyacrylamide gel 
electrophoresis alongside a range of concentrations of the recombinant 
Gsa45 (6-24ng). The samples were then quantified by assessing the 
binding of a [125I]-labelled goat anti-rabbit IgG to the colorimetrically 
developed immunoblots. Standard curves of the amount of Gsa45 and 
the corresponding number of [125I]-labelled goat anti-rabbit IgG counts 
bound were constructed (figure 3.14b) and the amount of G sa present in 
control and iloprost treated cell membranes calculated from these curves. 
This quantitation indicated that Gsa45 was present in NG108-15 cell 
membranes at some 9.6±1.5 pmoles/mg membrane protein (mean ± SD, 
n=4). Treatment with iloprost (lpM , 16 hours) decreased the membrane 
associated levels of this polypeptide to 3.0±0.3 pmoles/mg membrane 
protein (mean ± SD, n=3).
Treatment of NG108-15 cells with a range of concentrations of 
iloprost gave an EC50 of approximately 30nM iloprost for both G sa and 
IP prostanoid receptor down-regulation. (figure 3.15). The fractional 
occupancy of the IP prostanoid receptor was calculated for each 
concentration of iloprost used to treat the cells, using an estimated IC50
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(corrected for receptor occupancy) for iloprost displacement of PGE1 of 
14.8nM. At all concentrations of iloprost the molar ratio of Gsa and IP 
prostanoid receptor down-regulation was calculated (figure 3.16). The 
ratio was 1:7-10 receptor:Gsa and did not substantially vary with the 
fractional occupancy of the IP prostanoid receptor.
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Discussion
Prostaglandins produce a broad range of biological effects in 
diverse tissues and cells through their binding to specific receptors on the 
plasma membrane. The interaction of prostaglandin and prostacyclin 
receptors with G-proteins has been identified by both radioligand binding 
and biochemical studies (Haluska et al, 1989). A classification of 
different subtypes of prostaglandin receptor has been proposed by 
Coleman and co-workers (1985, 1987), based on functional criteria, 
using the rank order of potencies of natural prostaglandins and a few 
relatively selective agonists and antagonists. The five main types of 
prostaglandin receptor are TP, DP, IP, FP and EP recognising with high 
affinity thromboxane A2, PGD2, PGI2, PGF2o: and PGE2 respectively. 
The diverse and sometimes opposite effects of the prostaglandins on cell 
function have been attributed to their interaction with both adenylyl 
cyclase and phospholipase C (Samuelsson et al, 1978; Black and 
Wakelam, 1990), depending on the cell type or tissue assayed.
Scatchard manipulation of data obtained from saturation binding of 
[3H]-PGE1 revealed that NG108-15 cells express an apparent 1 - 1 . 5  
pmoles / mg membrane protein of an IP prostanoid receptor, which has a 
Kd of approximately 30nM for [3H]-PGE1 (figure 3.5). Alternatively, 
manipulation of the competition binding data (figure 3.3), using the 
equations derived by DeBlasi et al (1989), produced similar values for 
the IP prostanoid receptor levels and Kd estimates (figure 3.3 and 
appendix 1). Other measurements of the IP prostanoid receptor levels in 
NG108-15 cells have revealed much lower estimates (Kelly et al, 1990), 
but more recent studies have produced evidence of IP prostanoid receptor 
levels similar to those observed in this thesis (Donnelly et al, 1992). The
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pharmacological and molecular characteristics of this receptor have not 
been well-studied. However, on the basis of the relative potencies of 
PGE1 and iloprost to displace the specific binding of [3H]-PGE1 and 
[3H]-iloprost, and the lack of specific binding of [3H]-PGE2 to 
membranes of these cells, it has been argued that the receptor in NG108- 
15 cells is an IP prostanoid receptor rather than a receptor for E-series 
prostaglandins (Carroll and Shaw, 1989).
Until recently, very few receptors for metabolites of arachidonic 
acid had been defined at the molecular level. Recently, a receptor on the 
human platelet for thromboxane A2 (Ehrata et al, 1991), a murine PGF 
receptor (Sugimoto et al, 1994) and several murine receptors for 
prostaglandin E2 have been cloned. Examination of the primary amino 
acid sequences of these receptors revealed that they contained the seven 
hydrophobic stretches of amino acids which are indicative of G-protein- 
coupled receptors. Indeed, the thromboxane A2 receptor activates 
phospholipase C through the pertussis toxin insensitive protein, Gq/11 
(Shenker et al, 1991). Three subtypes of the receptors for PGE2 were 
identified; EP1 (Watabe et al, 1993), EP2 (Sugimoto et al, 1992) and 
EP3 (Honda et al, 1993), which are coupled to calcium mobilisation, and 
the stimulation and inhibition of adenylyl cyclase respectively, through 
the corresponding G protein(s). This characterisation has proven to be 
too simplistic. Recent studies from Namba and co-workers (1993) 
demonstrated that alternative splicing of the gene for the EP3 receptor 
generates four isoforms of the receptor differing only in their C-terminal 
tail. The C-terminal of a G-protein coupled receptor is known to be a 
site for determining G-protein interaction and specificity (Conklin and 
Bourne 1993a). These isoforms of the receptor differentially coupled to 
various second messenger systems, through their individual interaction
124
with different G-proteins (Negishi et al, 1989; Goureau et al, 1992). 
More receptors for metabolites of arachidonic acid are likely to be cloned 
in the near future, and it will be interesting to examine if these receptors 
are also alternatively spliced in the C-terminal tail.
A high affinity, G-protein coupled, IP prostanoid receptor was 
observed in the plasma membrane of NG108-15 cells after iloprost 
treatment (figure 3.8, table 3.1). Although apparently coupled to a G- 
protein it must be noted that the remaining IP prostanoid receptor may 
not all be coupled to Gs. Recent evidence from Negishi and co-workers 
(1993) showed that the EP3C receptor can couple to both Gs and Go, so 
it cannot be definitively stated that all of the IP prostanoid receptor 
couples only to Gs. Desensitisation of the 02-adrenergic receptor on 
treatment with agonist results in a rapid uncoupling of the receptor from 
Gs, due to phosphorylation of the receptor by the protein kinase /SARK, 
and subsequent binding of arrestin (Hausdorff et al, 1990). From the 
results presented here it cannot be determined if a rapid uncoupling of the 
IP prostanoid receptor from Gs occurs in the early stages of agonist 
exposure. Certainly on long term prostanoid exposure there appears to 
be no, or very little, uncoupling of the receptor from Gs. 50-70% of both 
the IP prostanoid receptor (figure 3.8) and G sa are down-regulated 
(figure 3.6) on iloprost treatment, and it is uncertain if IP prostanoid 
receptor-G-protein uncoupling occurs, either by a previously undefined 
"IP prostanoid receptor kinase" or protein kinase A (PKA), before the 
receptor and G-protein are internalised. Previous studies by Keen and 
co-workers (1992) are in agreement with these results. This group 
demonstrated that after iloprost, and also forskolin, treatment of NG108- 
15 cells, the IP prostanoid receptor is still coupled to a G-protein in the 
cell membrane (Krane and Keen, 1992).
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The similarity of the half-maximal concentrations for adenylyl 
cyclase activation (figure 3.9) and G sa down-regulation (figure 3.15), by 
iloprost (approximately 30nM), suggested that the G sa down-regulation 
may be mediated via cAMP-dependent events. Treating NG108-15 cells 
with the diterpene forskolin, which activates a combination of the 
adenylyl cyclase catalytic subunit and Gsa, elevating intracellular cAMP 
levels (Darfler et al, 1982), had no effect on the levels of membrane 
associated G sa (figure 3.10). Additionally iloprost treatment had no 
effect on the membrane associated levels of Gi2a (figure 3.6 and 3.12). 
These results were in direct contrast to studies in S49 lymphoma cells, 
which demonstrated that agonist activation of the 02-adrenergic receptor 
resulted in a cAMP-dependent decrease in G sa and an increase in Gi2a 
(Hadcock et al, 1990). The changes in membrane associated G sa and 
Gi2a were reflected in the corresponding mRNA levels. On the 
contrary, prostanoid treatment of NG108-15 cells resulted in no change in 
G sa mRNA levels (McKenzie and Milligan, 1990).
The cAMP dependent nature of the desensitisation in S49 
lymphoma cells has been attributed to an enhanced transcription rate of 
the gene for Gi2a. One of the cAMP-dependent transcription factors 
binds to the cAMP response element in the 5' promoter region of the 
Gi2a gene (Brann et al, 1987) and activates its transcription. No cAMP 
response element is present in the gene encoding G sa and the observed 
decrease in Gsa, in the S49 lymphoma cell line, is most likely to be the 
result of a cAMP-dependent decreased stability of the G sa mRNA. G sa 
mRNA contains two AUUUA rich consensus sequences in its 3' 
untranslated region which are thought to target the mRNA for enhanced 
degradation (Loganzo and Fletcher, 1993).
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On the contrary, G sa down-regulation by prostanoids in NG1 OS- 
15 cells is a cAMP-independent event (figure 3.10; Krane and Keen, 
1992; Keen et al, 1992), independent of the regulation of G a mRNA 
levels and also independent of regulation at the level of protein synthesis 
(McKenzie and Milligan, 1990). This suggests that the regulation of 
G sa protein levels is conducted through an enhanced proteolysis of the 
G-protein a-subunit, targetted either through the physical dissociation of 
the G-protein or some reversible covalent modification of the protein (as 
discussed in section 1.11). Certainly the mechanism of desensitisation of 
the IP prostanoid receptor appears to be different from that of the 02- 
adrenergic receptor, although this could also be attributed to differences 
in receptor desensitisation between cell types.
On short term exposure to agonist the 02-adrenergic receptor is 
rapidly sequestered from the plasma membrane (Hertel et al, 1983). 
Long term agonist exposure results in a cellular down-regulation of the 
02-adrenergic receptor (Collins et al, 1992). Although there are 
suggestions of PKA phosphorylation mediating an enhanced proteolysis 
of the 02-adrenergic receptor (Campbell et al, 1991; Bouvier et al,
1989), most evidence points to a down-regulation of the receptor through 
internalisation and transfer into the endosomal pathway where 
degradation subsequently occurs (von Zastrow et al, 1992). The 
sustained decreased cellular levels of 0 2 -adrenergic receptor are due to a 
cAMP-dependent decreased stability of the 02-adrenergic receptor 
mRNA, which contains an AUUUA rich sequence in its 3' non-coding 
region (Hadcock et al, 1989a). Several other G-protein coupled 
adenylyl cyclase-linked receptors contain this sequence in their mRNA, 
suggesting that perhaps they undergo a similar process in long term 
desensitisation (McFarland et al, 1989; Dearry et al, 1990; Sprengel et
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al, 1990). The IP prostanoid receptor down-regulation has been shown, 
at least in part, to be dependent on cAMP (Wiltshire et al, 1990; Keen et 
al, 1992). This indicates either the presence of the AUUUA consensus 
sequences in the 3' untranslated region of its mRNA allowing a decrease 
in its stability, or a CRE in the 5’ region of the gene allowing the binding 
of the transcription factor CREM which, unlike CREB, serves to down- 
regulate the transcription of the gene (Foulkes et al, 1991). However, 
the gene for the IP prostanoid receptor, in NG108-15 cells, has not yet 
been cloned and the presence of these, and potentially other, sequences 
which are capable of regulating the mRNA levels, will, until then, remain 
speculative.
Accumulating evidence suggests that an additional pathway exists 
to regulate $2-adrenergic receptor mRNA levels that is independent of 
cAMP. In S49 lymphoma cells isoprenaline gave a much greater 
decrease in receptor mRNA levels than forskolin (Hadcock et al, 
1989b). Additional studies with S49 lymphoma cells which have 
mutants in the cAMP-producing part of the pathway suggested that there 
is an additional pathway which exists for regulating receptor mRNA that 
does not require stimulated levels of cAMP but nonetheless does require 
unstimulated cAMP-dependent protein kinase activity (Hadcock et al, 
1989b). Forskolin stimulation of NG108-15 cells resulted in a 30% 
down-regulation of IP prostanoid receptor (Keen et al, 1992), whereas 
maximal down-regulation by iloprost was 50-70% (figure 3.8). Another 
unidentified pathway involved in IP prostanoid receptor down-regulation 
may exist in NG108-15 cells, perhaps identical to the cAMP-independent 
one discovered by Hadcock and co-workers (1988, 1989b).
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Time courses and dose responses for the down-regulation of the IP 
prostanoid receptor and Gsce are very similar suggesting that both 
polypeptides may be co-intemalised (figure 3.11). Green and co­
workers have similarly observed a concurrent down-regulation of the Al 
adenosine receptor and "Gi-like” proteins, in a ratio of receptor.Gi of 
1:10, in rat adipocytes on prolonged agonist exposure (Green et al, 
1990). It will be interesting to determine if both polypeptides are 
sequestered and degraded in the same membrane vesicle, or if distinct 
processes control the down-regulation of each polypeptide. The 
emerging body of evidence indicates that down-regulation of the 0 2 - 
adrenergic receptor requires its coupling to Gs (chapter 1) suggesting that 
the receptor-G-protein complex may be the target for down-regulation. 
The reason for this remains unclear because in the majority of studies 
G sa is not down-regulated along with the 02-adrenergic receptor 
(Gonzales et al, 1989; Rich and Iyengar, 1990). It may be that G- 
protein coupling serves to expose certain residues of the receptor, which 
act as substrates for, as yet, undefined cytoskeletal elements, potentially 
allowing the internalisation and subsequent down-regulation of the 
receptor, however this remains to be unequivocally determined. 
Certainly the 5-opioid receptor in NG108-15 cells is down-regulated on 
agonist exposure without coupling to Gi2a (Law et al, 1985), indicating 
the possible existence of distinct receptor specific mechanisms of 
receptor down-regulation.
Several isoforms of adenylyl cyclase have recently been cloned (as 
described in section 1.8.1). These have been shown to be differentially 
regulated by PKC, G-protein 07 dimers and Ca2+ (table 1.1). The exact 
nature of the adenylyl cyclase(s) expressed in NG108-15 cells is not 
known, however, there was no change in the functional capacity of the
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catalytic component of adenylyl cyclase on iloprost treatment, indicating 
no alteration in the levels of activity of the effector protein (table 3 .2). 
The decrease in basal adenylyl cyclase activity in membranes from 
iloprost treated NG108-15 cells appears to be due to the loss of tonic 
activation of adenylyl cyclase by the decreased levels of membrane 
associated Gsa. The diminished levels of IP prostanoid receptor may 
also contribute to the decreased basal adenylyl cyclase activity through 
decreasing the 'empty' receptor stimulation of adenylyl cyclase (more 
fully discussed in chapter 4).
There was no apparent release of the G sa subunit to the cytosol 
after 2-3 hours of iloprost treatment of NG108-15 cells (figure 3.13), 
unlike the &2-adrenergic receptor in S49 lymphoma cells which gave an 
agonist stimulated release of G sa to the cytosol (Ransnas et al, 1989). 
A PI pellet (which comprises of all the cellular material minus the cytosol 
- see figure legend 3.13) was examined immunologically for G sa levels 
in the above experiment. An approximate 50% decrease in G sa was 
observed upon iloprost treatment, with no increase in cytosolic levels, 
indicating a cellular down-regulation of Gsa, suggesting an 
internalisation of the polypeptide into endosomal compartments and 
subsequent protein degradation Two recent studies have demonstrated 
that iloprost treatment of mouse mastocytoma cells (Negishi et al, 1992) 
and human platelets (Mollner et al, 1992) resulted in a complexing of the 
G sa with an unknown protein in the cytosol and plasma membrane 
respectively. This is in agreement with Takahashi and co-workers 
(1991) who showed that factors present in the cytosol promoted the 
release of Gi2a from mouse mastocytoma cells, on receptor stimulation, 
and the released Gi2a was identified as a high molecular weight soluble 
complex with unidentified components. This unknown protein may
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serve to target the G-protein a-subunit for enhanced proteolysis, before 
internalisation.
Heterologous desensitisation and the down-regulation of G sa or 
the impairment of G sa function were shown to be coincidental 
occurrences in several systems upon prolonged agonist exposure (Rich et 
al, 1984; Garrity et al, 1983; Kassis and Fishman 1982; Green et al, 
1990, 1992). Kelly and co-workers (1990) demonstrated the iloprost 
mediated heterologous desensitisation of adenylyl cyclase in NG108-15 
cells and a coincidental loss of cholera toxin catalysed [32P]-ADP- 
ribosylation. Prostanoid mediated G sa down-regulation was first 
detected immunologically by McKenzie and Milligan (1990) in the 
NG108-15 cell line and studies performed here (figure 3.6) further 
confirm that data. Approximately one pmole of IP prostanoid receptor 
was down-regulated for every 7-10 pmoles G sa at various degrees of 
receptor occupancy by agonist (figure 3.16). This was in agreement with 
similar studies on the Al adenosine receptor in rat adipocytes which 
showed a down-regulation of receptor.Gila and receptor:Gi3a ratios of 
1:10 (Green et al, 1990).
Approximately 3 pmoles fully functional G sa were left in the 
plasma membrane after iloprost treatment of NG108-15 cells (figure 
3.11, 3.15). Kim and co-workers (unpublished observations) recently 
showed, using high affinity [3H]-forskolin binding to measure Gsa- 
adenylyl cyclase complexes in NG108-15 cells, that G sa is in a 70-fold 
excess over the adenylyl cyclase catalytic moiety. If heterologous 
desensitisation of adenylyl cyclase in NG108-15 cells by iloprost is 
mediated through Gsa down-regulation several points must be 
considered. Firstly, the quantity of G sa remaining in the plasma
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membrane after iloprost treatment must be examined to determine if it is 
sufficient to couple to all the A2 adenosine receptor (or secretin receptor) 
and then maximally activate adenylyl cyclase; and secondly the capacity 
of the remaining G sa to interact with each of the receptor and effector 
proteins of the signalling cascade must be explored. These points will be 
discussed below.
0.5 pmoles IP prostanoid receptor (approximately the amount 
remaining in NG108-15 cell membranes after iloprost treatment) will 
down-regulate approximately 3-5 pmoles G sa on agonist treatment, thus 
it appears that there is a sufficient amount of G sa left in the plasma 
membrane (approximately 3 pmoles) to be activated by a large 
proportion, if not by all, of the remaining IP prostanoid receptor. (This 
is only the case if the ratio of receptor:Gsa activation is similar to that of 
down-regulation. The ratio of receptor:Gsa activated is not necessarily 
identical to the stoichiometry of down-regulation. Rapid recycling of 
activated G sa by fiy dimers may make the ratio of G sa activation higher 
than that of its down-regulation.)
The levels of A2 adenosine receptor remain undetermined in 
NG108-15 cells due to the lack of availability, until recently, of a suitable 
radioligand (Keen et al, 1989) allowing no determination of the 
stoichiometry of A2 adenosine receptor:Gsa activation on agonist 
exposure. It is therefore uncertain if the A2 adenosine receptor requires 
more than 3 pmoles G sa to maximally activate adenylyl cyclase. The 
elucidation of the ratio of A2 adenosine receptor: G sa activation will be 
important in determining if the quantity of G sa remaining in the NG1 OS- 
15 cells after iloprost treatment is limiting for A2 adenosine receptor
132
activation of adenylyl cyclase and thus responsible for the resultant 
heterologous desensitisation.
After iloprost treatment all of the remaining membrane associated 
G sa is fully functional (figure 3.11). It may not, however, be capable of 
interacting with the IP prostanoid and A2 adenosine receptors and, 
indeed, the other components of the signalling cascade for a number of 
reasons. It has been shown that the lateral mobility of G-protein coupled 
receptors is greater than for those of the tyrosine kinase family (Jans, 
1992). Decreased lateral mobility of the V2 vasopressin receptor in 
LLC-PK1 renal epithelial cells, using pretreatments with either low 
temperature or NH4CI, resulted in a decreased receptor mediated 
production of cAMP, with no effect on non-receptor stimulated adenylyl 
cyclase activity. This suggests a role for the lateral mobility of receptors 
in regulating receptor coupling to G-proteins and hence the effector (the 
"mobile receptor hypothesis"). Although, as yet, poorly investigated the 
lateral mobility of G-proteins may also be important in determining its 
coupling to the receptor and effector. Indeed, preliminary studies in 
NG108-15 cells using fluorescently labelled (tetramethylrhodamine) Goa 
and I3y demonstrated their restricted mobility within the plane of the 
plasma membrane (Kwon et al, 1992). Constraints imposed on the 
lateral mobility of both receptor and G-protein, may therefore serve to 
control receptor-G and G-effector interactions, indicating the potential for 
another point of producing diversity in signalling pathways, whereby 
selective release of these constraints could result in either, one receptor 
activating only one or several G-proteins or several G-proteins activating 
only one or several effectors.
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Interestingly, temperature and NH4CI pretreatments which affect 
the lateral mobility of the V2 vasopressin receptor and subsequently 
decrease cAMP production, also affect the actin cytoskeleton (Jans et al
1992), suggesting that cytoskeletal elements may regulate the lateral 
mobility of the signalling elements in the plasma membrane. Evidence is 
accumulating from several groups that G-protein a-subunits can associate 
with cytoskeletal structures. Octyl glucoside, a detergent which 
preserves the membrane-cytoskeletal interaction, was used to extract 
these elements from rat brain synaptosomes. This yielded large guanine 
nucleotide sensitive polydisperse structures (Nakamura and Rodbell, 
1990). It is uncertain if these polydisperse structures of Go; subunits are 
distinct elements from single heterotrimeric G-proteins or if they 
represented the native form of the protein. It appears that the a-subunits 
of heterotrimeric G-proteins can self-associate along with cytoskeletal 
elements. Wang and co-workers (1990) have also shown that G sa and 
G ila  bind to tubulin with high affinity whereas Gi2a and Gi3a do not. 
Tubulin is a GTP-binding protein with structural homology to 
heterotrimeric G-proteins (Mandelkow et al, 1985; Rasenick et al, 
1989;). It can transfer its guanine nucleotides to both G sa and G ila  
thereby activating the G-protein. Because tubulin only transfers its GTP 
to Gsa and G ila  it has been suggested that tubulin is an adenylyl cyclase 
regulatory protein. Several 'in vivo' studies have been performed in S49 
lymphoma cells, which lack G ila , using the inhibitors of microtubule 
polymerisation, colchicine and vinblastine (Insel and Kennedy, 1978; 
Kennedy and Insel, 1979; Leiber et al, 1993). An enhancement of 0- 
adrenergic receptor stimulated adenylyl cyclase was observed in cells 
treated with these inhibitors. More recent studies on S49 lymphoma 
cells treated with colchicine demonstrated an increase in high affinity 
[3H]-forskolin binding, which measures the formation of Gsa-adenylyl
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cyclase complexes, when compared to untreated cells (Leiber et al,
1993). Inhibition of tubulin polymerisation appeared to enhance the 
interaction of Gs with adenylyl cyclase, suggesting that tubulin ordinarily 
places constraints on G sa adenylyl cyclase interactions and 
compartmentalisation of Gs exists, whereby not all of Gsa ordinarily has 
access to adenylyl cyclase. Constraints on the interaction of G sa and 
adenylyl cyclase may, therefore, be involved in the heterologous 
desensitisation of adenylyl cyclase in NG108-15 cells.
In NG108-15 cells there is a 70-fold excess of G sa over adenylyl 
cyclase (Kim et al, 1994, unpublished observations). Unless the 
stoichiometry of Gsa-adenylyl cyclase interaction is very much greater 
than one, the adenylyl cyclase catalytic component is quantitatively the 
limiting factor in the signalling cascade. If G sa is to account for iloprost 
mediated heterologous desensitisation of adenylyl cyclase in NG108-15 
cells, either constraints on the interaction of G sa and adenylyl cyclase 
must occur as suggested above, or all of the G sa activated does not 
interact with adenylyl cyclase. Indeed, G sa has been shown to couple to 
the inhibition of calcium channels (Khac et al, 1991), to allow opening of 
voltage dependent calcium channels (Kameyama et al, 1985; Yatani et al, 
1987), to inhibit the activity of voltage-dependent Na+ channels 
(Schubert et al, 1989) and to inhibit Mg2+ flux (Maguire and Erdos, 
1980). The interaction of G sa with these effectors must, therefore, be 
examined in NG108-15 cells.
Recent findings from Kleuss and co-workers (1992, 1993) have 
shown that preferential a-subunit coupling with subtypes of 0 and 7  G- 
protein subunits demonstrate differential coupling to receptors. All of 
the remaining Gsa in the plasma membrane after iloprost treatment may
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not be capable of interacting with the IP prostanoid or A2 adenosine 
receptors through preferential coupling to specific subtypes of fiy which 
signals G sa coupling to another receptor/effector. The EP3C receptor, 
recognising PGE2, has been shown to couple to both Gs and Go (Negishi 
et al, 1993). Some of the IP prostanoid receptor remaining after iloprost 
treatment may already be coupled to a G-protein distinct from Gs, and 
therefore be incapable of interacting it, and so stimulating adenylyl 
cyclase.
In rat adipocytes the involvement of the "Gi-like" protein down- 
regulation in agonist mediated heterologous desensitisation of adenylyl 
cyclase inhibition has been shown (Green et al, 1992), and it seems likely 
that G sa plays a pivotal role in heterologous desensitisation of adenylyl 
cyclase stimulation in NG108-15 cells. It must, however, be considered 
that the down-regulation of G sa and the development of heterologous 
desensitisation are merely coincidental occurrences and another 
mechanism is involved in mediating the iloprost induced heterologous 
desensitisation of adenylyl cyclase in NG108-15 cells. The most likely 
alternative is via a cAMP-dependent protein kinase, and, indeed, 
elevating intracellular cAMP with forskolin results in a 30% decrease in 
NEC A stimulated adenylyl cyclase activity in NG108-15 cells (Wiltshire 
et al, 1990; Keen et al, 1992). However, inhibitors of protein kinase A 
(H7) and /SARK (heparin) do not affect the desensitisation of the A2 
adenosine receptor (Malkhandi and Keen 1992) and it has been proposed 
by Keen and co-workers (1992) that cAMP plays only a minor role in the 
desensitisation because the loss of receptor responsiveness is much 
smaller with forskolin than with either iloprost or NECA. Alternatively 
heterologous desensitisation of adenylyl cyclase could be the result of 
increased phosphodiesterase activity breaking down cAMP produced by
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the adenylyl cyclase enzyme. In rat Sertoli cells the level of mRNA 
transcripts encoding a high affinity cAMP phosphodiesterase is increased 
by more than 100-fold when these cells are treated with dibutyryl cAMP 
(Swinnen et al, 1989). cAMP can therefore regulate the expression of 
one of its own degrading enzymes by an intracellular feedback 
mechanism and it must not be discounted that this is a possibility for 
iloprost mediated heterologous desensitisation in NG108-15 cells .
In summary, one pmole of IP prostanoid receptor is down- 
regulated for every 8-10 pmoles G sa in a cAMP-independent manner. 
Down-regulation of the IP prostanoid receptor and G sa demonstrate 
identical time courses and dose responses following iloprost treatment, 
indicating the temporally concurrent down-regulation of receptor and 
Gsa. The involvement of the down-regulation of G sa in iloprost- 
induced heterologous desensitisation of adenylyl cyclase in NG108-15 
cells remains to be unequivocally demonstrated, although emerging 
evidence strongly suggests that cytoskeletal elements serve to constrain 
G sa in specific "pools" within the plasma membrane of S49 lymphoma 
cells. This requires to be investigated more fully in NG108-15 cells. 
Potentially these "pools" could differentially interact with receptor and/or 
effector. Similarly the role of dimers in determining G-protein- 
receptor coupling, and perhaps Gsa-adenylyl cyclase coupling requires 
further investigation in NG108-15 cells.
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CHAPTER 4
Characterisation of the elements of the adenylyl cyclase signalling 
cascade in NG108-15 cells transfected with the /52-adrenergic
receptor.
Introduction
The NCB20 cell line is a half-sister of the NG108-15 cell line and 
was formed by the fusion of the N18TG2 mouse neuroblastoma with 
cells of embryonic hamster brain (Minna et al, 1972). NCB20 cells 
express approximately 100 fmoles/mg membrane protein of a high 
affinity IP prostanoid receptor (Kelly et al, 1990) . This receptor is 
likely to be of the same molecular species as the IP prostanoid receptor in 
the NG108-15 cell because of their joint parentage, the N18TG2 mouse 
neuroblastoma. The IP prostanoid receptor in NCB20 cells couples to 
adenylyl cyclase (Blair et al, 1980, 1981) through G sa activating it 10-15 
fold. Interestingly, there is no apparent down-regulation of G sa on 
iloprost treatment of NCB20 cells (Leigh et al, 1985; Mullaney and 
Milligan, unpublished observations). The down-regulation of G sa on 
iloprost treatment appears therefore not to be a unique feature of the IP 
prostanoid receptor, but it may be dependent either on the cell line 
expressing it or on its level of expression. The IP prostanoid receptor is 
expressed at high levels, 1.0 - 1.5 pmoles/mg membrane protein (figure 
3.5), in NG108-15 cells where it is capable of down-regulating G sa on 
prolonged agonist treatment, whereas in NCB20 cells the levels of IP 
prostanoid receptor expression are much lower. Additionally, G sa 
down-regulation, by the activation of the IP prostanoid receptor, has been 
shown to be dependent on receptor occupancy (figure 3.16). The 
agonist mediated down-regulation of G sa may, therefore, be dependent 
on the level of receptor expression.
The A2 adenosine and secretin receptors also activate adenylyl 
cyclase in NG108-15 cells, and prolonged agonist activation of these 
receptors does not result in a down-regulation of G sa (McKenzie et al,
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1990). These receptors may also be expressed at low levels unable to 
produce an apparent agonist mediated Gsa down-regulation. Until 
recently measuring the levels of A2 adenosine receptor expression in the 
NG108-15 cell has proved problematic due to the lack of a specific 
radioligand (Keen et al, 1989). It is therefore uncertain as to the level of 
A2 adenosine receptor expression in these cells. Certainly, the secretin 
receptor is expressed at very low levels, between 25-30 finoles/mg 
membrane protein, in NG108-15 cells (Gossen et al, 1990).
The expression of another Gsa-coupled receptor at similar levels 
to the IP prostanoid receptor in NG108-15 cells, and the examination of 
the effects of agonist at this receptor, would potentially determine if G sa 
down-regulation was unique to the IP prostanoid receptor in NG108-15 
cells. Furthermore, isolation of NG108-15 cells expressing differing 
levels of a distinct Gsa-coupled receptor would enable the further 
elucidation of the involvement of receptor levels in G sa down-regulation.
It has been well-established that the $1-adrenergic receptor 
activates adenylyl cyclase through Gsa. Several groups (Ransnas et al, 
1989; Hadcock et al, 1990) have detected a loss of G sa from the plasma 
membrane on prolonged isoprenaline treatment of S49 lymphoma cells. 
Transfection of NG108-15 cells with a cDNA for the /32-adrenergic 
receptor was undertaken, with the objective of selecting clones with 
differing levels of receptor expression and subsequently examining the 
effect of isoprenaline treatment on membrane associated G sa levels in 
these clones.
In this chapter the method of transfection of NG108-15 cells with a 
cDNA for the human /32-adrenergic receptor will be briefly described.
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The /32-adrenergic receptor expressed in the NG108-15 cells will be 
characterised, as will the elements proximal to cAMP production in the 
adenylyl cyclase signalling cascade, to determine whether the transfection 
process resulted in any changes in IP prostanoid receptor, G-protein or 
adenylyl cyclase protein expression.
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Figure 4.1 Full length nucleotide and deduced amino acid
sequence of a cDNA for the human £2-adrenergic 
receptor (Kobilka e t a l , 1987).
The ATG and the termination codon, TGA, in the 5' untranslated 
region are underlined. Within the coding sequence the sites of N-linked
glycosylation are indicated by *. The consensus cAMP-dependent
*
protein kinase A phosphorylation sites are boxed. In the 3' untranslated 
region three potential polyadenylation sequences are underlined.
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Figure 4.1
-11i
TGGAACTGGCAGGCACCGCGAGCCCCTAGCACCCGACAAGCTGAGTGTGCAGGACGAGTCCCCACCACACCCACACCAC
-32
AGCCGCTGAATGAGGCTTCCAGGCGTCCGCTCGCGGCCCGCAGAGCCCCGCCGTGGGTCCGCCCGCTGAGGCGCCCCCA
1 36 
GCCAGTGCGCTTACCTGCCAGACTGCGCGCC ATG GGG CAA CCC GGG AAC GGC AGC GCC TTC TIG CTG
Met Gly Gin Pro Gly Asn Gly Ser Ala Phe Leu Leu * 96
GCA CCC AAT AGA AGC CAT GCG CCG GAC CAC GAC GTC ACG CAG CAA AGG GAC GAG GTG TGG
Ala Pro Asn
*
Arg Ser His Ala Pro Asp His Asp Val Thr Gin Gin Arg Asp Glu Val Trp 
156
GTG GTG GGC ATG GGC ATC GTC ATG TCT CTC ATC GTC CTG GCC ATC GTG TTT GGC AAT GTG
Val Val Gly Met Gly H e Val Met Ser Leu lie Val Leu Ala lie Val Phe Gly Asn Val 
216
CTG GTC ATC ACA GCC ATT GCC AAG TIC GAG CGT CTG CAG ACG GTC ACC AAC TAC TTC ATC
Leu Val lie Thr Ala lie Ala Lys Phe Glu Arg Leu Gin Thr Val Thr Asn Tyr Phe lie 
276
ACT TCA CTG GCC TGT GCT GAT CTG GTC ATG GGC CTG GCA GTG GTG CCC TTT GGG GCC GCC
Thr Ser Leu Ala Cys Ala Asp Leu Val Met Gly Leu Ala Val Val Pro Phe Gly Ala Ala 
336
CAT ATT CTT ATG AAA ATG TGG ACT TTT GGC AAC TTC TGG TGC GAG TTT TGG ACT TCC ATT
His lie Leu Met Lys Met Trp Thr Phe Gly Asn Phe Trp Cys Glu Phe Trp Thr Ser lie 
396
GAT GTG CTG TGC GTC ACG GCC AGC ATT GAG ACC CTG TGC GTG ATC GCA GTG GAT CGC TAC
Asp Val Leu Cys Val Thr Ala Ser lie Glu Thr Leu Cys Val lie Ala Val Asp Arg Tyr
456
TTT GCC ATT ACT TCA CCT TTC AAG TAC CAG AGC CTG CTG ACC AAG AAT AAG GCC CGG GTG
Phe Ala lie Thr Ser Pro Phe Lys Tyr Gin Ser Leu Leu Thr Lys Asn Lys Ala Arg Val
516
ATC ATT CTG ATG GTG TGG ATT GTG TCA GGC CTT ACC TCC TTC TTG CCC ATT CAG ATG CAC
H e lie Leu Met Val Trp H e Val Ser Gly Leu Thr Ser Phe Leu Pro lie Gin Met His
576
TGG TAC CGG GCC ACC CAC CAG GAA GCC ATC AAC TGC TAT GCC AAT GAG ACC TGC TGT GAC
Trp Tyr Arg Ala Thr His Gin Glu Ala lie Asn Cys Tyr Ala Asn Glu Thr Cys Cys Asp 
636
TTC TTC ACG AAC CAA GCC TAT GCC ATT GCC TCT TCC ATC GTG TCC TTC TAC GTT CCC CTG
Phe Phe Thr Asn Gin Ala Tyr Ala lie Ala Ser Ser lie Val Ser Phe Tyr Val Pro Leu 
696
GTG ATC ATG GTC TTC GTC TAC TCC AGG GTC TTT CAG GAG GCC AAA AGG CAG CTC CAG AAG
Val lie Met Val Phe Val Tyr Ser Arg Val Phe Gin Glu Ala Lys Arg Gin Leu Gin Lys 
756
ATT GAC AAA TCT GAG GGC CGC TTC CAT GTC CAG AAC CTT AGC CAG GTG GAG CAG GAT GGG
lie Asp Lys Ser Glu Gly Arg Phe His Val Gin Asn Leu Ser Gin Val Glu Gin Asp Gly 
816
CGG ACG GGG CAT GGA CTC CGC AGA TCT TCC AAG TTC TGC TTG AAG GAG CAC AAA GCC CTC
Arg Thr Gly His Gly Leu Arg Are Ser . Ser! Lys Phe Cys Leu Lys Glu His Lys Ala Leu
876
AAG ACG TTA GGC ATC ATC ATG GGC ACT TTC ACC CTC TGC TGG CTG CCC TTC TTC ATC GTT
Lys Thr Leu Gly H e lie Met Gly Thr Phe Thr Leu Cys Trp Leu Pro Phe Phe lie Val 
936
AAC ATT GTG CAT GTG ATC CAG GAT AAC CTC ATC CGT AAG GAA GTT TAC ATC CTC CTA AAT
Asn lie Val His Val H e Gin Asp Asn Leu lie Arg Lys Glu Val Tyr lie Leu Leu Asn 
996
TGG ATA GGC TAT GTC AAT TCT GGT TTC AAT CCC err ATC TAC TGC CGG AGC CCA GAT TTC
Trp lie Gly Tyr Val Asn Ser Gly Phe Asn Pro Leu lie Tyr Cys Arg Ser Pro Asp Phe 
1056
AGG ATT GCC TTC CAG GAG CTT CTG TGC CTG CGC AGG TCT TCT TTG AAG GCC TAT GGG AAT
Arg lie Ala Phe Gin Glu Leu Leu Cys Leu Arg Arg iSer 1 Ser! Leu Lys Ala Tyr Gly Asn 
1116
GGC TAC TCC AGC AAC GGC AAC ACA GGG GAG CAG AGT GGA TAT CAC GTG GAA CAG GAG AAA
Gly Tyr Ser Ser Asn Gly Asn Thr Gly Glu Gin Ser Gly Tyr His Val Glu Gin Glu Lys 
1176
GAA AAT AAA CTG CTG TGT GAA GAC CTC CCA GGC ACG GAA GAC TTT GTG GGC CAT CAA GGT
Glu Asn Lys Leu Leu Cys Glu Asp Leu Pro Gly Thr Glu Asp Phe Val Gly His Gin Gly 
1236
ACT GTG CCT AGC GAT AAC ATT GAT TCA CAA GGG AGG AAT TGT AGT ACA AAT GAC TCA CTG
Thr Val Pro Ser Asp Asn H e Asp Ser Gin Gly Arg Asn Cys Ser Thr Asn Asp Ser Leu 
1313•  • . . . .
CTG TAA AGCAGTTTTTCTACTTHAAAGACCCCCCCCCCCCCAACAGAACACTAAACAGACTATTTAACTTGAGGGT 
Leu —
1392
AATAAACTTAGAATAAAATTGTAAAAATTGTATAGAGATATGCAGAAGGAAGGGCATr.CTTCTGr.CTTrrTTATTTTTT
1471
TAAGCTGTAAAAAGAGAGAAAACTTATTTGAGTGATTATTTGTTATTTGTACAGTTCAGTTCCTCTTTGCATGGAATTT
 • . . . . . .  1550
GTAAGTTTATGTCTAAAGAGCTTTAGTCCTAGAGGACCTGAGTCTGCTATATTTTCATGACTTTTCCATGTATCTACCT
1629
CACTATTCAAGTATTAGGGGTAATATATTGCTGCTGGTAATTTGTATCTGAAGGAGATTTTCCTTCCTACACCCTTGGA 
• ... • . . . . . .  1708
CTTGAGGATTrTGAGTATCTCGGACCTTTCAGCTGTGAACATGGACTCTTCCCCCACTCCTCTTATTTGCTCACACGGG
GTArnTAGGCAGGGATTTGAGGAGCAGCTTCAGTTGTTTTCCCGAGCAAAGGTCTAAAGTTTACAGTAAATAAAATGT
1810 ------
TTGACCATGAAAAAAAAAAAAAA
Figure 4.2 Plasmid map of the expression vector pSVL
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Figure 4.3 [3H]-DHA binding analysis in membranes prepared 
from control COS-1 cells and COS-1 cells which had 
been transfected with a cDNA for the human f t2- 
adrenergic receptor.
COS-1 cells were transfected with lOpg plasmid DNA (ft2- 
adrenergic receptor cloned into pSVL) as described in appendix ll(ii). 
Control and transfected cells were harvested, washed twice in PBS (xl) 
and membranes were prepared as described in section 2.3. The 
membranes were analysed for specific [3H]-DHA binding. 25 pg 
membranes from both control and transfected COS-1 cells were 
incubated with lOnM [3H]-DHA for 30 minutes at 30°C. Samples were 
then placed on ice, filtered through Whatman GF/C filters using a 
Brandell cell harvester and washed three times with 5ml ice cold buffer 
as described in section 2.7. Non-specific binding was determined by 
incubating a parallel set of membranes with lOnM [3H]-DHA and lOpM 
(-) propranolol. Untransfected COS-1 cell membranes specifically 
bound 120±12 fmoles/mg membrane protein (1) and transfected COS-1 
membranes bound 523±85 finoles/mg membrane protein (2), a 4.4-fold 
increase in [3H]-DHA binding.
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Figure 4.3
Figure 4.4 Plasmid map of the expression vector pJM16 or 
LK444 (Gunning e t  a l , 1987).
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Figure 4.4
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Figure 4.5 Increasing the incubation time of membranes,
prepared from /SN22 and /3N17 cells, with pH]- DHA.
Membranes from 0N22 (5gg) and 0N17 (25pg) cells were 
incubated with 0.5 nM pH]-DHA at 30°C for increasing lengths of time 
(0 - 45 minutes). Samples were then returned to ice, rapidly filtered 
through Whatman GF/C filters and washed three times with ice cold 
buffer as described in section 2.7. A parallel series of iilcubations were 
performed using lOpM (-) propranolol to determine non-specific binding. 
Figure 4.5a represents [3H]-DHA binding in membranes of /3N22 cells 
and figure 4.5b represents binding in 0N17 membranes. The results 
were expressed as the mean ± SD (n=3), of which two other identical 
experiment in 0N22 gave similar results.
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Figure 4.6 [3H]-DHA binding analysis on increasing amounts of
$N22 and f i Nl l  cell membranes.
0N22 (0 - 45pg) and /3N17 (0 - 50pg) membranes were incubated 
for 30 minutes at 30°C with [3H]-DHA. Samples were then returned to 
ice, rapidly filtered through Whatman GF/C filters and washed three 
times with ice cold buffer by a Branded cell harvester as described in 
section 2.7. Non-specific binding was determined for each protein 
amount using lOpM (-) propranolol. Figure 4.6a represents [3H]-DHA 
binding in 0N22 cell membranes and figure 4.6b represents its binding in 
/SN17. The results were expressed as mean ± SD (n=3), from a single 
experiment of which one other produced similar results in /3N22.
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Figure 4.7 [3H]-DHA saturation binding analysis in membranes
prepared from clone 0N22.
lOpg /3N22 cell membranes were incubated with various 
concentrations of [3H]-DHA (0 - 5.4 nM) for 30 minutes at 30°C. 
Samples were then returned to ice, rapidly filtered through Whatman 
GF/C filters using a Branded cell harvester and washed three times with 
ice cold buffer as described in section 2.7. Non-specific binding was 
determined at each concentration of [3H]-DHA using lOpM (-) 
propranolol. A saturation binding curve was constructed (figure 4.7a). 
Specific fmoles bound/mg membrane protein were plotted (□) and non­
specific binding ( • )  was also plotted expressed in dpm. The specific 
binding was manipulated according to Scatchard (1949) (figure 4.7b). A 
Bmax of 4300 fmoles/mg membrane protein with a Kd of 0.37 nM was 
calculated. Two other experiments were performed which essentially 
produced similar results.
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Figure 4.8 [3H]-DHA saturation binding analysis in membranes
prepared from clone /3N17.
25 pg /3N17 membranes were incubated with various 
concentrations of [3H]-DHA (0 - 5.5 nM) for 30 minutes at 30°C. 
Samples were placed on ice, rapidly filtered through Whatman GF/C 
filters and washed three times with ice cold buffer using a Brandell cell 
harvester according to section 2.7. Non-specific binding was determined 
at each concentration by the binding of [3H]-DHA in the presence of 
lOpM (-) propranolol. A saturation binding curve was constructed of 
the specific binding of [3H]-DHA in /3N17 cell membranes (figure 4.8a). 
Non-specific binding increased linearly with [(3H)-DHA] (results not 
shown). The data was manipulated according to Scatchard (1949) 
(figure 4.8b). A Bmax of 380 finoles bound/mg membrane protein and a 
Kd of 0.26 nM was calculated. This was a representative experiment of 
three performed.
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Figure 4.9 Saturation binding of [3H]“PGE1 in membranes from
clones £N22 and £N17.
25pg membranes prepared from /3N22 and 0N17 cells were 
incubated with 5 or lOnM [3H]-PGE1 and increasing [PGE1] (0-90nM), 
for 30 minutes at 30°C, as described in appendix 1. Samples were then 
placed on ice, filtered through Whatman GF/C filters and washed three 
times with ice cold buffer by a Brandell cell harvester, as described in 
section 2.7. The data was manipulated according to Scatchard (1949) 
for /3N22 (figure 4.9a) and jSN17 (figure 4.9b). The Bmax was 2100 
ffnoles/mg membrane protein and the Kd was 26.0 nM for /3N22 cell 
membranes. For /3N17 the Bmax was 1120 ffnoles/mg membrane 
protein and the Kd was 21.1 nM. Two other identical experiments 
produced essentially the same results in /3N22 membranes and one other 
experiment was performed in /3N17 membranes with a similar result.
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Figure 4.10 Western blotting analysis of Ga in membranes
prepared from /SN22 and NG108-15 cells.
Membranes prepared from wild-type NG108-15 cells and /3N22 
cells were TCA precipitated, loaded onto a 10% (w/v) acrylamide / 
0.25% N,N'-methylene bisacrylamide gel and western blotted for the 
various Go:, as described in section 2.6. Lane 1 was loaded with 
NG108-15 membranes and lane 2 with /3N22 membranes. Panel A 
shows 40gg membrane protein western blotted with CS1 (1:250); panel 
B shows 50pg protein blotted with SGI (1:400); panel C shows lOOgg 
protein blotted for I3B (1:1000); panel D shows 50gg protein blotted 
with IM1 (1.250) and panel E shows 50gg protein blotted with CQ2 
(1:1000) as described in table 2.1. Colorimetrically developed blots 
were densitometrically scanned and /3N22 levels taken as a percentage of 
NG108-15 levels as follows: Gso: = 98±6%; Gi2o; = 93±7%; Gi3a = 
99±6%; Goa = 103±8% and G q/Ua = \00±\0%  (mean ± SD, n=3). 
The results were from three immunoblots using individual membrane 
preparations of cells.
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Figure 4.11 Western blotting analysis of Ga in membranes from
0N17 and NG108-15 cells.
Membranes prepared from wild-type NG108-15 cells and /3N17 
cells were TCA precipitated, loaded onto a 10% (w/v) acrylamide / 
0.25% N,N'-methylene bisacrylamide gel and western blotted for the 
various Gee, as described in section 2.6. Lane 1 was loaded with 
NG108-15 membranes and lane 2 with 0N17 membranes. Panel A 
shows 50pg membrane protein western blotted with SGI (1:400); panel 
B shows lOOgg protein blotted for I3B (1:1000); panel C shows 50gg 
protein blotted with CQ2 (1:1000); panel D shows 40gg membrane 
protein western blotted with CS1 (1:250) and panel E shows 50gg 
protein blotted with IM1 (1.250) and as described in table 2.1. 
Colorimetrically developed blots were densitometrically scanned and 
j6N17 levels taken as a percentage of NG108-15 levels as follows: G sa = 
100±11%; Gi2a = 94±1%; Gi3a = 100±6%; Goa = 145±6% and 
G q /lla  = 105±13% (mean ± SD, n=3). The results were from three 
immunoblots using individual membrane preparations of cells.
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Figure 4.12 Examination of the cellular morphology of NG108-15 
(a) and £N17 (b) cells.
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Figure 4.13 Displacement of 0.5nM pH]-DHA by increasing
concentrations of isoprenaline ± IOOjuM GTPyS, in
membranes prepared from /3N22 cells.
lOpg 0N22 membranes were incubated with 0.5nM [3H]-DHA 
and increasing concentrations of isoprenaline (0 - lOOgM), in the 
presence and absence of IOOjiM GTPyS, for 30 minutes at 30°C. 
Samples were returned to ice, rapidly filtered through Whatman GF/C 
filters using a Brandell cell harvester and washed as described in section 
2.7. The IC50 (corrected for receptor occupancy) (-GTPyS) was 86nM 
(o) and the IC50 (corrected for receptor occupancy) (+ GTPyS) was 
207nM (□). In the experiment shown there was an approximate two­
fold increase in the IC50 (corrected for receptor occupancy) on 
incubation with IOOjiM GTPyS. However, another three experiments 
were performed and on pooling the data this increase did not achieve 
statistical significance : IC50 (-GTPyS) = 141±55nM and IC50 (+ 
GTPyS) = 216±30nM (mean ± SD, n=4), p=0.11.
153
% 
m
ax
im
al
 
sp
ec
ifi
c 
bi
nd
in
g
Figure 4.13
100 Q -
0.0001
[isoprenaline] (M)
Figure 4.14 Displacem ent of 0.5nM pH ]-DH A with increasing
concentrations of isoprenaline ± IOOjliM G TP7S, in
membranes prepared from #N17 cells.
25pg /3N17 membranes were incubated with 0.5nM [3HJ-DHA 
and increasing concentrations of isoprenaline (0 - 100gM), in the 
presence and absence of lOOgM GTP7 S, for 30 minutes at 30°C. 
Samples were placed on ice and rapidly filtered through Whatman GF/C 
filters using a Branded cell harvester and washed three times with ice 
cold buffer as described in section 2.7. The IC50 (corrected for receptor 
occupancy) (-GTP7 S) was 41nM(o) and the IC50 (corrected for receptor 
occupancy) (+ GTP7 S) was 263nM (□). There was an approximate ten­
fold increase in the IC50 (corrected for receptor occupancy) on 
incubation with lOOpM GTP7 S. The results were expressed as the 
mean of triplicate assay points. One other identical experiment produced 
a similarl result.
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Figure 4.15 Analysis of the ability of sodium cholate extracts of 
membranes, prepared from NG108-15 and /JN22 
cell, to activate adenylyl cyclase when reconstituted 
into S49 lymphoma eye- cell membranes.
2pg each of /3N22 and NG108-15 cell membranes were solubilised 
using 1% (w/v) sodium cholate (1 hour, 4°C), extracts were reconstituted 
into S49 lymphoma eye- cell membranes and adenylyl cyclase activity 
measured as described in section 2.9. The adenylyl cyclase activity was 
amplified in the presence of lOmM NaF. NG108-15 cells (1) gave a 
20.5±1.4 pmoles cAMP formed/min/mg membrane protein stimulation 
over basal with NaF, and 0N22 cells (2) gave a 23.0±1.8 pmoles cAMP 
formed/ min/mg membrane protein stimulation. The results were 
expressed as the mean ± SD (n=3), of a single experiment. Two others 
produced similar results.
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Figure 4.16 Measurement of adenylyl cyclase activity in
membranes prepared from /3N22 and /3N17 cells in 
response to increasing concentrations of iloprost.
lOpg membranes prepared from either /3N22 (o) or /3N17 (□) cells 
were analysed for adenylyl cyclase activity as described in section 2 .8 . 
Adenylyl cyclase activity was amplified in the presence of increasing 
concentrations of iloprost (0-1 OpM). The basal enzyme activity was 
subtracted from the adenylyl cyclase activity measured at each 
concentration of iloprost. Each value was then calculated as a 
percentage of the maximal adenylyl cyclase response. The results were 
expressed as the mean of tripicate assay points, from a single experiment. 
Two others produced similar results in both 0N22 and 0N17 cell 
membranes.
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Figure 4.17 Measurement of adenylyl cyclase activity in
membranes prepared from /SN22 and 0N17 cells in 
response to increasing concentrations of isoprenaline.
lOpg membranes prepared from either /3N22 (□) or 0N17 (o) cells 
were assayed for adenylyl cyclase activity as described in section 2 .8 , in 
the presence of increasing concentrations of isoprenaline (0 - lOOpM). 
The basal enzyme activity was subtracted from the adenylyl cyclase 
activity measured at each of the concentrations of isoprenaline. Each 
value was then taken as a percentage of the maximal adenylyl cyclase 
response and plotted graphically. The results were taken as the mean of 
triplicate assay points, from a single experiment of which two others 
(/SN17) and four others (0N22) produced similar results.
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Table 4.1 Measurement of [3HJ-DHA binding in membranes
prepared from wild-type NG108-15 cells.
25pg membranes prepared from NG108-15 cells were incubated 
with either 5.4nM or 1.45 nM [3H]-DHA for 30 minutes at 30°C. The 
reaction was placed on ice, filtered through Whatman GF/C filters using a 
Brandell cell harvester and washed three times with ice cold buffer as 
described in section 2.7. Non-specific binding was determined in the 
presence of lOpM (-) propranolol. The results were expressed as the 
mean ± SD (n=3), from a single experiment of which three others gave 
similar results.
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Table 4.1
[3H-DHA]
(nM)
5.4
1.45
dpm
non-specific binding
3109±71
1018±48
total binding
2969±130
1128±33
Table 4.2 Incubation of membranes prepared from /3N22 and 
/8N17 with [3H]-PGE1 in the presence of lOOpM 
GTP7 S.
25pg membranes prepared from /3N22 and /3N17 cells were 
incubated with lOnM [3H]-PGE1 in the presence or absence of lOOpM 
GTP7 S for 30 minutes at 30°C and analysed for [3H]-PGE1 binding as 
described in section 2.7. Non-specific binding was determined using 
lOpM PGE1. The results were expressed as the mean ± SD (n=3), from 
a single experiment. Three others produced similar results.
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Table 4.2
Treatment
PN22 - GTP7S 
PN22 + GTPyS 
PN17 - GTP7S 
PN17 + GTPyS
[3H]-PGE1 (fmoles %
*
bound/mg protein) control
147±15.4 100
39.7112.1 27
163123 100
87.714.0 54
Table 4.3 Measurement of agonist stimulated adenylyl cyclase
activity in /JN22, 0N17 and NG108-15 cell membranes.
lOgg /3N22 and NG108-15 cell membranes were analysed for 
adenylyl cyclase activity as described in section 2.8, in the presence of 
lOgM isoprenaline and lgM  iloprost (table 4.3a). The results were the 
mean ± SD (n=3), from a single experiment. Two others produced 
similar results.
Similarly, in a separate experiment, lOgg 0N17 and NG108-15 
cell membranes were analysed for adenylyl cyclase activity as described 
in section 2.8, in the presence of lOgM isoprenaline and lgM  iloprost 
(table 4.3b). The results were the mean ± SD (n=3) of a single 
experiment. Two others produced similar results.
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Table 4.3
a) Adenylyl cyclase activity
(pmoles/min/mg membrane protein)
NG108-15 j8N22
basal 25.4±5.0 81.5±7.0
isoprenaline (lOgM) 29.0±3.0 193±5.8
iloprost (lgM ) 180±4.2 192±5.2
b) Adenylyl cyclase activity
(pmoles/min/mg membrane protein)
NG108-15 0N17
basal 25.4±10.9 21.0±5.9
isoprenaline (lOgM) 16.8±8.7 138.1±1.0
iloprost (lgM ) 248.0±5.8 183.0±13.2
Table 4.4 Measurement of basal adenylyl cyclase activity in
the presence of 20mM MnCh in membranes prepared 
from clones #N22 and 0N17.
Basal adenylyl cyclase was measured in lOpg membranes prepared 
from 0N22, 0N17 and NG108-15 cells as described in section 2.8. Basal 
adenylyl cyclase activity was also measured in the presence of 20mM 
MnCte- When MnCh was included in the assay, the MgCh routinely 
added was excluded. The results were the mean ± SD (n=3), from a 
single experiment. Two others gave similar data.
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Table 4.4
Basal 
+ Mn
Adenylyl cyclase activity 
(pmoles/min/mg membrane 'protein)
N G 108-15 pN22 p N 1 7
31.6+1.3 84.3±1.1 31.0±1.3
11.2±1.2 12.7±1.4 11.0±1.6
Table 4.5 Measurement of basal adenylyl cyclase activity in 
0N22 and NG108-15 cell membranes on incubation 
with lOpM propranolol.
lOpg membranes prepared from /3N22 and NG108-15 cells were 
analysed for adenylyl cyclase activity as described in section 2 .8 , in the 
presence of lOpM propranolol. The results were the mean ± SD (n=3), 
from a single experiment. Two others produced similar results.
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Table 4.5
Adenylyl cyclase activity
*
(pmoles/min/mg membrane protein) 
N G 108-15 pN22
Basal 33.0±2.3 89.1±4.3
Propranolol (10p.M) 33.3±2.3 60.4+0.7
Results
Before commencing the longer, more laborious task of producing 
stable transfects of NG108-15 cells with a cDNA for the 02-adrenergic 
receptor, it was first necessary to determine that the cDNA available 
(figure 4.1) would express the 02-adrenergic receptor, by use of a 
transient transfection system. A cDNA for the human 02-adrenergic 
receptor was cloned into the plasmid pSVL (figure 4.2) downstream of 
the late SV40 promoter as described in appendix ll(ii). lOpg plasmid 
DNA was used to transiently transfect simian COS-1 cells using the 
Lipofectin reagent as explained in section 2.22. Transfected COS-1 cells 
were harvested 51 hours after the addition of 2 0% foetal calf serum and 
membranes were prepared from the cells as described in section 2.3. 
The /3-adrenergic receptor antagonist [3H]-dihydroalprenolol ([3H]- 
DHA)(10nM) was used to assess 02-adrenergic receptor binding. 
Samples were incubated for 30 minutes at 30°C and non-specific binding 
was determined in the presence of lOgM (-) propranolol. Transiently 
transfected COS-1 cell membranes demonstrated a 4.4-fold increase in 
[3H]-DHA binding over control COS-1 cell membranes (figure 4.3), 
indicating that the cDNA for the human 02-adrenergic receptor encoded 
for the receptor in COS-1 cells.
NG108-15 cell membranes were assayed for specific [3H]-DHA 
binding to determine if the cells endogenously expressed any 02- 
adrenergic receptor. This was found not to be the case (table 4.1). 
Having established that the cDNA would encode a 02-adrenergic 
receptor, NG108-15 cells were stably transfected with this cDNA as 
described in appendix ll(iii). The cDNA for the human 02-adrenergic 
receptor was cloned into the plasmid pJM16 (figure 4.4) downstream of
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the 0-actin promoter. NG108-15 cells were stably transfected with 10pg 
plasmid DNA as explained in section 2.22. Geneticin resistant 
(0.8mg/ml) cell colonies were picked and expanded. Membranes were 
prepared from the clones as described in section 2.3 and analysed for the 
02-adrenergic receptor using [3H]-DHA binding as described for the 
transient transfection (figure 4.3).
Two geneticin resistant clones 0N22 and /3N17 were selected 
which expressed 4000 and 300 fmoles 02-adrenergic receptor/mg 
membrane protein respectively. Time courses of 0.5nM [3H]-DHA 
binding on both clones showed that binding equilibrium was achieved 
after approximately 20 minutes incubation at 30°C (figure 4.5). Samples 
were incubated at 30°C for 30 minutes to ensure equilibrium binding. 
The amount of membrane protein in the binding assay was increased and 
the corresponding number of specifically bound [3H]-DHA counts were 
measured in both clones (figure 4.6). A linear relationship between the 
amount of membrane protein and the number of specifically bound counts 
was observed in 0N22 cell membranes with up to 45pg membrane 
protein. Subsequently up to 25pg membrane protein was used in /3N22 
[3H]-DHA binding assays. In 0N17 cells the number of specifically 
bound counts increased linearly with the amount of membrane protein up 
to 50gg. Routinely up to 40gg membrane protein was used in j6N17 
[3H]-DHA binding assays.
Saturation binding using [3H]-DHA was performed on both of the 
positive clones selected. Scatchard analysis of the data revealed that 
0N22 expressed 4317±375 fmoles receptor/mg membrane protein (mean 
± SD, n=3) and this bound with high affinity (Kd = 0.32±0.20nM) 
(figure 4.7). Similarly, /3N17 expressed 292±76 fmoles receptor/mg
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membrane protein (mean ± SD, n=3) which also bound with high affinity 
(Kd = 0.52±0.20 nM) (figure 4.8). Non-specific binding increased 
linearly with [3H-DHA] in both cell lines.
The level of IP prostanoid receptor expression was measured in 
both clonal cell lines by saturation binding of [3H]-PGE1 as described in 
appendix 1. /3N22 expressed 1210±731 fmoles receptor/mg membrane
protein (mean ± SD, n=3) with a Kd for [3H]-PGE1 of 21.7±7.9 nM 
(mean ± SD, n=3) (figure 4.9a), and 0N17 expressed 1048±103 
fmoles/mg membrane protein with a Kd for [3H]-PGE1 of 18.7±3.5 nM 
(mean ± SD, n=2) (figure 4.9b). In both clones, 0N22 (p=0.86) and 
/3N17 (p=0.82) the levels of IP prostanoid receptor were not significantly 
different to that measured by saturation binding in the wild-type NG1 OS- 
15 cell line (1208±397 fmoles bound/mg protein). The pseudo Hill 
coefficients were calculated for [3H]-PGE1 binding in 0N22 (1.03±0.1) 
and in /3N17 (1.03±0.07). There was at least a 50% decrease in specific 
[3H]-PGE1 binding, in membranes prepared from both clones, when 
measured in the presence of lOOpM GTP7 S (table 4.2).
Equivalent amounts of NG108-15 and /3N22 cell membranes were 
western blotted for various Go: subunits using antisera raised against the 
C-terminal decapeptide of G a as described in table 2.1. Expressed as a 
percentage of Go: levels in NG108-15 membranes there were no changes 
in membrane associated G sa (98±6%); Gi2a (93±7%); Gi3a (99±6%); 
Goa (103±8%) and G q /lla  (100±10) in /3N22 membranes (mean ± SD, 
n=3) (figure 4.10). There were also no changes in levels of G sa 
(100±11), Gi2a (94±1%), Gi3a (100±6%) and G q /lla  (105±13%) in 
0N17 cell membranes, expressed as a percentage of NG 108-15 G a levels 
(mean ± SD, n=3)(figure 4.11). Surprisingly, Goa levels were
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substantially higher in j3N17 cells (145±6%, mean ± SD, n=3, p<0.005). 
Wild-type NG108-15 cells exliibit a 250-300% increase in membrane 
associated Goo: on cellular differentiation, which can be induced by 
treatment of the cells with various cAMP-elevating agents (Mullaney and 
Milligan, 1989). Differentiation of NG 108-15 cells results in cells with 
very long neuronal-like processes which adhere less well to the flask 
surface (Hamprecht et al, 1985). Examination of jSNl 7 cells revealed no 
detectable difference in the cellular morphology when compared to wild- 
type NG108-15 cells, indicating that the /3N17 cells were not 
differentiated (figure 4.12).
Membranes prepared from /3N22 cells were incubated with 0.5nM 
[3H]-DHA and the radioligand was displaced with increasing 
concentrations of isoprenaline (0-100pM). The displacement was 
additionally performed in the presence of lOOpM GTP7 S. The IC50 
(corrected for receptor occupancy) was 141 ±5 5 nM (mean ± SD, n=4) in 
/3N22 membranes, and on incubation with GTP7 S the IC50 (corrected for 
receptor occupancy) was 216±30nM (mean ± SD, n=4). There was no 
significant difference in the IC50 (corrected for receptor occupancy) on 
incubation of /3N22 cell membranes with GTP7 S, p=0.11 (figure 4.13). 
The pseudo Hill coefficient of /3N22 in the absence of GTP7 S was 
0.72±0.05 and in the presence of lOOpM GTP7 S was 0.78±0.11.
Isoprenaline (O-lOOjuM) displacement of 0.5nM [^HJ-DHA in 
membranes from (3N17 cell membranes was also examined. (3N17 
membranes gave an IC50 (corrected for receptor occupancy) of 41 ± 11 
nM (mean ± SD, n=3). On incubation with GTPyS the IC50 (corrected 
for receptor occupancy) was 280 ± 25 nM (mean ± SD, n=2). In the 
presence of GTPyS there was an approximate 7-fold increase in the
166
IC50 (corrected for receptor occupancy) in [3N17 cell membranes. 
This was statistically significant p=0.007 (figure 4.14). The pseudo 
Hill coefficient for isoprenaline displacement of [3h]-DHA in (3N17 in 
the absence of GTPyS was 0.54 ±0.1 while in the presence of GTPyS it 
increased to 1.02 ± 0.13.
Both iloprost and isoprenaline gave a robust stimulation of 
adenylyl cyclase activity in membranes prepared from /3N22 and /3N17 
cells (table 4.3). However, basal adenylyl cyclase activity in /3N22 
membranes was 2-3 fold higher than that observed in wild-type NG1 OS- 
15 and /3N17 membranes (table 4.3). Wild-type NG108-15 cell 
membranes and membranes prepared from both clones showed no 
significant difference in basal adenylyl cyclase levels when assayed in the 
presence of 20mM MnCh (table 4.4), indicating the expression of similar 
amounts of adenylyl cyclase in all three cell lines.
To determine if some of the membrane associated G sa had been 
constitutively activated during the transfection process, membranes from 
both /3N22 and NG108-15 cells were solubilised with 1% (w/v) sodium 
cholate, reconstituted into S49 lymphoma eye- membranes and adenylyl 
cyclase activity measured as described in section 2.9. Extracts from 
both NG108-15 and /3N22 gave identical basal adenylyl cyclase activities 
in reconstituted eye- membranes and lOmM NaF was necessary for 
adenylyl cyclase stimulation over basal levels in both cell lines (figure
4.15).
Basal adenylyl cyclase activity was measured in both /3N22 and 
NG108-15 membranes in the presence of lOpM (-) propranolol (a /3- 
adrenergic antagonist ) (table 4.5). There was a 28.0±3.6% (mean ±
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SD, n=3) decrease in 0N22 basal adenylyl cyclase activity on incubation 
with propranolol, with no reduction in basal activity in NG108-15 
membranes.
Iloprost stimulation of adenylyl cyclase activity in membranes from 
both jSN22 and /3N17 cells gave EC50 values which did not significantly 
differ from that of wild-type NG108-15 cells (figure 4.16). The EC50 
for iloprost stimulation of adenylyl cyclase in 0N22 was 21.8±16.4 nM 
(mean ± SD, n=3, p=0.813), in 0N17 it was 29.7±5.3 nM (mean ± SD, 
n=3, p=0.681) and in NG108-15 cells it was 25.8±9.1 nM (mean ± SD, 
n=3).
Incubation of wild-type NG108-15 cell membranes with lOgM 
isoprenaline gave no significant stimulation of adenylyl cyclase activity 
over basal levels (table 4.3). Membranes prepared from both clones 
/3N22 and 0N17 were incubated with increasing concentrations of 
isoprenaline and adenylyl cyclase activity measured (figure 4.17). EC50 
values for isoprenaline stimulated adenylyl cyclase activity were 
calculated for both clones. The EC50 was 57.7±28.9 nM (mean ± SD, 
n=3) for adenylyl cyclase activation by isoprenaline in 0N17 membranes 
and the EC50 was 8.1±4.7 nM (mean ± SD, n=5) for /3N22 membranes. 
There was an approximate 7-fold decrease in the EC50 value for adenylyl 
cyclase activation by isoprenaline in /3N22 membranes when compared to 
0N17,p=O.OO7 (figure 4.17).
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Discussion
Prolonged treatment of NG 108-15 cells with a prostanoid agonist 
results in a sustained down-regulation of cellular levels of G sa (Kelly et 
al, 1990; McKenzie and Milligan, 1990; figure 3.6) whereas agonist 
treatment of other less highly expressed Gsce coupled receptors in the 
same cell do not affect membrane associated Gsc* levels (McKenzie et al, 
1990). To examine the effect of an agonist on a Gso'-linked receptor, 
distinct to the IP prostanoid receptor, in NG108-15 cells, but expressed at 
similar levels, the cells were transfected with a cDNA for the human 132- 
adrenergic receptor. The transfection process produced two cell lines 
which were examined in detail, namely /3N22 and j8N17, which 
expressed some 4000 (figure 4.7) and 300 (figure 4.8) fmoles 
receptor/mg membrane protein respectively. This was assessed by the 
specific binding of the /3-adrenergic antagonist [3H]-DHA ([3H]- 
dihydroalprenolol).
Expression of foreign DNA in cells may perturb the metabolism 
and gene expression of proteins ordinarily expressed in the cell, because 
the DNA can insert into the host chromosome at a non-specified site. 
Indeed the high basal adenylyl cyclase activity in /3N22 cells (table 4.3) 
which serves to elevate cAMP within the cell, may itself result in the 
altered gene and/or protein expression of one or more of the components 
of the adenylyl cyclase cascade for several reasons more fully detailed in 
chapter 1. cAMP can induce the destabilisation of mRNA if the correct 
consensus sequences are present (Hadcock et al, 1989); it can also 
enhance or inhibit gene transcription if the gene contains a cAMP 
response element and cAMP can also activate PKA which 
phosphorylates numerous cellular proteins with a variety of resultant
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effects (Collins et al, 1992). However, the high basal production of 
cAMP in /3N22 cells did not affect the polypeptide levels of G-protein a- 
subunits (figure 4.10) in this cell line. The levels of IP prostanoid 
receptor expression in /3N22 cells (figure 4.9a) were not significantly 
different to those in wild-type NG108-15 cells despite the down- 
regulation of this receptor in NG108-15 cells being partially dependent 
on cAMP (Wiltshire et al, 1990).
13N17 cells showed no increased basal adenylyl cyclase activity 
when compared to wild-type NG108-15 cells (table 4.3) and there was no 
change in the levels of expression of the IP prostanoid receptor (figure 
4.9b) or G-protein a-subunits except Goa (figure 4.11). There was an 
unexpected 45% increase in Goa expression in 0N17 cells. Wild-type 
NG108-15 cells will differentiate when treated with agents which elevate 
intracellular cAMP and there is a resultant 250-300% increase in 
membrane associated Goa. The morphology of the NG 108-15 cells also 
changes, exhibiting slow growth and extending long neuronal-like 
processes (Hamprecht et al, 1985; Mullaney and Milligan, 1989). 
Examination of the morphology of /3N17 (figure 4.12), revealed no 
change from wild-type NG108-15 cells indicating no cellular 
differentiation. It is uncertain of the reason for this increase in 
membrane associated Goa. /3N17 cells do not have a higher basal 
adenylyl cyclase activity than wild-type NG108-15 cells, so it is unlikely 
to be a cAMP dependent process. It may simply be that the transfection 
process has disrupted the genome in some manner affecting the 
expression of Goa or even perhaps decreasing its rate of turnover.
Receptor theory predicts that after the addition of GTP7 S, a 
condition that should uncouple all the receptor from G sa giving a pseudo
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Hill coefficient of 1.0, agonist binding will decrease as the affinity of the 
receptor for agonist and not antagonist decreases. This should produce a 
rightward shift in the agonist displacement curve (Ross et al, 1977). This 
was not the case in /3N22 (figure 4.14), although in some experiments 
there was a small (2 -fold) effect this did not achieve statistical 
significance when the data from several experiments was pooled. 
Because the pseudo Hill coefficient did not increase to 1.0 in the 
presence of excess guanine nucleotides, this indicates two affinity states 
of the receptor (G-protein-coupled and uncoupled). The lack of "shift" is 
therefore not simply a result of contaminating guanine nucleotides in the 
membrane preparation which would uncouple the f$2-adrenergic receptor 
from Gs before it was assayed in the binding experiment. Indeed, at 
least a 50% decrease in [3H]-PGE1 binding was observed in 0N22 cell 
membranes on incubation with lOOpM GTPyS (table 4.2), essentially 
identical to that observed in NG108-15 cells. It appears that even in the 
presence of an excess of a guanine nucleotide there might still exist a 
small pool of G-protein coupled /32-adrenergic receptor. The 
observation of a guanine nucleotide resistant population of receptors has 
been made in several systems, including the pituitary D2 dopamine 
receptor (Wregget and DeLean, 1984), the brain dopamine receptor 
(Wregget and Seeman, 1984) and the cardiac muscarinic cholinergic 
receptor (Burgisser et al, 1982). Grigoriadis and Seeman (1983) 
postulated that complete conversion with guanine nucleotide in these 
systems would only be observed in the presence of millimolar 
concentrations of sodium ions, but this was not the case for the pituitary 
D2 dopamine receptor (Wregget and DeLean, 1984). Sodium ions at 
this concentration have been shown to uncouple a variety of receptors 
from their G-protein (Gierschik et al, 1989), and it may be useful to 
perform the GTPyS 'shift' in /3N22 cell membranes in the presence of
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millimolar concentrations of sodium ions. It was, however, evident that 
at least some of the 02-adrenergic receptor in 0N22 cells was capable of 
coupling to G sa because of the robust receptor mediated adenylyl 
cyclase stimulation (table 4.3).
There was a 7-fold increase in the IC50 (corrected for receptor 
occupancy) of the agonist displacement curve in the presence of excess 
guanine nucleotide in 0N17 cell membranes (figure 4.14) indicating that 
at least some of the 300 fmoles 02- adrenergic receptor coupled to Gsa. 
Unlike the 02-adrenergic receptor in 0N22 cells, the pseudo Hill 
coefficient increased to 1.0 in the presence of GTP7 S demonstrating that 
all the receptor had been uncoupled from Gsa in 0N17 cell membranes.
Isoprenaline was able to stimulate adenylyl cyclase activity in 
membranes isolated from both clone 0N22 and 0N17 but not wild-type 
NG108-15 cells (table 4.3). The measured EC50 for isoprenaline 
stimulated adenylyl cyclase activity in 0N22 cells (8nM) was some 7- 
fold to the left of the dose response curve in membranes from 0N17 cells 
(figure 4.17), whereas dose responses measuring iloprost stimulated 
adenylyl cyclase activity were identical in both clones (figure 4.16). IP 
prostanoid receptor levels expressed in 0N17 and 0N22 cells were 
similar (figure 4.9) whereas the level of expression of the 02-adrenergic 
receptor in the two clones differs by some 13-fold (figure 4.7, 4.8). In 
chapter 3, a stoichiometry of down-regulation of Gso; and the IP 
prostanoid receptor in NG108-15 cells was calculated of some 8 pmoles 
Gsod pmole receptor at all levels of receptor occupancy. If this 
represents the ratio of activation of G-protein by receptor, then as the IP 
prostanoid receptor is present at approximately 1 pmole/mg membrane 
protein and Gsa at some 10 pmoles/mg membrane protein there is likely
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to be a slight molar excess of Gso: even when the entire pool of Gsce is 
activated by high concentrations of prostanoid agonist. If the 02- 
adrenergic receptor were to show similar G-protein interaction 
stoichiometry it might be anticipated that the entire pool of available Gs 
would be activated by agonist occupation of only a fraction of the 
available 02-adrenergic receptor in 0N22 and as such the dose response 
curve for G-protein and hence adenylyl cyclase activation might be 
anticipated to be to the left of the receptor occupancy curve, as indeed is 
the case. There appears, therefore, to be "spare" 02-adrenergic 
receptors in clone 0N22, whereby a fractional occcupancy can produce a 
maximal response, unlike 0N17 where maximal occupancy is necessary 
to elicit a maximal response.
Basal adenylyl cyclase levels in 0N22 membranes were 
approximately 2-fold higher than in both NG108-15 and 0N17 cell 
membranes (table 4.3). This was not due to either increased levels of 
expression (figure 4.10) or an increased intrinsic activity of G sa (figure
4.15) in 0N22 cells, produced by some artefact of the transfection 
process.
The basal level of an effector enzyme represents its activity in the 
absence of agonist activation of the receptor. This is not necessarily the 
same as being independent of receptor regulation. "Empty" receptor 
regulation of G-proteins has been recorded for the 6-opioid receptor in 
NG108-15 cells (Costa and Herz, 1989; Costa et al, 1990). Evidence in 
favour of such a model comes from the ability of agents with "negative 
intrinsic" activity to reduce basal high affinity GTPase activity (Costa and 
Herz, 1989; Costa et al, 1990). The observation that antagonists with 
"negative intrinsic" activity can decrease the basal GTPase activity
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tonically activated by "empty” receptor indicates that the "empty" 
receptor can stimulate the G-protein, although it is not possible to 
determine whether this apparent activation results from a truly 
spontaneous interaction between "empty" receptors and G-proteins or 
from some other mechanism. Certainly it was not possible to ascertain 
whether a /3-receptor antagonist would be able to reduce either basal or 
agonist stimulation of GTPase activity in membranes of /3N22 cells 
because of the well-established technical difficulties in recording 
receptor-mediated stimulation of Gs GTPase activity within the 
background of the basal activity of other high affinity GTPases (Milligan, 
1988). However, addition of the /3-adrenergic receptor antagonist 
propranolol resulted in a substantial reduction in basal adenylyl cyclase in 
membranes of /3N22 cells without altering the basal adenylyl cyclase in 
membranes from wild-type NG108-15 cells (table 4.5). Addition of an 
agonist stabilises or promotes the probability of a receptor adopting an 
active conformation which can then stimulate a signalling cascade. An 
antagonist by contrast must limit or deny the receptor such a 
conformation. As such, in cells expressing high levels of a receptor it 
may be that the number of receptors anticipated to be in the 'agonist' 
conformation at any instant may be sufficient to significantly stimulate the 
signal pathway.
Clearly a simple explanation for the elevated basal adenylyl 
cyclase activity in /3N22 membranes might relate to an enhanced 
expression of the adenylyl cyclase catalytic moiety in the cells, associated 
either with the transfection process or simply within the clone isolated. 
The basal adenylyl cyclase activities in membranes of wild-type NG1 OS- 
15 cells and from both clone /3N22 and /3N17 were not different when the 
assay was performed in the presence of Mn2+ rather than in the presence
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of Mg2+ (table 4.4). This condition is believed to be the best indication 
of the basal activity of the catalytic moiety of adenylyl cyclase without 
regulation of this activity by guanine nucleotide binding proteins (Limbird 
et al, 1979). Such results further indicate that the enhanced basal 
activity of adenylyl cyclase in 0N22 membranes results from tonic G- 
protein stimulation of the effector rather than elevated levels of the 
adenylyl cyclase catalytic moiety resulting artefactually from the 
transfection process.
In summary, clones 0N22 and 0N17 express 4000 and 300 fmoles 
02-adrenergic receptor / mg membrane protein respectively. Both clones 
expressed identical levels of IP prostanoid receptor, adenylyl cyclase 
catalytic subunit and the a-subunits from Gi2, Gi3, Gs and Gq/11, as did 
the wild-type NG108-15 cell. There was a 45% increase in Goa 
expression in 0N17 with no accompanying change in cell morphology. 
Both the IP prostanoid receptor and the 02-adrenergic receptor were 
coupled to G sa in 0N17 and 0N22. A robust isoprenaline stimulation of 
adenylyl cyclase in 0N22 was observed but there was no shift to the right 
in the agonist displacement curve of the 0 2 -adrenergic receptor on 
addition of excess guanine nucleotides. Both clones gave a robust 
stimulation of adenylyl cyclase activity by iloprost and isoprenaline. 
"Spare" 02-adrenergic receptors exist for adenylyl cyclase activation in 
0N22 but not in 0N17. The high basal adenylyl cyclase activity 
measured in 0N22 cell membranes appears to be, at least in part, a result 
of "empty" receptor regulation of adenylyl cyclase.
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CHAPTER 5
Examination of the effects of prolonged agonist 
treatment on membrane associated G-protein a -  
subunit levels in transfected NG108-15 cells.
Introduction
Agonist regulation of G-protein a-subunit levels has been 
demonstrated in several cellular systems. As described in detail in 
chapter 3 prolonged prostanoid treatment of NG108-15 cells gave a 
down-regulation of cellular Gso: levels (Kelly et al, 1990; Milligan and 
McKenzie, 1990). In rat adipocytes PIA treatment resulted in a 90% 
decrease in membrane associated levels of G ila  and Gi3a, and a 50% 
decrease in Gi2a and /3-subunit (Green et al, 1990). Chronic exposure 
of each of the HM1 receptor in transfected CHO cells (Mullaney et al, 
1993), the GnRH receptor in aT3 cells (Shah and Milligan, unpublished 
observations) and the TRH receptor long form in EMBK cells (Kim et al, 
unpublished observations) to agonists resulted in a non-selective down- 
regulation of G q /lla . In the aforementioned systems the activated G- 
protein a-subunit was subsequently down-regulated. Additionally, in 
other cases the levels of G-protein a-subunit which had not been 
activated were also regulated. Treatment of S49 lymphoma cells with 
isoprenaline which activates the 02-adrenergic receptor gave a 25% 
decrease in membrane associated levels of G sa and a 3-fold increase in 
Gi2a (Hadcock and Malbon, 1990).
The emerging body of evidence suggests that the down-regulation 
of the activated G-protein a-subunit on prolonged agonist exposure is a 
general phenomenon (Milligan and Green, 1991). There are, however, 
several exceptions. Treatment of the 6-opioid receptor in NG108-15 
cells with agonist results in a down-regulation of the 6-opioid receptor 
but not of Gi2a, (Law et al, 1985) and prolonged agonist stimulation of 
the 0 2 -adrenergic receptor in several cell lines does not give a 
coincidental down-regulation of G sa (Rich and Iyengar, 1989; Gonzales
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et al, 1992). As discussed in chapter 4 agonist treatment of the A2 
adenosine and secretin receptors in NG108-15 cells (McKenzie et al, 
1990b) and the IP prostanoid receptor in NCB20 cells demonstrated no 
down-regulation of G sa (Kelly et al, 1990, Mullaney and Milligan, 
unpublished observations). The reason for the discrepancy in agonist 
mediated down-regulation of Ga  between systems remains uncertain. 
Several possibilities exist; the genetic make-up of the cell in which the 
receptor is expressed may differentially control the agonist-mediated 
down-regulation of Ga. Alternatively, the amount of Gsa down- 
regulated may be dependent on the amount of each receptor expressed in 
every individual cell. Indeed, in chapter 3 it was shown that the IP 
prostanoid receptor will down-regulate G sa in a molar ratio of 
approximately 1:8 , at various levels of receptor occupancy on prostanoid 
treatment.
In chapter 4 the generation and characterisation of two clones of 
NG108-15 cells, /3N22 and /3N17, expressing very high (4000 ffnoles/mg 
membrane protein) and moderate (300 fmoles/mg membrane protein) 
levels of /32-adrenergic receptor respectively was described.
Examination of the agonist regulation of G sa levels in these transfected 
NG 108-15 cells, where treatment with a prostanoid agonist results in a 
down-regulation of G sa and agonist treatment of the A2 adenosine and 
secretin receptors do not, should allow the further elucidation of the role 
of receptor levels in G-protein a-subunit down-regulation.
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Figure 5.1 Analysis of Gsa levels in membranes prepared from 
control and isoprenaline treated NG108-15 cells by 
western blotting.
NG108-15 cells were treated with lOpM isoprenaline for 16 hours. 
Control and treated cells were harvested and cell membranes made as 
described in section 2.3. 20pg (lanes 1, 2), 40gg (lanes 3, 4) and 60gg 
(lanes 5, 6) membranes were TCA precipitated, loaded onto a 10% (w/v) 
acrylamide / 0.25% (w/v) N, N'-methylene bisacrylamide gel and western 
blotted for G sa using the antiserum CS3 (1:250 dilution), as described in 
section 2.6. Lanes 1,3 and 5 were loaded with control membranes and 
lanes 2,4 and 6 were loaded with membranes prepared from isoprenaline 
treated cells. The developed immunoblot was densitometrically scanned 
and the results taken as a percentage of control Gsa levels; 20pg protein: 
110%; 40pg protein: 104% and 60gg protein: 112%. Results obtained 
from one other identical experiment performed on a separate membrane 
preparation of cells gave similar results.
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Figure 5.2 Analysis of Ga levels in membranes prepared from 
control and isoprenaline treated 0N22 membranes, 
by western blotting.
Cell membranes were prepared from control and isoprenaline 
(lOpM, 16 hours) treated 0N22 cells according to section 2.3. 
Membranes were loaded onto a 10% (w/v) acrylamide / 0.25% N,Nf- 
methylene bisacrylamide gel and western blotted as described in section 
2.6. Lanes 1 and 2 in (A) were loaded with 40gg membrane protein, 
lanes in panel D were loaded with lOOgg membrane protein and all other 
lanes were loaded with 50gg protein. Lane 1 was loaded with control 
13N22 membranes, lane 2 membranes prepared from isoprenaline treated 
0N22 cells. Panel A was western blotted with CS3 (1:250) recognising 
Gsce, panel B with SGI (1:400) recognising Gi2ce, panel C with CQ2 
(1:1000) for Gq/llce, panel D with IM1 (1:250) for Goce and panel E 
with I3B (1.1000) for Gi3ce as described in table 2.1.
Colorimetrically developed blots were densitometrically scanned 
and the isoprenaline treated membrane Gee levels taken as a percentage of 
control levels for that particular Gee. Isoprenaline treatment resulted in 
the following membrane associated levels of Gee: Gsce = 48±10%, Gi2ce 
= 105±5%, Gi3ce = 104±17%, Goce = 110±5%, Gq/1 Ice = 96±19%. The 
results were expressed as mean ± SD, from the analysis of separate 
membrane preparations, n=14 for Gsce and n=3 for the other Gee.
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Figure 5.3 Molar quantitation of Gsa levels in membranes
prepared from control and isoprenaline (lOpM, 16
hours) treated £N22 cells.
30gg 0N22 cell membranes prepared from control (lanes 1) and 
isoprenaline (lOgM, 16 hours) treated (lanes 2) cells were run on a 10% 
(w/v) acrylamide / 0.25% N,N-methylene bisacrylamide gel and western 
blotted for G sa with antiserum CS3 (1:250) as described in section 2.6 
(figure 5.3a). Increasing amounts of recombinant G sa long form (2- 
25pg) were loaded alongside the samples (lane 3, 2gg; lane 4, 4pg; lane 
5, 6gg; lane 6, 8gg; lane 7, lOpg; lane 8, 15gg; lane 9, 20gg and lane 10, 
25gg). The colorimetrically developed blot was densitometrically 
scanned and the amount of Gsa long form plotted graphically against the 
corresponding value from the densitometric scan analysis (figure 5.3b).
The amount of Gso: 45 present in control and isoprenaline /3N22 
membranes was calculated from the standard curve, and the results from 
all three experiments were pooled and expressed as mean ± SD: control = 
8.4±1.1 pmoles and isoprenaline treated = 4.9±0.9 pmoles.
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Figure 5.4 Analysis of G-protein /3-subunit levels, by western 
blotting, in membranes prepared from control and 
isoprenaline (lOpM, 16 hours) treated /3N22 cells.
50pg membrane protein prepared from control (lane 1) and 
isoprenaline treated (lane 2) /3N22 cells were run on a 10% (w/v) 
acrylamide / 0.25% N,N’-methylene bisacrylamide gel and western 
blotted for the G-protein /3-subunit using the antipeptide antiserum BN3 
(1:200 dilution), as described in section 2.6. The developed immunoblot 
was densitometrically scanned and the /3-subunit levels in isoprenaline 
treated membranes expressed as a percentage of control levels. The 
results from scans of three identical immunoblots, from separate 
membrane preparations of cells were pooled and the treated value taken 
as a percentage of the control (90±9% [mean ± SD, n=3]).
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Figure 5.5 Analysis of Gsa levels, by western blotting, in
membranes prepared from £N22 cells exposed to 
increasing concentrations of isoprenaline for 16 hours.
0N22 cells were treated with increasing concentrations (O-lOOgM 
of isoprenaline for 16 hours. Membranes were made from these cells a^  
described in section 2.3. 30gg membrane protein from cells treated witl 
each concentration of isoprenaline was loaded on to a 10% (w/v 
acrylamide / 0.25% N,N'-methylene bisacrylamide gel and westerr 
blotted for Gsce using the antipeptide antiserum CS3 (1:250), as describee 
in section 2.6. Lane (1) was loaded with control /3N22 membranes, (2> 
0.1 nM, (3) InM, (4) lOnM, (5) lOOnM, (6) lpM , (7) lOpM, (8) 100plv 
isoprenaline treated cell membranes (figure 5.5a). The developed 
immunoblots were densitometrically scanned and Gsce levels expressed 
as a percentage of control levels (figure 5.5b). The results were 
expressed as mean ± SD from data pooled from analysis of three 
individual membrane preparations.
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Figure 5.6 Analysis of Gsa levels, by western blotting, in
membranes prepared from /3N22 cells which were 
treated with 10pM isoprenaline for increasing lengths 
of time.
i S N 2 2  cells were treated with lOpM isoprenaline for varying 
lengths of time. Cell membranes were made as described in section 2.3, 
and 30gg membrane protein from each time point was loaded on to a 
10% (w/v) acrylamide / 0.25% N,N'-methylene bisacrylamide gel and 
western blotted for G sa using CS3 (1:250) as described in section 2.6. 
Lane (1) was loaded with control membranes; lane (2) 1 hour 
isoprenaline treatment; (3) 2 hours; (4) 4 hours; (5) 8 hours; (6) 12 hours; 
(7) 16 hours (figure 5.6a). Developed blots were densitometrically 
scanned and the results obtained from three individual membrane 
preparations were pooled and expressed as a percentage of control 
values, mean ± SD (n=3) (figure 5.6b).
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Figure 5.7 Analysis of Gsa levels, by western blotting, in
membrane and cytosol prepared from /3N22 cells, 
treated individually with lOpM isoprenaline and 
lpM  iloprost.
0N22 cells were treated individually with lOpM isoprenaline and 
lgM  iloprost for 3 hours. The cells were harvested, washed twice in 
PBS (x l) and homogenised as described in section 2.3. The homogenate 
was spun at 150 000 x g for 30 minutes in a Beckman airflige. The 
supernatant was taken as "cytosol" and the pellet as "membranes". 30pg 
membrane protein (lanes 1,3 and 5) and cytosol protein (lanes 2,4 and 6) 
from control (lanes 1,2), isoprenaline treated (lanes 3,4) and iloprost 
treated (lanes 5,6) 0N22 cells were TCA precipitated, resolved on a 10% 
(w/v) acrylamide / 0.25% N,N'-methylene bisacrylamide gel and western 
blotted for G sa using CS3 antisera (1:250), as described in section 2.6 
(figure 5.7). No detectable increase in cytosolic Gsa was observed in 
iloprost and isoprenaline treated cells. The membrane protein bands 
were densitometrically scanned and expressed as a percentage of control: 
isoprenaline treated was 22% and iloprost was 47% (for the immunoblot 
displayed). The results were from a single experiment representative of 
three performed.
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Figure 5.8 Analysis of the ability of sodium cholate extracts of 
membranes, prepared from control and lOpM 
isoprenaline treated 0N22 cells, to activate adenylyl 
cyclase when reconstituted into S49 lymphoma cyc- 
cell membranes.
2pg each of control and isoprenaline treated (IOjiM, 16 hours) 
/3N22 cell membranes were solubilised in 1% (w/v) sodium cholate on 
ice for 1 hour, reconstituted into lOgg eye- membranes and adenylyl 
cyclase activity measured as described in section 2.9. lOmM NaF gave 
a stimulation of adenylyl cyclase activity over basal levels of 10.1 ±1.7 
pmoles cAMP formed/minute/mg membrane protein in control cell 
membranes (1) and 5.2±2.0 pmoles cAMP formed/minute/mg membrane 
protein in membranes from isoprenaline treated cells (2), a decrease of 
51.5% (p<0.05). The results were expressed as mean ± SD (n=3), of a 
single experiment which was representative of two others performed.
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Figure 5.9 Analysis of G a  levels, by western blotting, in
membranes prepared from control and isoprenaline
treated /SN17 cells.
Membranes were prepared from control and isoprenaline (lOpM, 
16 hours) treated 0N17 cells according to section 2.3. Membranes were 
loaded on to a 10% (w/v) acrylamide / 0.25% N,N'-methylene 
bisacrylamide gel and western blotted as described in section 2.6. Lanes 
1 and 2 in (A) were loaded with 40pg and 20pg membrane protein (left 
to right) and all other lanes were loaded with 50gg membrane protein. 
Lane 1 was loaded with control 0N17 membranes and lane 2 with 
membranes from isoprenaline treated /3N17 cells. Panel A was western 
blotted with CS3 (1:250) recognising Gsce, panel B with SGI (1:400) 
recognising Gi2ce, panel C with I3B (1.1000) for Gi3ce, panel D with IM1 
(1:250) for Goce and panel E with CQ2 (1:1000) for Gq/llce as 
described in table 2.1.
Colorimetrically developed blots were densitometrically scanned 
and the isoprenaline treated membrane Gee levels taken as a percentage of 
control levels. Isoprenaline treatment gave the following levels of Gee: 
Gsce = 97±9%, Gi2ce = 102±9%, Gi3ce = 98±24%, Goce = 102±11%, 
Gq/llce = 104±6%. The results were expressed as mean ± SD from 
analysis of separate membrane preparations, n=6 for Gsce, n=2 for 
Gq/11 ce and n=3 for the other Gee.
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Figure 5.10 Analysis o f G «  levels, by western blotting, in
membranes prepared from control and iloprost
treated £N22 cells.
Membranes were prepared from control and iloprost (lgM , 16 
hours) treated 0N22 cells as described in section 2.3. Membranes were 
loaded onto a 10% (w/v) acrylamide / 0.25% (w/v) N,N'-methylene 
bisacrylamide gel and western blotted as described in section 2.6. Lanes 
1 and 2 in (A) were loaded with 40pg membrane protein and all other 
lanes were loaded with 50pg membrane protein. Lane 1 was loaded 
with control /3N22 and lane 2 with membranes from iloprost treated 
(lpM ; 16 hours) 0N22 cells. Panel A was western blotted with CS3 
(1:250) recognising Gsce, panel B with SGI (1:400) recognising Gi2ce, 
panel C with 13B (1:1000) recognising Gi3ce, panel D with IM1 (1:250) 
for Goce, panel E with CQ2 (1:1000) for Gq/llce as described in table
2 . 1 .
Colorimetrically developed blots were densitometrically scanned 
and the iloprost treated membrane Gee levels taken as a percentage of 
control for that particular Gee. Iloprost treatment gave the following 
levels of Gee: Gsce = 50±15%, Gi2ce = 107±12%, Goce = 106±11%, 
Gq/llce = 97±1%. The results were expressed as mean ± SD from 
analysis of separate membrane preparations, n=7 for Gsce and n=3 for the 
other Gee.
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Figure 5.11 Analysis o f G a  levels, by western blotting, in
membranes prepared from control and iloprost
treated £N17 cells.
Membranes were prepared from control and iloprost (lgM , 16 
hours) treated /3N17 cells as described in section 2.3. Membranes were 
loaded onto a 10% (w/v) acrylamide / 0.25% (w/v) N,N'-methylene 
bisacrylamide gel and western blotted as described in section 2.6. Lanes 
1 and 2 in (A) were loaded with 40pg membrane protein and all other 
lanes were loaded with 50gg membrane protein. Lane 1 was loaded 
with control /3N17 membranes and lane 2 with membranes prepared from 
iloprost treated /3N17 cells (figure 5.11). Panel A was western blotted 
with CS3 (1:250) recognising Gsce, panel B with SGI (1:400) recognising 
Gi2ce, panel C IM1 (1:250) for Goce, panel D with CQ2 (1:1000) for 
Gq/11 ce as described in table 2.1.
Colorimetrically developed blots were densitometrically scanned 
and the iloprost treated membrane Gee levels taken as a percentage of 
control for that particular Gee. Iloprost treatment gave the following 
levels of Gee: Gsc* = 49±14%, Gi2ce = 89±11%, Goce = 96±10%, Gq/llce 
= 99±10%. The results were expressed as mean ± SD of analysis from 
separate membrane preparations (n=3).
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Figure 5.12 Analysis of G s a  levels in membranes prepared from 
/3N22 cells treated with increasing concentrations of 
iloprost.
/3N22 cells were treated for 16 hours with increasing 
concentrations of iloprost. Membranes were prepared form the treated 
cells and 30gg loaded onto a 10% (w/v) acrylamide / 0.25% N,Nf- 
methylene bisacrylamide gel and western blotted for Gsce using the 
antiserum CS3 (1:250) as described in section 2.6. Lane 1 was loaded 
with control j6N22 membranes, lane 2 with InM iloprost treated cells, 
lane 3: lOnM, lane 4: 50nM, lane 5: lOOnM, lane 6: 500nM, lane 7: lpM 
and lane 8: lOgM (figure 5.12a). The developed blot was 
densitometrically scanned and the results from three individual 
experiments pooled (mean ± SD) and expressed graphically (figure 
5.12b).
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Figure 5.13 Analysis of Gsa levels in membranes prepared from 
0N22 cells treated with lpM iloprost for increasing 
lengths of time.
0N22 cells were treated with 1 pM iloprost for increasing lengths 
of time (0-16 hours). Membranes were made from each treatment as 
described in section 2.3. 30pg membrane was loaded on to a 10% (w/v) 
acrylamide / 0.25% N,N'-methylene bisacrylamide gel and western 
blotted using the antiserum CS3 (1:250). Lane 1 was loaded with control 
j3N22 membranes, lane 2 with 0N22 cell membranes treated for 1 hour 
with iloprost, lane 3: 2 hour, lane 4: 4 hour, lane 5: 8 hour, lane 6: 12 
hour and lane 7: 16 hour (figure 5.13a). The developed blot was 
densitometrically scanned and the results from three individual 
experiments pooled (mean ± SD) and expressed graphically (figure 
5.13b).
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Figure 5.14 Measurement of the adenylyl cyclase activity, in
response to increasing concentrations of isoprenaline, 
in membranes prepared from control and isoprenaline 
treated /3N22 cells.
lOpg membranes produced from control (o) and isoprenaline (□) 
treated (10pM, 16 hours) /3N22 cells were incubated with increasing 
concentrations of isoprenaline (0 - 0.1 mM) and the adenylyl cyclase 
activity measured as described in section 2.8. The EC50 for adenylyl 
cyclase stimulation by isoprenaline in control membranes was 4.3 nM 
and in isoprenaline treated membranes was 14.3 nM. The result was 
from a single experiment representative of three performed.
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Figure 5.15 The effect of isoprenaline, iloprost and a combination 
of these agonists on membrane associated levels of 
Gsa in £N22 cells as assessed by western blotting.
/3N22 cells were treated with isoprenaline (10gM) or iloprost 
(lpM ) or a combination of these two agonists for 16 hours. Cells were 
harvested and membranes prepared as described in section 2.3. 40gg 
membrane protein was loaded on to a 10% (w/v) acrylamide / 0.25% 
(w/v) N,N'-methylene bisacrylamide gel and western blotted for Gsce 
using the antiserum CS3 (1:250) as described in section 2.6. Lane (1) 
was loaded with control membranes, lane (2) with membranes prepared 
from isoprenaline treated cells, lane (3) with membranes prepared from 
iloprost treated cells and lane (4) with membranes from cells which had 
been treated with both isoprenaline and iloprost. The developed 
immunoblots were densitometrically scanned and values taken as a 
percentage of control G sa levels. The following levels of G sa were 
observed on treatment with isoprenaline: 53±10% (mean ± SD, n=6), 
iloprost: 52±16% (mean ± SD, n=6) and both agonists: 36±8% (mean ± 
SD, n=6).
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Table 5.1 [3H)-PGE1 binding analysis in membranes prepared
from control and iloprost treated 0N22 and #N17
cells.
25pg membranes from control and iloprost treated /3N22 and /3N17 
cells were incubated with lOnM [3H]-PGE1 for 30 minutes at 30°C. 
The reaction was returned to ice and rapidly filtered through Whatman 
GF/C filters as described in section 2.7. Non-specific binding in 
membranes was defined as the [3H]-PGE1 bound in the presence of 
lOpM PGE1. The results were expressed as the mean ± SD (n=3) of a 
single experiment. Two others produced similar results.
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Table 5.1
Cell
(3N22
[3H]-PGE1 bound (fmoles/ 
mg membrane protein)
control iloprost
226±77 136±32
%
control
40
pN17 246±5 134+10 54
Table 5.2 Measurement of adenylyl cyclase activity in
membranes from control and isoprenaline treated 
/3N22 cells in the presence of 20mM MnCl2.
lOpg membranes prepared from control and isoprenaline treated 
(lOpM, 16 hours) 0N22 cells were assayed for basal adenylyl cyclase 
activity as described in section 2.8. In some cases 20mM MnCh was 
added to the incubation, and in these cases MgCh was excluded from the 
reaction mix. The results were expressed as the mean ± SD (n=3) from 
a single experiment which was representative of three performed.
194
Table 5.2
Treatment
control
control + Mn
isoprenaline (10//M) 
isoprenaline + Mn
Adenylyl cyclase activity  
(pmoles /min/mg membrane protein)
86.6±10.3
23.7±10.6
17.0±9.6
18.3±9.9
Table 5.3 Measurement of basal and iloprost stimulated
adenylyl cyclase activity in membranes from control 
and iloprost treated /3N22 cells.
lOgg membranes prepared from control and iloprost treated (lpM , 
16 hours) 0N22 cells were assayed for adenylyl cyclase activity as 
described in section 2.8 in the presence of lpM  iloprost. The results 
were the mean ± SD (n=3) of a single experiment. One other produced a 
similar result.
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Table 5.3
Treatment
control
Adenylyl cyclase activity 
(pmoles /min/mg membrane protein)
basal iloprost (l|iM )
157±10.3 489±46.1
iloprost (l|iM ) 52.0±9.8 319±13.8
Table 5.4 Measurement of agonist stimulated adenylyl cyclase 
activity in membranes from control, isoprenaline 
treated (lOpM) and iloprost treated (IjliM) /3N17 cells.
Adenylyl cyclase activity was measured according to section 2.8 in 
membranes (10pg) prepared from control, isoprenaline (lOpM, 16 hours) 
and iloprost (lpM , 16 hours) treated /3N17 cells. In several cases 
adenylyl cyclase activity was amplified in the presence of agonist (either 
lOpM isoprenaline or lpM  iloprost). Results were taken from a single 
experiment mean ± SD (n=3). Two others produced similar results.
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Table 5.4
Treatment
control
isoprenaline (10|iM) 
iloprost (l|iM )
Adenylyl cyclase activity 
(pmoles/min/mg membrane protein)
basal isoprenaline iloprost
60.0±5.0 281±16.7 378±10.5
49.7±9.3 74.6±8.2
32.1±5.7 - 195±7.6
Table 5.5 [3H]-DHA binding analysis in membranes prepared
from control and isoprenaline treated #N17 and /3N22
cells.
25pg membranes prepared from control and isoprenaline treated 
(lOpM, 16 hours) /3N17 (a) and /3N22 cells (b) were incubated with 
[3H]-DHA for 30 minutes at 30°C. /3N17 membranes were incubated
with 0.5nM [^H]-DHA and 0N22 membranes were incubated with the 
concentrations indicated in table 5.5b. The reaction was terminated by 
returning the samples to ice and filtering through Whatman GF/C filters 
as described in section 2.7. Non-specific binding was determined by the 
binding of [^H]-DHA to cell membranes in the presence of lOpM (-) 
propranolol. Results were expressed as the mean ± SD (n=3), from a 
single experiment. Two others produced similar results.
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Table 5.5a
Treatm ent [3H]-DHA (fmoles bound/mg
membrane protein)
control 281±8.6
isoprenaline (10pM) 65.9±5.4
Table 5.5b
[3H-DHA] fmoles bound/mg protein %
(nM ) control isoprenaline control
1.1 3100±160 2520±73 81
0.13 1202±53 936±29 78
Results
Wild-type NG108-15 cells were treated with lO^tM isoprenaline 
for 16 hours. The membrane-associated levels of G sa did not vary 
between control membranes ( 100%) and membranes prepared from 
isoprenaline treated cells (104±10%, mean ± SD, n=4) (figure 5.1), 
indicating that prolonged isoprenaline treatment of wild-type NG108-15 
cells does not result in G sa down-regulation.
0N22 cells, expressing approximately 4000 fmoles @2-adrenergic 
receptor/mg membrane protein, were treated with lOpM isoprenaline for 
16 hours. Membranes prepared from these cells showed a decrease in 
G sa levels to 48±11% (mean ± SD, n=14) of control membranes, as 
measured by the C-terminal decapeptide antiserum CS3 (figure 5.2, panel 
A). The membrane associated levels of other G-protein a-subunits were 
determined in both control and isoprenaline treated /3N22 cells by 
western blotting using specific antipeptide anti sera as described in table
2.1. The results were expressed as a percentage of control levels (mean 
± SD n=3). No changes in levels of membrane associated Gi2a 
(105±5%), Gi3a (104±17%), Goa (110±5%), G q /lla  (102±13%) and 0- 
subunit (90±9%) were observed after isoprenaline treatment of 0N22 
cells (figure 5.2, 5.4).
Control and isoprenaline (lOpM, 16 hours) treated 0N22 cell 
membranes were resolved by SDS-PAGE alongside various amounts (2- 
25ng) of the E. Coli expressed long form of G sa (45kDa) (figure 5.3a). 
The colorimetrically developed blot was densitometrically scanned and 
the amount of recombinant G sa 45kDa loaded on to the gel plotted 
against the corresponding numerical value of the densitometric scan
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(figure 5.3b). The amount of G sa long form in both control and 
isoprenaline treated 0N22 cell membranes was then calculated from the 
standard curve. Control 0N22 had 8.4±1.1 pmoles Gsa/mg membrane 
protein (mean ± SD, n=3) and membranes from isoprenaline treated 
0N22 cells had 4.9±0.9 pmoles Gsa/mg membrane protein (mean ± SD, 
n=3).
The loss of G sa from the plasma membrane of /3N22 cells on 
exposure to isoprenaline was both dependent on the concentration of 
isoprenaline used and the length of time the cells were exposed to it. 
The half-maximal time for isoprenaline mediated G sa down-regulation 
was 2-4 hours in 0N22 cells (figure 5.6), and the concentration of 
isoprenaline necessary to produce half-maximal G sa down-regulation 
was approximately 0.5 - 1.0 nM (figure 5.5).
0N22 cells were treated separately with lOpM isoprenaline and 
lpM  iloprost for 3 hours, the time determined to be half-maximal for 
down-regulation of G sa for both iloprost and isoprenaline. Equivalent 
amounts of "membrane" and "cytosol" prepared (as described in figure 
legend 5.7) from both control and agonist treated (3N22 cells were 
western blotted for G sa using the antipeptide antiserum CS3 (figure 5.7). 
There was no detectable increase in cytosolic levels of G sa after 
treatment of /3N22 cells with either isoprenaline or iloprost.
Sodium cholate extracts prepared from membranes of control and 
isoprenaline treated 0N22 cells were reconstituted into S49 lymphoma 
eye- cell membranes and adenylyl cyclase activity measured as described 
in section 2.9. A 45.6±14.9% (mean ± SD, n=3) decrease in lOmM NaF 
stimulated adenylyl cyclase activity was observed in eye- cell
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membranes, reconstituted with solubilised extracts from isoprenaline 
treated 0N22 membranes, when compared to control extracts (figure 5.8). 
This was similar to the amount of immimologically detectable G sa lost 
from the plasma membrane on iloprost treatment (figure 5.2).
j8N17 cells were treated with lOpM isoprenaline for 16 hours and 
membrane associated G a levels measured by western blotting with 
antipeptide antisera specific for the individual G a as described in table
2.1. Expressed as a percentage of control G a levels, no change in 
membrane associated G sa levels on isoprenaline treatment of the clone 
0N17 was observed (97±9%, mean ± SD, n=6). No apparent change in 
levels of the other G-protein a-subunits was observed, Gi2a = 102±9% 
(n=3), Gi3a -  98±24% (n=3), Goa = 102±11% (n=3) and G q /lla  = 
104±6% (n=2) (figure 5.9).
Iloprost treatment (lpM , 16 hours) of both 0N22 and 0N17 cells 
resulted in a loss of membrane associated Gsa. Expressed as a 
percentage of control levels, G sa levels were decreased to 50±15% 
(mean ± SD, n=7) in /3N22 cell membranes (figure 5.10) and to 49±14% 
(mean ± SD, n=3) in /SN17 membranes (figure 5.11). Treatment of 
j6N22 cells with increasing concentrations of iloprost revealed a half- 
maximal concentration for G sa down-regulation of approximately 50nM 
(figure 5.12). Time courses of iloprost treatment of 0N22 cells showed a 
half-maximal time of 1-2 hours for G sa down-regulation (figure 5.13). 
In both /3N22 and /3N17 cell membranes no change in other G a subunit 
levels were observed on prostanoid treatment, as assessed by western 
blotting with specific antipeptide antisera for the various G a subunits. 
Densitometric scan analysis, expressed as a percentage of control values 
(mean ± SD, n=3), revealed quantitative levels of Gi2a (107±12%), Goa
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(106±11%) and Gq/1 l a  (97±1%) in 0N22, and in 0N17 Gi2a (89±11%), 
Goa (96±10%) and Gq/1 l a  (99±10%). A decrease in lOnM [3H]-PGE1 
binding was observed on iloprost treatment: [3H]-PGE1 binding in 
iloprost treated 0N22 cells was 49.0±7.9% (expressed as a percentage 
control levels) and in iloprost treated /3N17 cells was 53.0±5.6% (table
5.1). The percentage loss of G sa and [3H]-PGE1 binding from the 
plasma membrane on iloprost treatment of both clones was essentially 
identical to that in wild-type NG108-15 cells.
Adenylyl cyclase activity, measured in membranes prepared from 
control and isoprenaline treated (lOgM, 16 hours) 0N22 cells, showed an 
EC50 for adenylyl cyclase activation by isoprenaline in control 
membranes of 7.8±6.6 nM (mean ± SD, n=3) and 28.1±14.3nM (mean ± 
SD, n=3) in membranes prepared from isoprenaline treated cells (figure 
5.14). There was no significant difference in the EC50 on isoprenaline 
treatment (p=0.060). Basal adenylyl cyclase activity decreased to 
41,7±9.0% (mean ± SD, n=3) of control levels on isoprenaline treatment 
of /3N22 cells. Similarly maximal isoprenaline stimulation of adenylyl 
cyclase decreased to 42.0±18.0% (mean ± SD, n=3) of control. Basal 
adenylyl cyclase activity in the presence of 20mM M11CI2 was identical 
in membranes prepared from both control and isoprenaline treated 0N22 
cells (table 5.2).
Iloprost treatment (lpM , 16 hours) of /3N22 cells demonstrated a 
decrease in basal (30%) and iloprost activated (65%) adenylyl cyclase. 
The results were expressed as a percentage of adenylyl cyclase activity 
measured in control membranes (table 5.3).
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Isoprenaline treatment of /3N17 cells resulted in no change in basal 
adenylyl cyclase activity, when compared to that of control /3N17 cells. 
Whereas isoprenaline gave a robust stimulation of adenylyl cyclase in 
control j8N17 membranes, little or no stimulation of adenylyl cyclase with 
isoprenaline was observed in membranes prepared from isoprenaline 
treated /3N17 cells (table 5.4). A decrease in basal (39.5±15.8%, mean ± 
SD, n=3) and iloprost stimulated (50.3±16.6%, mean ± SD, n=3) 
adenylyl cyclase was observed in membranes prepared from iloprost 
treated (lpM , 16 hours) /3N17 cells (the results were expressed as a 
percentage of control levels).
Using a single concentration of [3H]-DHA (table 5.5), membranes 
prepared from control /3N22 and isoprenaline (lOpM, 16 hours) treated 
cells were assayed for specific [3H]-DHA binding. Non-specific binding 
was determined using lOpM (-) propranolol. Specific [3H]-DHA 
binding in membranes prepared from isoprenaline treated /3N22 cells was 
75.8±12% (mean ± SD, n=7, p=0.004) of control levels (table 5.5b). 
Similarly, membranes prepared from 0N17 cells treated with 
isoprenaline demonstrated a decrease in [3H]-DHA binding to 21.8±3.8% 
(mean ± SD, n=3, p=0.001) of control levels (table 5.5a).
0N22 cells were treated with lOpM isoprenaline and lpM  iloprost 
both together and separately for 16 hours and the G sa levels examined in 
membranes prepared from these cells using the antipeptide antiserum 
CS1 as described in table 2.1 (figure 5.15). Expressing the results as a 
percentage of control G sa levels, isoprenaline treatment reduced levels of 
G sa to 53±10% (mean ± SD, n=6 ), iloprost treatment reduced levels of 
G sa to 52±16% (mean ± SD, n=6) and a combination of both agonists to 
36±8% (mean ± SD, n=6 ). The down-regulation of G sa levels in cells
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which had been treated with both agonists was however less than 
additive with down-regulation of Gsce in cells which had been treated 
with each agonist separately.
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Discussion
Receptor levels have been implicated in regulating the amount of 
G-protein a-subunit down-regulated on prolonged agonist treatment of 
cells (chapter 3). In NG108-15 cells, chronic exposure of the IP 
prostanoid receptor to agonist results in a down-regulation of Gsa (Kelly 
et al, 1990; McKenzie and Milligan, 1990) whereas agonist activation of 
the apparently less highly expressed A2 adenosine and secretin receptors 
do not (McKenzie et al 1990).
NG108-15 cells expressing 4000 fmoles 02-adrenergic 
receptor/mg membrane protein (0N22 cells) were treated for 16 hours 
with the agonist isoprenaline. A dose-dependent, time-dependent down- 
regulation of some 50% of the cellular Gsa: was observed (figure 5.5, 
5.6). The membrane associated levels of other Ga: were unchanged 
(figure 5.2), as were the membrane associated levels of 0-subunit (figure 
5.4). G sa down-regulation was therefore not a distinct molecular feature 
of the IP prostanoid receptor in the NG108-15 cell line.
Moreover, NG108-15 cells expressing 300 fmoles 02-adrenergic 
receptor (0N17 cells) did not detectably down-regulate G sa on 
prolonged isoprenaline exposure (figure 5.10). Although it is virtually 
impossible to examine the expression and function of every protein in the 
two clones to determine if the transfection process has disrupted the 
cellular metabolism, both clones express essentially identical amounts of 
Gsa, Gi2a, IP prostanoid receptor and adenylyl cyclase (chapter 4). 
The major difference between the two cell lines appears to be their 
relative levels of 02-adrenergic receptor expression. Receptor number, 
therefore, appears to be pivotal to isoprenaline mediated down-regulation
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of G sa in the transfected NG108-15 cell. Clone 0N22, which expresses 
extremely high levels (4000 fmoles/mg membrane protein) of the 02- 
adrenergic receptor, will down-regnlate G sa on prolonged agonist 
exposure, whereas 0N17, which expresses moderate levels (300 
fmoles/mg membrane protein) of the receptor, does not appear to down- 
regulate Gsa. Indeed, higher levels of receptor occupancy by agonist 
are capable of down-regulating more G sa than lower levels of receptor 
occupancy, as previously described. The IP prostanoid receptor in 
NG108-15 cells, can down-regulate Gsa, in a molar ratio of 
approximately 1:8 (receptor:G) at various degrees of receptor occupancy 
by iloprost (chapter 3). It seems likely that as the level of receptor 
expression increases (to a maximal) the amount of G sa down-regulated 
by agonist treatment also increases and eventually reaches a plateau. If 
G sa down-regulation does increase linearly with increasing levels of 
receptor expression then isoprenaline treatment of the clone 0N17 may 
result in a barely detectable down-regulation in the levels of G sa which 
cannot be measured within the sensitivity of the assays used. It would 
therefore be informative to select more clones of NG108-15 cells 
expressing 02-adrenergic receptor levels of between 300 and 4000 
fmoles and examine the effect of agonist on cellular G sa levels in these 
cells.
Having demonstrated that isoprenaline mediated down-regulation 
of G sa in transfected NG108-15 cells is dependent on the level of 02- 
adrenergic receptor expression, it seems likely that the A2 adenosine and 
secretin receptors also down-regulate G sa on prolonged agonist exposure 
but to such a small degree that it is not detectable within the sensitivity of 
the assays used. Certainly, NG108-15 cells express approximately only 
25-30 fmoles/mg membrane protein of the secretin receptor (Gossen et
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al, 1990), which would, on agonist treatment, potentially down-regulate 
only 1-2% G sa (if the stoichiometry of secretin receptor:Gsa down- 
regulation was similar to that of the IP prostanoid receptor and Gsa) and 
this would not be detected by western blotting. The measurement of the 
levels of A2 adenosine receptor expression has proven problematic until 
recently (Keen et al, 1989), but the determination of these levels will help 
to further elucidate the role of the receptor in G sa down-regulation. 
Although it has been shown that agonist mediated G sa down-regulation 
is not unique to the IP prostanoid receptor it may not be a general 
phenomenon and may still be restricted to certain subtypes of G-protein 
coupled receptors, that is, the IP prostanoid receptor and the 02- 
adrenergic receptor when each is expressed at a sufficiently high level in 
a cell.
No apparent down-regulation of G sa was observed on prostanoid 
treatment of NCB20 cells (Kelly et al, 1990; Mullaney and Milligan, 
unpublished observations), and this is most likely to be a result of the low 
levels of IP prostanoid receptor expression (100 fmoles) in these cells 
(Kelly et al, 1990). If the stoichiometry of down-regulation of the IP 
prostanoid receptor:Gsa in NCB20 cells is similar to that of the IP 
prostanoid receptor and G sa in NG108-15 cells, then 100 fmoles IP 
prostanoid receptor would down-regulate approximately 5% total cellular 
G sa if NCB20 cells express similar amounts of G sa to NG108-15 cells. 
A 5% loss of G sa cannot be detected within the sensitivity of our assays.
Recent studies, in transfected NCB20 cells expressing 
approximately 6000 fmoles /52-adrenergic receptor, demonstrated a 
down-regulation of 50-70% membrane associated G sa on prolonged 
isoprenaline treatment (Mullaney and Milligan, unpublished
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observations). Isoprenaline mediated down-regulation of Gsa, unlike 
iloprost, does not distinguish between NG108-15 and NCB20 cells. 
Furthermore, the role of receptor levels in G a down-regulation is 
additionally validated by this data. From this data it seems likely that the 
down-regulation of G-protein a-subunits on prolonged agonist exposure, 
is a general phenomenon and stoichiometrically dependent on the level of 
receptor. Examination of the levels of receptor expression in cell lines 
which do not appear to down-regulate their respective G-protein a- 
subunit on prolonged agonist exposure will also be useful in determining 
the role of receptor number in the down-regulation of Ga.
In both clones, /3N22 (figure 5.10, 5.12, 5.13) and 0N17 (figure 
5.11), chronic treatment with iloprost produced a down-regulation of both 
the IP prostanoid receptor (table 5.1) and G sa essentially identical to that 
of wild-type NG108-15 cells. The lack of G sa down-regulation by 
isoprenaline in /3N17 was not an artefact produced by the transfection 
process preventing G sa down-regulation in this clone. Co-addition of 
maximal concentrations of iloprost and isoprenaline to /3N22 cells 
resulted in a less than additive down-regulation of G sa in 0N22 cell 
membranes (figure 5.15). It appears that the IP prostanoid and 132- 
adrenergic receptors work through the same pool of G sa in the cell 
membrane and only 50-70% G sa is capable of interacting with both 
receptors. This leaves at least 30% cellular G sa which cannot be 
mobilised by a combination of agonist, and is therefore inaccessible to, or 
incapable of, being activated by both receptors. 20-30% G sa in S49 
lymphoma cells is present in a low density membrane fraction (Svoboda 
et al, 1992), which may indicate the presence of G sa in discrete 
membrane compartments. Similarly /3-adrenergic receptor activation in 
rat adipocytes can modify the cellular distribution of Gs and of Gi, by
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promoting a movement of these proteins to a low density endosomal 
fraction (Haraguchi and Rodbell, 1990), indicating the potential for 
compartmentalisation of Gs and Gi in rat adipocytes. The crude 
’'membrane” preparation used in the experiments with NG108-15 cells 
and the two clones (described in section 2.3) will include these low 
density membrane fractions because only the heavier nuclear components 
and cytosol are removed during the "membrane" production. If Gs is 
present in these low density vesicles in NG108-15 cells it will not be 
immediately accessible to the plasma membrane, and hence the receptor, 
thereby restricting the agonist mediated down-regulation of Gsa. It will 
be interesting to examine the effect of co-addition of half-maximal 
concentrations of agonist to determine if 50% G sa is down-regulated at 
these concentrations - 25% by each agonist.
In previous studies (chapter 3) prostanoid induced down-regulation 
of Gs in NG108-15 cells (figure 3.15) was shown to follow an agonist 
dose-response curve which mirrored agonist occupancy curves for the 
receptor (figure 3.4), indicating the lack of "spare" receptors. This was 
not the same for the /32-adrenergic receptor in /3N22 cells where 
approximately 100-fold less agonist is required to produce half-maximal 
G sa down-regulation (figure 5.5) than is required for half-maximal 
receptor occupancy (figure 4.13) The combination of these observations 
demonstrates an apparent receptor reserve ("spare" receptors) for the /32- 
adrenergic receptor, but not the IP prostanoid receptor mediated G sa 
down-regulation in the 0N22 clone. "Spare" /32-adrenergic receptors 
were also noted in chapter 4 when the EC50 for adenylyl cyclase 
activation by isoprenaline in /3N22 was 25-fold less than the 
concentration of isoprenaline required for half-maximal receptor 
occupancy. This may well be a reflection of the relative levels of the
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receptors and Gs. A stoichiometry of down-regulation of Gs by the IP 
prostanoid receptor of approximately 8 pmoles Gs: 1 pmole receptor was 
calculated at all levels of receptor occupancy (chapter 3). If the 02- 
adrenergic receptor were to show similar G-protein activation 
stoichiometry, it might be anticipated that the entire pool of available Gs 
would be activated by agonist occupation of only some 25-35% of the 
available receptors, and as such the dose response curve for G-protein 
activation and down-regulation might be anticipated to be to the left of 
the receptor occupancy curve, as was indeed the case.
Preliminary data showed an approximate 20-25% down-regulation 
of the 0 2 -adrenergic receptor on prolonged isoprenaline treatment of 
0N22 cells (table 5.5b). This was approximately 1000 ftnoles receptor. 
If the stoichiometry of 02-adrenergic receptor: G sa down-regulation in 
clone 0N22 was similar to that of the IP prostanoid receptor and Gs in 
wild-type NG108-15 cells, it would be anticipated that 1000 ftnoles 02- 
adrenergic receptor would down-regulate 50-70% total cellular Gsa, as 
indeed was the case. In 0N17, although there was no apparent down- 
regulation of Gsa on isoprenaline treatment there was a marked 80% 
down-regulation of 02-adrenergic receptor (table 5.5a). This represents 
some 240 ftnoles 02-adrenergic receptor and it might be anticipated, that 
there would be an approximate 10% concurrent down-regulation of G sa 
on isoprenaline treatment of 0N17 cells which would be very difficult to 
detect by western blotting and scan analysis. We must, however, be 
wary of drawing strong conclusions from a single point binding assay 
using a single concentration of antagonist and competing drug. Although 
the change in specific antagonist binding is most likely to be the result of 
a physical loss of the receptor polypeptide from the plasma membrane, 
this may not necessarily be the case. Antagonist binding has been shown
209
to vary depending on the coupling state of the receptor with the G-protein 
(Wregget and DeLean, 1984; Schutz and Freissmuth, 1992 and 
references therein). Saturation binding analysis must therefore be 
performed in both control and isoprenaline treated 0N22 and 0N17 cells 
to affirm if the apparent loss of 0 2 -adrenergic receptor from the plasma 
membrane of these cells, on isoprenaline treatment, is a physical loss of 
the polypeptide or simply the result of some affinity change in the 
receptor.
No detectable release of G sa to the cytosol was observed upon 
iloprost and isoprenaline treatment of 0N22 cells (figure 5.9), contrary to 
observations by Ransnas and co-workers (1989), who demonstrated a 
50% increase in cytosolic Gsa in S49 lymphoma cells treated with 
isoprenaline. However, Haraguchi and Rodbell (1990) showed that 
isoprenaline treatment of rat adipocytes redistributed Gs into low density 
membrane fractions, suggesting the internalisation of Gs in discrete 
membrane vesicles in S49 lymphoma cells. In both wild-type and 
transfected NG108-15 cells Gscx may be internalised either separately, or 
with the respective receptor, on agonist exposure and subsequently 
degraded. Certainly, as discussed in chapter 3, the coupling of the 
receptor and G-protein has been shown to be necessary for receptor 
down-regulation to occur in several systems, even with receptors which 
do not down-regulate their respective G-protein on prolonged agonist 
exposure (Gonzales et al, 1989; Rich and Iyengar, 1990). It may well be 
that the combination of receptor and G-protein a-subunit in NG108-15 
cells is the target for cellular down-regulation.
Homologous desensitisation of prostanoid mediated adenylyl 
cyclase activity was observed in both clones, 0N22 (table 5.3) and 0N17
2 1 0
(table 5.4), essentially identical to wild-type NG108-15 cells. 
Homologous desensitisation of isoprenaline mediated adenylyl cyclase 
activity occurred in 0N22 (figure 5.14) and 0N17 cells, although further 
characterisation, through dose response curves is necessary in 0N17 
membranes. Inclusion of 20mM manganese chloride in the adenylyl 
cyclase assay revealed essentially identical levels of basal adenylyl 
cyclase activity in both control and isoprenaline treated 0N22 cells. No 
functional modification of the catalytic subunit of adenylyl cyclase 
occurred on isoprenaline treatment, indicating that the decrease in basal 
adenylyl cyclase activity on isoprenaline stimulation appeared to be a 
result of either the loss of membrane associated Gsa, or a combination of 
the loss of G sa and (32-adrenergic receptor which tonically stimulates 
adenylyl cyclase (table 5.2).
In summary, receptor number appears to be pivotal in determining 
G sa down-regulation on chronic isoprenaline exposure of transfected 
NG108-15 cells. NG108-15 cells expressing 4000 fmoles /32-adrenergic 
receptor down-regulate G sa on prolonged isoprenaline exposure, in a 
time and concentration dependent manner, whereas NG108-15 cells 
expressing only 300 fmoles &2-adrenergic receptor do not. Preliminary 
studies on the 0 2 -adrenergic receptor levels after isoprenaline treatment 
in 0N22 cells suggest a similar stoichiometry of receptor:Gsa down- 
regulation as does the IP prostanoid receptor and Gsa  in wild-type 
NG108-15 cells. Although homologous desensitisation of adenylyl 
cyclase, by both iloprost and isoprenaline, has been demonstrated in both 
clones 0N22 and 0N17, the role of G sa in heterologous desensitisation 
of adenylyl cyclase in both these cell lines can now be examined in these 
model systems.
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CHAPTER 6 - CONCLUSIONS
Chapter 6 - discussion
The mechanism of agonist-mediated, G-protein a-subunit down- 
regulation has been and is presently being widely studied. As discussed 
more fully in the previous chapters, control of protein turnover appears 
to be the major contributing factor to the down-regulation of the a- 
subunit, however the role that the receptor plays in this process has not 
been explored in great depth. Studies presented in this thesis 
demonstrate that the level of receptor expression and, indeed, the degree 
of receptor occupancy by agonist, determine the amount of G-protein 
a-subunit down-regulated. Dose response curves of both iloprost and 
isoprenaline treatment of wild-type and transfected NG108-15 cells 
respectively show at low receptor occupancy with agonist relatively 
small amounts of G sa are down-regulated, whereas at a high degree of 
receptor occupancy there is a large amount of G sa down-regulation 
(chapter 3). Also, NG108-15 cells expressing relatively low levels of 
the |32-adrenergic receptor (|3N17 cells) do not show a down-regulation 
of Gsa on agonist treatment, whereas a high level of |32-adrenergic 
receptor expression ((3N22 cells) results in a marked (50%) G sa down- 
regulation on agonist treatment (chapter 5).
The mechanism whereby the receptor influences the levels of G sa 
down-regulation has not been unequivocally determined, however, the 
stoichiometry of IP prostanoid receptor:Gsa down-regulation has been 
calculated to be approximately 1:8-10  at various degrees of receptor 
occupancy, indicating that as receptor occupancy by agonist increases so 
does the amount of G sa down-regulated. Although this ratio may not 
be identical to the ratio of IP prostanoid receptor:Gsa activation, it 
appears that G-protein activation is a prerequisite for the down-
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regulation of Gsa. Levis and co-workers (1992) demonstrated that the 
activation of Gs resulted in a conformational change which increased the 
susceptibility of the protein (Gsa) to proteolysis. The enhanced 
proteolysis of the G-protein a-subunit upon agonist exposure does not 
appear to be dependent on its activation specifically by the receptor, 
because activation of G sa by cholera toxin has also resulted in an 
increased turnover of the Gsa polypeptide (Chang and Bourne, 1989). 
The enhanced proteolysis appears, therefore, to rely on the prior 
activation of the G-protein. Since the amount of G-protein activated 
will increase with a higher degree of receptor occupancy with agonist, 
there will be an increased susceptibility to proteolysis and eventually 
cellular down-regulation.
As well as the activation induced conformational change of Ga, 
the addition or removal of covalent modifications of the G-protein a- 
subunit have also been implicated in targetting the protein for 
proteolysis. These include ADP-ribosylation and palmitoylation (as 
discussed in chapter 1). In addition, several cases of prolonged 
activation of the G-protein through receptor stimulation have resulted in 
the association of G a with another unidentified polypeptide, which may 
function to signal the protein for an enhanced proteolysis (Takahashi et 
al, 1991; Mollner et al, 1992; Negishi et al, 1992).
Prostanoid treatment of NG108-15 cells resulted in a concurrent 
down-regulation of IP prostanoid receptor and Gsa. There was no 
apparent loss of functional adenylyl cyclase from the plasma membrane 
on agonist treatment, thus it appears that the receptor and G-protein a- 
subunit are the only known elements of the membrane associated signal 
transduction cascade internalised. It is still unclear if the receptor and
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Gsa are taken up in the same endocytic vesicle and degraded together. 
Alternatively it is possible that they may be taken up separately or there 
may be a branching point after internalisation of both proteins, whereby 
receptor and G-protein are "sorted" either for degradation or 
alternative intracellular functions.
Rodbell's "programmable messenger hypothesis" originally arose 
from the observation that G-protein a-subunits were not irreversibly 
associated with the plasma membrane (Rodbell, 1985). It postulates 
that G-protein a-subunit release from the plasma membrane could 
potentially result in the activation of non-plasma membrane bound 
effectors in discrete cellular compartments (Rodbell, 1985). Gs has 
been identified in discrete vesicles subcellularly (Haraguchi and Rodbell, 
1990; Svoboda et al, 1992), and functions in addition to the activation 
of adenylyl cyclase have also been detected (as discussed in section
1.4.1). It is uncertain if these additional functions are connected to the 
subcellular localisation of Gs, although it may be the case that the 
internalisation of G sa on prolonged agonist exposure results in the 
activation of intracellular effectors before G sa is degraded.
As well as a potential role for activating subcellular effector 
proteins, the internalisation and subsequent down-regulation of G sa has 
been heavily implicated in heterologous desensitisation of adenylyl 
cyclase activity (as discussed in depth in chapter 3). NG108-15 cells
transfected with the |32-adrenergic receptor ((3N22 cells) represent an 
ideal system in which to study the role of G sa down-regulation in the 
heterologous desensitisation of adenylyl cyclase. Preliminary studies, 
examining the effect of dual agonist (isoprenaline and iloprost) 
treatment on G sa levels in (3N22 cells, revealed a less than additive loss
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of G sa from the plasma membrane when compared to individual 
agonist treatment suggesting that the interaction of G sa with its receptor 
may be restricted in some way, perhaps through cytoskeletal restraints 
or differential (3y dimer affinities which serve to arrange the plasma 
membrane associated Gsa subunit into separate "pools" within the 
plasma membrane. Recent evidence, from Kim and co-workers 
(1994), reveals that in NG108-15 cells a 70-fold molar excess of G sa 
over Gsa-adenylyl cyclase complexes exists, suggesting that the 
interaction of G sa and adenylyl cyclase is also limited, perhaps for 
similar reasons to the interaction of receptor and Gsa.
Using transfected NG108-15 cell lines, expressing the p2- 
adrenergic receptor (|3N22 and PN17), the role of Gsa down-regulation 
in heterologous desensitisation of adenylyl cyclase can be examined in 
greater detail, using agonist treatment of the p2 -adrenergic receptor and 
the IP prostanoid receptor. Although more difficult to explore, the 
identification of "sub-pools" of Gs which distinguish in their interaction 
with receptor and effector, can potentially be investigated in the 
transfected cell lines using both inhibitors of cytoskeletal elements and 
radiolabelled agonist binding studies in a similar manner to Graeser and 
co-workers (1993).
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APPENDICES
Appendix 1 [3H]-PGE1 binding analysis
Maguire and co-workers (1976) first observed that guanine 
nucleotides decreased the affinity of the 0 2 -adrenergic receptor for 
agonist. Furthermore, competition curves whereby radiolabelled 
antagonist is competed by agonist gives a pseudo Hill coefficient of less 
than 1.0 indicating the presence of more than one affinity state of the 
receptor (DeLean et al, 1980) An agonist has thus been shown to bind 
with high affinity to a receptor that is coupled to its G-protein and with 
low affinity to a receptor that is not coupled to its G-protein. Using a 
radiolabelled agonist to quantify the amount of receptor expressed in a 
cell is therefore problematic as the measured amount of receptor detected 
will depend on the affinity state of the receptor at the time of the assay. 
The affinity of a receptor for antagonist, on the contrary, has not been 
shown to decrease in the presence of guanine nucleotides, although small 
increases in affinity have been observed in some cases (Schutz et al, 
1992). It is therefore more accurate to use a radiolabelled antagonist, 
than agonist, to determine receptor number.
There is, however, no commercially available radiolabelled 
antagonist specific for the IP prostanoid receptor. It has therefore been 
necessary to use the [3H]-agonist, [3H]-PGE1, to determine the levels of 
IP prostanoid receptor expression in NG108-15 cells. DeBlasi and co­
workers (1989) have derived the equations necessary to estimate the Kd 
and Bmax of a receptor population using a radiolabelled agonist and 
competing with the same unlabelled agonist. There are two ways of 
performing the experiments.
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I(i) Competitive binding
Competition binding is performed by taking a single concentration 
of radioligand and competing it with increasing concentrations of the 
same unlabelled ligand. A displacement curve can then be plotted, 
producing three values: the top plateau (total binding of radioligand 
without competitor); the bottom plateau (non-specific binding of the 
ligand); and the IC50 (the concentration of unlabelled ligand that 
displaced half the specific binding of the radioligand). Subtracting the 
value (cpm) of the bottom plateau from that of the top plateau yields the 
specific binding (Bo). Derivations from the equation of Cheng and 
Prussoff (1973) (1) allow the Kd and Bmax to be calculated from these 
values (Kc is the Kd of the unlabelled ligand, and Kli is the Kd of the 
radiolabelled ligand).
If it is assumed that the affinity of the radioligand for the receptor 
is the same as that of unlabelled ligand (Kc=Kh=Kd) then the Kd can be 
calculated using equation 2, where L is the concentration of radiolabelled 
ligand used.
IC50 = Kc(l+L/Kh) 0 )
Kd = IC50 - L (2)
According to the law of mass action:
Bmax = Bo(Kd+L)/L (3)
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By substituting equation 3 with equation 2 the Bmax can be 
calculated using equation 4.
Bmax = Bo IC50 / L (4)
To sum up, the equations 1-4 allow the calculation of receptor 
number and affinity from the measured values Bo and IC50 obtained 
from the competitive binding data. These equations are based on four 
assumptions.
1. The labelled and unlabelled ligands must have an identical affinity 
for the receptor.
2. There must be no cooperativity between ligand binding sites.
3. Only a small fraction of the total ligand is bound to the receptors 
so that the free [ligand] = total [ligand].
4. Only one class of affinity site exists. Because agonist binding is 
being examined it is highly likely that the receptor is present in two 
affinity states, coupled and uncoupled to a G-protein. The agonist 
binding experiments were therefore performed in the presence of a high 
concentration of Mg2+ (20mM). Under such conditions all the receptors 
in the untreated cell membranes are converted into a high affinity state for 
agonists (Costa et al, 1990) and hence are all presumably coupled to a G- 
protein.
The mechanism by which magnesium ions mediate this effect is 
currently unknown and open to debate. It is well-established that Mg2+ 
is a requirement for G-protein function (Iyengar and Bimbaumer, 1982), 
however the concentration of Mg2+ required for GTPase activity is vastly 
different from the concentration required for hormonal stimulation of
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adenylyl cyclase (5nM and lOpM, respectively), which may indicate that 
Mg2+ can affect G-protein function by two distinct mechanisms (Gilman,
1987). When GTP or GTP7 S is bound to the G-protein a-subunit, the 
interaction of Mg2+ at the active site occurs with high affinity, and is 
presumably sufficient for G-protein activation (Higashijima et al, 1987), 
however the presence of high Mg2+ concentrations seems to be a 
requirement for dissociation of GDP, association of GTP and subunit 
dissociation (Brandt and Ross, 1986).
Neomycin, an inositol phospholipid binding aminoglycoside 
antibiotic can exert a similar effect on the binding of agonist to receptor 
as Mg2+ (Herrmann et al, 1989). In contrast to magnesium, neomycin 
did not induce G-protein activation in the presence of GTP, suggesting 
that the induction of high affinity binding was not a consequence of an 
ability to promote G-protein dissociation. The effect of neomycin was 
also noted for two other aminoglycoside antibiotics, gentamycin and 
streptomycin. These cationic compounds are commonly employed as 
inhibitors of phospholipid hydrolysis (Cockcroft and Gomperts, 1985) 
and have been shown to specifically interact with inositol phospholipids, 
an ability also observed for magnesium (McLaughlin and Whitaker,
1988). It is possible to speculate that the induction of a high affinity 
state of receptor for agonist is not as a consequence of a direct interaction 
of Mg2+ with either G-protein or receptor, but instead as a result of the 
binding of magnesium and neomycin to the membrane lipid components, 
to produce an alteration in the local lipid environment surrounding the 
receptor and G-protein which facilitates the coupling of G-proteins to 
agonist bound receptors (Herrmann et al, 1989).
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l(ii) Saturation binding
Saturation binding analysis can be performed on membranes using 
a very similar protocol to the competition binding data. A single, non­
saturating, concentration of [3H]-PGE1 (lOnM) and various 
concentrations of unlabelled PGE1 (0-90nM) are incubated with 
membranes and the binding assay performed as described in section 2.7. 
The results are calculated by dividing the specific binding by the specific 
radioactivity of the ligand. This yields the number of receptors occupied 
by both labelled and unlabelled ligand. The data can then be 
manipulated according to Scatchard (1949) and the Bmax and Kd of the 
receptor population calculated.
The saturation binding analysis generates values with large errors, 
as the large number of binding sites (of labelled and unlabelled ligand) at 
high concentrations of unlabelled ligand is derived by dividing a few 
specific cpm by a very low specific activity. However, DeBlasi and co­
workers (1989) compared the efficiency of both saturation and 
competitive binding analysis using the same amount of radioligand in 
each case. The accuracy of either method decreased as the amount of 
non-specific binding increases, but for any particular value of non­
specific and total binding the accuracy of either method was essentially 
identical.
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Appendix 11 Transfection of mammalian cells with plasmid DNA
The introduction of genes into mammalian cells and their 
subsequent expression requires the insertion of the gene into a 
mammalian expression vector. One of the most commonly used 
expression vectors is the plasmid. Plasmids usually contain prokaryotic 
sequences that facilitate the propagation of the vector in bacteria. A 
gene encoding antibiotic resistance will permit the selection of bacteria 
that harbour the recombinant plasmids, allowing their growth and DNA 
multiplication and extraction. A limited number of unique restriction 
sites in non-essential regions of the plasmid are also required to be 
present to allow the insertion of DNA sequences. The most basic 
eukaryotic expression vector contains a eukaryotic promoter element to 
mediate transcription of foreign DNA sequences and also the signals 
necessary for the efficient polyadenylation of the transcript (Sambrook et 
a!, 1989).
Unlike the signals for RNA processing which can function 
efficiently in all mammalian cells, the activities of transcription 
controlling elements can vary considerably between different cell types. 
Promoters and enhancers consist of short arrays of DNA sequences that 
interact specifically with cellular proteins involved in transcription. The 
combination of different recognition sequences and varying levels of 
expression of transcription factors determines the efficiency with which a 
given gene is transcribed in a particular cell type. The simian virus 40 
(SV40) early gene promoter is active in a variety of tissues and for this 
reason vectors incorporating this promoter have been widely used 
(Sambrook et al, 1989).
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Il(i) The simian virus 40 (SV40) promoter
The SV40 origin of replication comprises of a coding region of 
approximately 300 base pairs. The early and late genes are transcribed 
in opposite directions, and hence opposite strands, from the origin of 
replication. The early gene region of SV40 is transcribed immediately 
after viral infection. This gene encodes for two proteins, through 
differential RNA splicing, the small T antigen and the large T antigen. 
The large T antigen represses its own synthesis by binding to the mRNA 
start site for early gene expression. It also activates late gene 
transcription by binding to the late SV40 promoter. The large T antigen 
binds with a weaker affinity to the site of late gene activation than to the 
early promoter, therefore it first shuts off its own synthesis and then 
activates late gene transcription (McKnight et al, 1981).
Both the SV40 early and late promoters have been constructed into 
vectors and used to control the expression of genes in a variety of 
mammalian cell lines. The use of SV40 origin containing transient 
expression vectors was greatly facilitated by the development of COS-1 
cells that were derived by the transformation of simian CV-1 cells with 
an origin defective SV40 genome. COS-1 cells constitutively express 
the wild-type SV40 large T antigen and contain all of the cellular factors 
necessary to drive the replication of SV40 origin containing plasmids 
(Gluzman et al, 1981). High levels of gene expression can result if the 
cDNA to be expressed is cloned into a plasmid under the control of a 
SV40 late promoter, and transfected into COS-1 cells. The constitutive 
production of the large T antigen in COS-1 cells will overexpress the 
cloned gene by activating the late SV40 promoter.
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ll(ii) Transient expression of the 02-adrenergic receptor in COS-1
cells
A cDNA for the human 02-adrenergic receptor (figure 4.1) was 
cloned into the plasmid pSVL (figure 4.2) downstream of the SV40 late 
promoter and transiently transfected into COS-1 cells as follows.
The cDNA for the human 02-adrenergic receptor was cloned into 
the unique Eco R1 restriction site (5-3' with respect to the T7 promoter) 
of the plasmid pGEM-7Zf (+). To excise out the cDNA for the 02- 
adrenergic receptor, the pGEM-7Zf (+) plasmid was digested with the 
restriction enzymes Xhol and BamHl (section 2.14). The restriction 
digest was run on a 1% (w/v) agarose gel (section 2 .11) and the band 
corresponding to the human 02-adrenergic receptor cDNA (2305 base 
pairs) "Genecleaned" (section 2.19).
The plasmid pSVL was also digested with Xhol and BamHl. 
The cut pSVL and "Genecleaned" human 02-adrenergic receptor cDNA 
were then ligated together (section 2.14), and the ligation reaction 
transformed into competent E.Coli (section 2.16, 2.17), which were 
subsequently plated out on ampicillin (25pg/ml) bactoagar plates. The 
DNA was extracted from ampicillin resistant colonies of E.Coli (section 
2.18) and restriction digests performed on the plasmid DNA with Pstl 
and BamHl (section 2.14) to determine the orientation of the insert in the 
plasmid. Purified plasmid DNA was produced, using CsCf? 
centrifugation (section 2 .20), from one of the colonies which contained 
the plasmid with the receptor cDNA insert present in the correct 
orientation. 10pg purified plasmid DNA was used to transiently 
transfect COS-1 cells using the Lipofectin reagent (section 2.22).
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ll(iii) Stable expression of the human /32-adrenergic receptor in
NG108-15 cells
To ensure high levels of expression of a cloned gene it is necessary 
to use a very strong promoter to drive transcription and so drive high 
gene expression. Most promoters show a significant variation between 
different cell types. It is much more convenient to use a promoter that is 
highly active in all cells. Since /3-actin is abundantly expressed in all 
non-muscle cells it was reasoned that the /3-actin promoter may give a 
high level of gene expression in a wide range of cell lines. Gunning and 
co-workers (1987) evaluated the ability of the /3-actin promoter to drive 
high level accumulation of antisense transcripts in a variety of human and 
rodent cell lines and discovered that the /3-actin promoter was 
consistently as strong or stronger than the SV40 promoter. For this 
reason they constructed a plasmid which contained the /3-actin promoter 
linked to unique restriction sites and a SV40 polyadenylation signal. 
This plasmid pJM16 (or LK444) (figure 4.4) also contained a neomycin 
resistant gene, controlled by the early SV40 promoter, suitable for 
selection of successfully transfected mammalian cells with geneticin 
sulphate (G418).
Successful transfection of NG108-15 cells with a cDNA for a 
P400 protein encoding an IP3 receptor was shown by Furiuchi and co­
workers (1989). The cDNA used was cloned into a modified version of 
the plasmid pbact-CAT9 (Supattapone et al, 1988) downstream of the 0- 
actin promoter and the plasmid then transfected into NG108-15 cells. A 
moderate level of expression of the IP3 receptor was obtained. NG108- 
15 cells were therefore able to express the necessary control elements to 
initiate transcription from the 0-actin promoter. It was thus decided to
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use this promoter for expressing the human 02-adrenergic receptor in 
NG108-15 cells. The cDNA for the human 02-adrenergic receptor was 
cloned into the plasmid pJM16 and transfected into NG108-15 cells as 
described below.
pJM16, or LK444 (figure 4.4), was digested (section 2.14) with 
the restriction enzymes BamHl and Sail (which is compatible with a 
Xhol site during ligation reactions). "Genecleaned” 02-adrenergic 
receptor cDNA [as prepared for section ll(ii)], cut with Xhol and 
BamHl, was ligated into the digested pJM16 (section 2.15). Competent 
E.Coli were transformed with the ligation reactions (section 2.16, 2.17), 
spread on ampicillin (25gg/ml) bactoagar plates and ampicillin resistant 
colonies of E.Coli were selected. Plasmid DNA was extracted from the 
bacterial colonies (section 2.18) and run on a 1% (w/v) agarose gel 
(section 2.11) to determine the presence of the cDNA insert. The 
plasmid DNA from a colony with an insert present, and thus in the 
correct orientation, was purified using CsCh centrifugation (section 
2.20). lOgg purified plasmid DNA was then stably transfected (section 
2.22) into NG108-15 cells using the Lipofectin reagent. Cells were 
grown in the presence of 0.8mg/ml geneticin, the minimum concentration 
determined to kill all wild-type NG108-15 cells.
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